US20120322133A9 - Separating material and method for collecting cell or the like using the same - Google Patents
Separating material and method for collecting cell or the like using the same Download PDFInfo
- Publication number
- US20120322133A9 US20120322133A9 US13/403,212 US201213403212A US2012322133A9 US 20120322133 A9 US20120322133 A9 US 20120322133A9 US 201213403212 A US201213403212 A US 201213403212A US 2012322133 A9 US2012322133 A9 US 2012322133A9
- Authority
- US
- United States
- Prior art keywords
- group
- polyurethane
- oligosaccharide
- sugar
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000463 material Substances 0.000 title claims abstract description 202
- 238000000034 method Methods 0.000 title claims abstract description 153
- 238000002955 isolation Methods 0.000 claims abstract description 266
- 210000001124 body fluid Anatomy 0.000 claims abstract description 37
- 239000010839 body fluid Substances 0.000 claims abstract description 37
- 238000003306 harvesting Methods 0.000 claims abstract description 27
- 235000000346 sugar Nutrition 0.000 claims description 228
- 229920002635 polyurethane Polymers 0.000 claims description 217
- 239000004814 polyurethane Substances 0.000 claims description 217
- 239000007788 liquid Substances 0.000 claims description 153
- 150000002482 oligosaccharides Polymers 0.000 claims description 152
- 229920001542 oligosaccharide Polymers 0.000 claims description 135
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 56
- 239000000126 substance Substances 0.000 claims description 47
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 238000005406 washing Methods 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 40
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 150000002016 disaccharides Chemical class 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 15
- 229910052783 alkali metal Inorganic materials 0.000 claims description 11
- 150000001340 alkali metals Chemical group 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 8
- 210000004027 cell Anatomy 0.000 abstract description 159
- 210000001616 monocyte Anatomy 0.000 abstract description 143
- 210000004443 dendritic cell Anatomy 0.000 abstract description 99
- 102000004169 proteins and genes Human genes 0.000 abstract description 79
- 108090000623 proteins and genes Proteins 0.000 abstract description 79
- 238000004519 manufacturing process Methods 0.000 abstract description 22
- 239000000047 product Substances 0.000 description 193
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 119
- 239000000203 mixture Substances 0.000 description 105
- 239000000243 solution Substances 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 90
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 82
- -1 polyethylene Polymers 0.000 description 78
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- 238000001556 precipitation Methods 0.000 description 51
- 238000001914 filtration Methods 0.000 description 50
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 49
- 230000015572 biosynthetic process Effects 0.000 description 49
- 238000003786 synthesis reaction Methods 0.000 description 49
- 229920000642 polymer Polymers 0.000 description 48
- 229910001873 dinitrogen Inorganic materials 0.000 description 47
- 238000003756 stirring Methods 0.000 description 47
- 239000002904 solvent Substances 0.000 description 46
- 108090001090 Lectins Proteins 0.000 description 43
- 102000004856 Lectins Human genes 0.000 description 43
- 239000002523 lectin Substances 0.000 description 43
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 42
- 150000002430 hydrocarbons Chemical group 0.000 description 40
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- 0 CC[2*]CCN[1*]NCC.C[3*]CC(C)(CC)CCN[1*]NCC Chemical compound CC[2*]CCN[1*]NCC.C[3*]CC(C)(CC)CCN[1*]NCC 0.000 description 32
- 238000011084 recovery Methods 0.000 description 28
- 239000000758 substrate Substances 0.000 description 28
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 25
- 229920001451 polypropylene glycol Polymers 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- 239000004793 Polystyrene Substances 0.000 description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 229930182830 galactose Natural products 0.000 description 21
- 229920002223 polystyrene Polymers 0.000 description 21
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000006285 cell suspension Substances 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 19
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 19
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 19
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 19
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 18
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 17
- 239000008101 lactose Substances 0.000 description 17
- 150000004804 polysaccharides Chemical class 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 16
- 239000012046 mixed solvent Substances 0.000 description 16
- 239000011148 porous material Substances 0.000 description 16
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 229920001282 polysaccharide Polymers 0.000 description 15
- 239000005017 polysaccharide Substances 0.000 description 15
- 229940014800 succinic anhydride Drugs 0.000 description 15
- 239000004698 Polyethylene Substances 0.000 description 14
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 13
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 13
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 13
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 13
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 13
- 150000002009 diols Chemical class 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 125000004076 pyridyl group Chemical group 0.000 description 12
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 11
- 108010062580 Concanavalin A Proteins 0.000 description 11
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- LCTORNIWLGOBPB-DVKNGEFBSA-N (2s,3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound N[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-DVKNGEFBSA-N 0.000 description 9
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 9
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000002329 infrared spectrum Methods 0.000 description 9
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 8
- 101000729818 Bacillus licheniformis Glutamate racemase Proteins 0.000 description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 8
- 229910045601 alloy Inorganic materials 0.000 description 8
- 239000000956 alloy Substances 0.000 description 8
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 229920000573 polyethylene Polymers 0.000 description 8
- 238000000164 protein isolation Methods 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 125000005442 diisocyanate group Chemical group 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000004743 Polypropylene Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000035790 physiological processes and functions Effects 0.000 description 6
- 229920002959 polymer blend Polymers 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 125000004436 sodium atom Chemical group 0.000 description 6
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 description 5
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 239000004952 Polyamide Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 235000010290 biphenyl Nutrition 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 229960002986 dinoprostone Drugs 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 5
- 229920002647 polyamide Polymers 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940081735 acetylcellulose Drugs 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000007769 metal material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920002492 poly(sulfone) Polymers 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 230000001180 sulfating effect Effects 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 4
- 125000000647 trehalose group Chemical group 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 101150110592 CTS1 gene Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920000306 polymethylpentene Polymers 0.000 description 3
- 239000011116 polymethylpentene Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000001226 reprecipitation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 229920002725 thermoplastic elastomer Polymers 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- ANLVEXKNRYNLDH-UHFFFAOYSA-N 1,3-dioxonan-2-one Chemical group O=C1OCCCCCCO1 ANLVEXKNRYNLDH-UHFFFAOYSA-N 0.000 description 2
- PAALZGOZEUHCET-UHFFFAOYSA-N 1,4-dioxecane-5,10-dione Chemical group O=C1CCCCC(=O)OCCO1 PAALZGOZEUHCET-UHFFFAOYSA-N 0.000 description 2
- VGHCVSPDKSEROA-UHFFFAOYSA-N 2-methyl-1,4-dioxecane-5,10-dione Chemical group CC1COC(=O)CCCCC(=O)O1 VGHCVSPDKSEROA-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 2
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 2
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 239000004760 aramid Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 229920003235 aromatic polyamide Polymers 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000010559 graft polymerization reaction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 150000002641 lithium Chemical group 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- AFDQGRURHDVABZ-UHFFFAOYSA-N n,n-dimethylformamide;sulfur trioxide Chemical compound O=S(=O)=O.CN(C)C=O AFDQGRURHDVABZ-UHFFFAOYSA-N 0.000 description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000004957 naphthylene group Chemical group 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical group O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- LCTORNIWLGOBPB-PHYPRBDBSA-N (2s,3r,4s,5r,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound N[C@@]1(O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-PHYPRBDBSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- AJSKFBFHLYPSEM-UHFFFAOYSA-N 1,16-diisocyanatohexadecane Chemical compound O=C=NCCCCCCCCCCCCCCCCN=C=O AJSKFBFHLYPSEM-UHFFFAOYSA-N 0.000 description 1
- NNOZGCICXAYKLW-UHFFFAOYSA-N 1,2-bis(2-isocyanatopropan-2-yl)benzene Chemical compound O=C=NC(C)(C)C1=CC=CC=C1C(C)(C)N=C=O NNOZGCICXAYKLW-UHFFFAOYSA-N 0.000 description 1
- FKTHNVSLHLHISI-UHFFFAOYSA-N 1,2-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=CC=C1CN=C=O FKTHNVSLHLHISI-UHFFFAOYSA-N 0.000 description 1
- LUYHWJKHJNFYGV-UHFFFAOYSA-N 1,2-diisocyanato-3-phenylbenzene Chemical compound O=C=NC1=CC=CC(C=2C=CC=CC=2)=C1N=C=O LUYHWJKHJNFYGV-UHFFFAOYSA-N 0.000 description 1
- MTZUIIAIAKMWLI-UHFFFAOYSA-N 1,2-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC=C1N=C=O MTZUIIAIAKMWLI-UHFFFAOYSA-N 0.000 description 1
- RXUVWJWQFPJWOV-UHFFFAOYSA-N 1,2-diisocyanatoethene Chemical compound O=C=NC=CN=C=O RXUVWJWQFPJWOV-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RUTDYOMEDKTYGF-UHFFFAOYSA-N 1,3-diisocyanatoprop-1-ene Chemical compound O=C=NCC=CN=C=O RUTDYOMEDKTYGF-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 1
- OVBFMUAFNIIQAL-UHFFFAOYSA-N 1,4-diisocyanatobutane Chemical compound O=C=NCCCCN=C=O OVBFMUAFNIIQAL-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- DFPJRUKWEPYFJT-UHFFFAOYSA-N 1,5-diisocyanatopentane Chemical compound O=C=NCCCCCN=C=O DFPJRUKWEPYFJT-UHFFFAOYSA-N 0.000 description 1
- AXKZIDYFAMKWSA-UHFFFAOYSA-N 1,6-dioxacyclododecane-7,12-dione Chemical group O=C1CCCCC(=O)OCCCCO1 AXKZIDYFAMKWSA-UHFFFAOYSA-N 0.000 description 1
- QUPKOUOXSNGVLB-UHFFFAOYSA-N 1,8-diisocyanatooctane Chemical compound O=C=NCCCCCCCCN=C=O QUPKOUOXSNGVLB-UHFFFAOYSA-N 0.000 description 1
- RNQBCZCPNUHWLV-UHFFFAOYSA-N 1,8-dioxacyclotetradecane-2,7-dione Chemical group O=C1CCCCC(=O)OCCCCCCO1 RNQBCZCPNUHWLV-UHFFFAOYSA-N 0.000 description 1
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical compound OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 description 1
- NHEKBXPLFJSSBZ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5-octafluorohexane-1,6-diol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)CO NHEKBXPLFJSSBZ-UHFFFAOYSA-N 0.000 description 1
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- HDNIDWXLYXGKBI-UHFFFAOYSA-N 6-(2,2-dimethylpropoxy)-6-oxohexanoic acid Chemical group CC(C)(C)COC(=O)CCCCC(O)=O HDNIDWXLYXGKBI-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LVZMWMDZRQQWNB-UHFFFAOYSA-N C1N2OOOC12 Chemical compound C1N2OOOC12 LVZMWMDZRQQWNB-UHFFFAOYSA-N 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N CC(O)O Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- QDCWMPHJELLHBD-UHFFFAOYSA-N CCC1(C)CC(C)CC(C)(C)C1 Chemical compound CCC1(C)CC(C)CC(C)(C)C1 QDCWMPHJELLHBD-UHFFFAOYSA-N 0.000 description 1
- KBZMKKVAZLMBPR-UHFFFAOYSA-N CCC1=CC=C(CC)C=C1.CCC1CCCC(C)C1 Chemical compound CCC1=CC=C(CC)C=C1.CCC1CCCC(C)C1 KBZMKKVAZLMBPR-UHFFFAOYSA-N 0.000 description 1
- DSNHSQKRULAAEI-UHFFFAOYSA-N CCc1ccc(CC)cc1 Chemical compound CCc1ccc(CC)cc1 DSNHSQKRULAAEI-UHFFFAOYSA-N 0.000 description 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
- 235000010518 Canavalia gladiata Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001723 Entada phaseoloides Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ADYVCZCQSVYNPQ-UHFFFAOYSA-N N=C=O.N=C=O.C=1C=CC=CC=1C(C)C1=CC=CC=C1 Chemical compound N=C=O.N=C=O.C=1C=CC=CC=1C(C)C1=CC=CC=C1 ADYVCZCQSVYNPQ-UHFFFAOYSA-N 0.000 description 1
- DKBWKERAUSECPF-UHFFFAOYSA-N N=C=O.N=C=O.CCC1=CC=CC=C1 Chemical compound N=C=O.N=C=O.CCC1=CC=CC=C1 DKBWKERAUSECPF-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- KXBFLNPZHXDQLV-UHFFFAOYSA-N [cyclohexyl(diisocyanato)methyl]cyclohexane Chemical compound C1CCCCC1C(N=C=O)(N=C=O)C1CCCCC1 KXBFLNPZHXDQLV-UHFFFAOYSA-N 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JXCHMDATRWUOAP-UHFFFAOYSA-N diisocyanatomethylbenzene Chemical compound O=C=NC(N=C=O)C1=CC=CC=C1 JXCHMDATRWUOAP-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000921 polyethylene adipate Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000909 polytetrahydrofuran Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000011527 polyurethane coating Substances 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 125000005628 tolylene group Chemical group 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 125000006839 xylylene group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
Definitions
- the present invention relates to a novel material useful for selectively isolating a cell such as monocyte and the like from a body fluid or a protein contained in an animal or plant and a production method thereof, a physiological material using the material and an isolation material using the same, as well as a method of harvesting a cell such as monocyte and the like, a method of harvesting a protein by the use of the isolation material, and a method of preparing a dendritic cell.
- sugar chain present in the cell surface is deeply involved in various vital phenomena (cell recognition, transduction of information, cell adhesion, differentiation and proliferation, canceration, virus infection, blood coagulation, immune reaction and the like).
- the target molecule in the phenomenon is a sugar chain
- the interaction is classified into a “sugar chain-sugar chain” interaction
- the target molecule is a protein
- it is classified into a “sugar chain-protein” interaction.
- cell surface sugar chains in a particular sugar chain structure combinatory relationship are bound to each other.
- one of the cell surface sugar chains recognizes and binds to a sugar chain recognition protein on the other cell surface, where lectin, glycosyltransferase and glycohydrolase are said to be involved as the sugar chain recognition protein.
- lectin, glycosyltransferase and glycohydrolase are said to be involved as the sugar chain recognition protein.
- sugar chain polymer As polymers incorporating a sugar chain such as monosaccharide, disaccharide, oligosaccharide and the like (hereinafter sugar chain polymer),
- patent document 5 discloses selective adhesion and collection of hepatocytes as well as cancer cell recognition using a sugar chain polymer-coated substrate.
- monocyte has blood vessel regeneration capability (non-patent documents 4, 5), and is drawing attention as a precursor cell of a dendritic cell to be used for a dendritic cell therapy, which is one of the cell immunity therapies (non-patent document 6).
- a method for isolating monocytes from a body fluid such as blood and the like the following have been reported.
- Examples of a method of isolating peripheral blood monocytes include a density-gradient centrifugation method wherein the difference in the specific gravity of the cells is utilized for isolation, a method wherein a blood component containing monocytes is isolated from the peripheral blood by apheresis and the like, highly adhesive monocytes are attached to a physical and chemical instrument such as a polystyrene flask and the like, and non-adhesive cells are removed to isolate the monocytes, a method wherein monocytes are selectively isolated by utilizing magnetic beads bound with an antibody to the monocyte and the like.
- the isolated monocytes are cultured with cytokine such as IL-4, GM-CSF and the like to induce differentiation into dendritic cells, which are used as cancer treatment cells.
- the method of isolating monocytes by the density-gradient centrifugation method is associated with many problems yet to be solved, such as a safety problem of the liquid to be used for density gradient (cytotoxicity and the like), an operability problem because of a long time required for centrifugation, washing operation and the like, much loss of cells, an open system operation allowing easy contamination and the like, isolation efficiency (insufficient removal of non-adhesive cells, contamination with lymphocytes) and the like.
- the isolation method using magnetic beads with antibody can isolate monocytes at a comparatively high purity, but the cell treatment requires a long time, and also, is expensive.
- a cell suspension is centrifuged in a chamber having a slope, while flowing a buffer in an opposite direction from the centrifugation to form a particular cell layer.
- This method affords high purity monocytes, but the apparatus is expensive, and requires a skillful operation technique.
- the cell isolation problematically requires a long time.
- patent document 18 discloses a method of collecting nuclear cells by trapping nuclear cells on a filter that traps nuclear cells but passes red blood cells, and inducing a liquid current in the opposite direction from the first liquid flow direction.
- this document is directed to a filter for collecting nuclear cells, where selectivity to monocyte is absent.
- patent document 19 discloses monocyte and/or monocyte-derived macrophage selective removal filter apparatus.
- this document is directed to a physical filtration filter wherein the average pore cross sectional area and bulk density of the filter were defined in consideration of the particle size of macrophage, which is clearly different from the present invention wherein monocytes are selectively isolated utilizing the affinity for the monocytes.
- Patent document 20 also discloses that the monocyte trap rate increases by defining the packing density and fiber diameter of the filter. For the same reasons as mentioned above, it is clearly different from the present invention. In addition, the property is not sufficient because the monocyte recovery rate is about 50% and the purity is about 40%.
- Lectin widely present in the biological world including animals, plants, microorganisms etc. is a generic term of proteins that recognize a sugar chain.
- Lectin specifically binds to a sugar chain having a particular structure, which is present in blood cell, cell surface and the like, and has an activity to aggregate blood cells and cells.
- sword bean-derived concanavalin A (ConA) and wheat germ agglutinin (WGA) are known to aggregate malignant cells.
- ConA concanavalin A
- WGA wheat germ agglutinin
- lectin is medically highly useful as a cell fractionation reagent, clinical diagnostic reagent, clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like.
- affinity chromatography using a carrier having a sugar such as maltose, lactose and the like immobilized thereon as a ligand (patent documents 21-24), and affinity chromatography using a methacrylate polymer bound with a sugar such as maltose, lactose (patent document 25), albumen-derived sugar chain (patent document 26) and the like have been utilized. As shown, various materials and methods for isolating lectin have been disclosed.
- Sulfated sugar is known to have affinity for influenza virus and AIDS virus, and development of a new material capable of trapping viruses utilizing the principle and its production method is desired. With such backgrounds, various sulfated sugar chain-containing polymers have been reported. For example, a sulfated galactose-inducing polyacrylate type (e.g., patent document 27), sulfated sugar-inducing polyethylene type (e.g., patent document 28), sulfated glucosamine-inducing polyethylene type (e.g., patent document 29) and the like are known.
- a sulfated galactose-inducing polyacrylate type e.g., patent document 27
- sulfated sugar-inducing polyethylene type e.g., patent document 28
- sulfated glucosamine-inducing polyethylene type e.g., patent document 29
- the biological functions such as recognition, adhesion and the like of cell, protein containing lectin or virus are expressed due to a “sugar chain-sugar chain interaction” or a “sugar chain-protein interaction” between a sugar chain aggregate (cluster) on the cell surface and a sugar chain aggregate complementary thereto, and the strength of the interaction is known to correlate with the sugar chain density.
- the polyurethane type sugar chain polymer disclosed in patent document 17 is preferable.
- the production step for introducing a sugar chain into the side chain requires complicated protection and deprotection operations, the production cost may problematically increase.
- An object of the present invention is to provide a novel material having superior film forming capability, which is expected to show various physiological functions such as biocompatibility, blood compatibility, affinity for cell or protein, and the like, and a convenient and low cost production method thereof, provide a physiological material containing the material and an isolation material using the same, and to provide a convenient and efficient method of harvesting a cell such as monocyte and the like or a protein as well as a convenient and efficient method of preparing a dendritic cell, using the isolation material.
- the present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems and found that a cell such as monocyte and the like or a protein can be isolated conveniently and efficiently by the use of an isolation material containing, on at least a part of the surface, a substance having a sugar structure, and that a dendritic cell can be prepared conveniently and efficiently from a monocyte.
- a sugar chain-containing polymer having a particular structure defined below particularly has superior film forming capability, is expected to have various physiological functions such as biocompatibility, blood compatibility, affinity for a cell or a protein and the like, and is useful for harvesting a cell such as monocyte and the like or a protein, and that the sugar chain-containing polymer can be produced by a convenient method at a low cost.
- the present invention provides the following.
- a method of harvesting a monocyte comprising performing
- a step for trapping a monocyte in an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- a method of preparing a dendritic cell comprising inducing further differentiation of a monocyte collected by the method of the above-mentioned [1] or [2] into a dendritic cell.
- a method of preparing a dendritic cell comprising performing
- a step for trapping a monocyte in an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- composition comprising a dendritic cell obtained by the method of the above-mentioned [3] or [4].
- a method of harvesting a protein comprising performing
- the sugar constituting the substance having a sugar structure is at least one sugar selected from the group consisting of mannose, glucose, galactose, lactose, fucose, trehalose, maltose and cyclo ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ 1.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1, and m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety
- s shows the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ r
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety
- s shows the number of hydroxyl groups of a sugar residue R 4 modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ 4
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00.
- R 1 is a divalent C 2-26 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-22 oxyalkylene unit and a divalent C 2-22 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety
- s is the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ r
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety
- s is the number of hydroxyl groups of a sugar residue R 4 modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ 4
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are
- a monocyte isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure, wherein the substance having a sugar structure is a sugar chain-containing polymer having, as a partial structure, (i) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group, or (ii) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative.
- a monocyte isolation device comprising a container provided with a liquid inlet and/or a liquid outlet, wherein the container comprises a monocyte isolation material of any one of the above-mentioned [42]-[45] in at least one part thereof.
- a physiological material comprising a polyurethane of any one of the above-mentioned [17]-[40].
- An isolation material comprising a polyurethane of any one of the above-mentioned [17]-[40] at least on a part of a surface thereof.
- the isolation material of the above-mentioned [48] which is a cell isolation material.
- the isolation material of the above-mentioned [48] which is a protein isolation material.
- the isolation material of the above-mentioned [51] which is a lectin isolation material.
- An isolation device comprising a container provided with a liquid inlet and/or a liquid outlet, wherein the container comprises an isolation material of the above-mentioned [48]-[55] in at least one part thereof.
- ConA concanavalin A
- WGA wheat germ agglutinin
- R 1 is a divalent C 2-26 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-22 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are as defined above, comprising reacting an oligosaccharide-containing polyurethane represented by the following formula [1-3]:
- R 1 , R 2 , m, n, r and OLS are each as defined above, with an acid anhydride represented by the following formula [1-4]:
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00, comprising reacting a carboxyl group-mod
- R 1 , R 2 , R 3 , p, q, r, m, n and OLS are each as defined above, with an aminated sugar represented by the following formula [1-5]:
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- s is as defined above
- X is an acid-derived moiety
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00, comprising reacting an oligosaccharide-containing polyurethane represented by the following formula [1-3]:
- R 1 , R 2 , OLS, r, m and n are as defined above, with an acid modifying reagent.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety
- s is the number of hydroxyl groups of a sugar residue R 4 modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ 4
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are
- n and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, n/(m+n) is a number within the range of 0.01-1.00, comprising reacting a sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [1-1]:
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s)
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s)
- R 3 is a C 2-4 alkylene group
- R 4 is a monosaccharide- or disaccharide-derived sugar residue
- OLS is an oligosaccharide skeleton having two primary hydroxyl groups
- r shows the total number of secondary hydroxyl groups of oligosaccharide
- p and q are each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1
- m and n are each a repeat unit number
- m is an integer of 0-1000 and n is an integer of 1-1000
- n/(m+n) is a number within the range of 0.01-1.00, with an acid modifying reagent.
- the isolation material to be used for the method of the present invention characteristically contains a substance having a sugar structure on at least a part of the surface.
- “contains a substance having a sugar structure on at least a part of the surface” encompasses both cases where 1) the isolation material itself is constituted with a substance having a sugar structure, and 2) the substrate of the isolation material is different from the substance having a sugar structure, and the entirety or a part of the surface of the isolation material is constituted with a substance having a sugar structure.
- the “substance having a sugar structure” to be used in the method of the present invention is not particularly limited as long as it contains monosaccharide, oligosaccharide and/or polysaccharide structures as a partial structure, which can be formed into an isolation material by itself, or immobilized or coated on the surface of a substrate of the isolation material.
- a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group, a sugar chain-containing polymer having, as a partial structure, a monosaccharide, an oligosaccharide and/or a polysaccharide, and the like can be mentioned.
- sugar in a substance having a sugar structure is not particularly limited, monosaccharides such as mannose, glucose, galactose, fucose and the like, and oligosaccharide or polysaccharide containing these sugar units are preferable.
- monosaccharides such as mannose, glucose, galactose, lactose, fucose, trehalose, maltose, cyclo ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ and the like.
- the kind of sugar may be single or plural.
- the sugar structure means a partial structure or derivative of these sugars.
- the sugar of the sugar structure is oligosaccharide or polysaccharide, it may have a straight chain structure or a branched structure.
- the terminal sugar of a sugar structure preferably has a structure selected from glucose, galactose and fucose.
- the terminal sugar here means a sugar on the terminal at the nonreducing terminal side.
- the immobilizing method when a substance having a sugar structure is immobilized on a substrate of the isolation material, the immobilizing method includes an ion bond method, a covalent bond method and the like.
- the immobilization method various known methods can be used without any particular limitation.
- a monosaccharide derivative, an oligosaccharide derivative and a polysaccharide derivative, each having a reactive functional group are preferably used as substances having a sugar structure.
- the reactive functional group of a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative is not particularly limited as long as it can chemically bind to a substrate of the isolation material directly or via a spacer.
- a hydroxyl group, an amino group, an aldehyde group, a carboxyl group, a thiol group, a silanol group, an amide group, an epoxy group, a halogen group, a succinoylimide group, an acid anhydride group and the like can be mentioned.
- a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group is immobilized on an isolation material, a reactive group may be introduced onto the surface of a substrate of the isolation material.
- a reactive group for example, immobilization of halogen or pseudohalogen as disclosed in JP-A-2-261833, introduction of an epoxy group as disclosed in JP-A-6-219051 and JP-B-1887096, and the like are preferably utilized.
- a substance having a sugar structure or a precursor thereof can also be immobilized by graft polymerization onto a substrate of the isolation material.
- monosaccharide, oligosaccharide and/or polysaccharide derivative, having, as a reactive functional group, a styrene group, a methacryl group, a vinyl group, an acrylic group and the like capable of graft polymerization can be used as a substance having a sugar structure.
- an immobilization method therefor known methods using radiation or electron beam can be employed without any particular limitation.
- a sugar chain-containing polymer having monosaccharide, oligosaccharide and/or polysaccharide as a partial structure is preferably used as the substance having a sugar structure.
- sugar chain-containing polymer examples include synthetic polymers represented by polyurethane, polystyrene, polyethylene, polyolefin, polyacrylamide, polyester, nylon, polyimide, aramid, polyamide, acrylic resin and the like, natural polymers represented by chitin, chitosan, acetyl cellulose, cellulose, rayon, agarose, alginic acid and the like, into which at least one kind of monosaccharide, oligosaccharide and/or polysaccharide structure has been introduced, and the like.
- synthetic polymers represented by polyurethane, polystyrene, polyethylene, polyolefin, polyacrylamide, polyester, nylon, polyimide, aramid, polyamide, acrylic resin and the like natural polymers represented by chitin, chitosan, acetyl cellulose, cellulose, rayon, agarose, alginic acid and the like, into which at least one kind of monosaccharide, oligosaccharide and/
- the method of coating a substrate of the isolation material with a substance having a sugar structure is not particularly limited, for example, coating methods including immersing a substrate of the isolation material into a liquid containing a substance having a sugar structure which forms a coating layer, spraying the solution on a substrate of the isolation material, injecting the solution on a substrate of the isolation material and the like can be mentioned.
- the substrate after a coating treatment may be used after removing the remaining solution by washing, or used after drying without washing. Alternatively, the substrate may be used after washing but without drying, and known methods can be used without any particular limitation.
- a coating layer may be formed by applying a solution containing a substance having a sugar structure and a polymerizable compound in combination, and crosslinking the solution.
- the form of the isolation material of the present invention is not particularly limited and may be, for example, a tool having a flat plate structure such as petri dish, flask, plate, bag, cartridge, cassette and the like, a structure having continuous pores (e.g., filter) such as non-woven fabric, fiber, porous material, spherical carrier and the like, and the like.
- a tool having a flat plate structure such as petri dish, flask, plate, bag, cartridge, cassette and the like
- a structure having continuous pores (e.g., filter) such as non-woven fabric, fiber, porous material, spherical carrier and the like, and the like.
- a substrate of the isolation material to be used in the present invention is petri dish, flask, plate, bag, cartridge, cassette and the like
- its form and size are not particularly limited.
- the materials thereof are not particularly limited.
- an inert polymer, or a metal material such as bioaffinity metal, alloy thereof and the like, and the like are preferably used.
- a material coated or plated with such inert polymer, bioaffinity metal and the like may be used.
- the inert polymer examples include acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like, halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene and the like, polyamide, polysulfone, polycarbonate, polyethylene, polypropylene, vinyl chloride-acrylic copolymer, carbonate-acrylonitrile-butadiene-styrene copolymer, styrene-butadiene copolymer, polystyrene and the like.
- acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like
- halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene
- metal material examples include stainless steel, titanium, platinum, tantalum, gold, alloys thereof, as well as gold-plated alloy iron, platinum-plated alloy iron, cobalt chromium alloy, titanium nitride-coated stainless steel and the like.
- a germproof or sterile material is particularly preferable.
- glass, polypropylene, polyvinyl chloride, polycarbonate, polysulphone, polymethylpentene and the like coated with silicon can be mentioned.
- a material having a gas permeable structure is also used preferably.
- the material having a gas permeable structure include a material having an ultrafine pore structure or a slit structure of the level permitting suppression of contamination, a material inherently having high gas permeability and the like.
- the material inherently having high gas permeability include, but are not limited to, polymethylpentene, cyclic polyolefin, olefin type thermoplastic elastomer, styrene type thermoplastic elastomer, polyamide type thermoplastic elastomer and the like.
- a substrate of the isolation material to be used in the present invention may be a non-woven fabric or a porous material.
- an average pore size of the substrate is, for example, preferably within the range of 9 ⁇ m-80 ⁇ m.
- the material of the substrate is not particularly limited, it is, for example, a synthetic polymer such as polyurethane, polystyrene, polyethylene, polyolefin, polyacrylamide, polyester, nylon, polyimide, aramid, polyamide, acrylic resin and the like, a natural polymer such as chitin, chitosan, acetyl cellulose, cellulose, rayon, agarose, alginic acid and the like, an inorganic material such as hydroxyapatite, glass, alumina and the like, a metal such as stainless, titanium and the like, and the like.
- the porous state form may be any form such as sponge-like, felt-like, cotton-like, fiber-like, particles-like, pipy, discotic and cylindrical shape forms and the like.
- a substrate of the isolation material is a spherical carrier, its particle size is preferably 10 ⁇ m-2000 ⁇ m, more preferably 70 ⁇ m-1000 ⁇ m, from treatment efficiency.
- the material of the spherical carrier examples include, but are not limited to, inorganic carriers such as glass beads, silica gel and the like, synthetic polymer compounds such as crosslinked polyvinyl alcohol, crosslinked polyacrylate, crosslinked polyacrylamide, crosslinked polystyrene, ethylene-vinyl acetate copolymer saponifiable substance, crosslinked polyacrylic acid, crosslinked polymethacrylic acid, polymethyl methacrylate, polyacrylamide grafted polyethylene and the like, organic carrier comprised of polysaccharides such as crystalline cellulose, crosslinked cellulose, cellulose derivatives, crosslinked agarose, crosslinked dextrin, chitin, chitosan and the like, composite carriers obtained by combining them, such as organic-organic, organic-inorganic composite carriers and the like, and the like.
- inorganic carriers such as glass beads, silica gel and the like
- synthetic polymer compounds such as crosslinked polyvinyl alcohol, crosslinked polyacrylate, crosslinked polyacryl
- isolation material may be directly used as a harvesting method of cell, protein and the like, or can also be used in the form of an isolation device.
- the “isolation device” means a device wherein the aforementioned isolation material is contained at least in one part of a container having a liquid inlet and/or a liquid outlet.
- the isolation material preferably used for the isolation device of the present invention is a structure having continuous pores, such as non-woven fabric, fiber, porous material, spherical carrier, filter and the like.
- the isolation device of the present invention refers to a device wherein such isolation material structure is mounted on or filled in a container suitable for the form thereof, such as column, bag, cassette and the like, or housed in an incubator such as flask, bag and the like, and the like.
- the aforementioned isolation material is filled in the aforementioned container.
- the form, material and size of the container are not particularly limited, and any form such as dish/bottle, bag, tube, column, cassette, flask and the like may be employed.
- Examples of the isolation device of the present invention include an isolation device in the form of a column of an about 0.1-500 ml transparent or translucent cylindrical container having a diameter of about 0.1-10 cm filled with a structure having continuous pores such as spherical carrier etc., and the like.
- the device is preferably mounted on or filled in a container having a body fluid inlet and a body fluid outlet to divide the body fluid inlet from the body fluid outlet to give a filter or a cross-flow module.
- a non-woven fabric or a porous material When a non-woven fabric or a porous material is mounted on or filled in a container, it may form a single layer or a laminate of a plurality thereof, or it may also be combined with a material having a surface not constituted with a substance having a sugar structure and then mounted on or filled in a container.
- Such isolation device is useful for harvesting, for example, cell (e.g., monocyte and the like), protein (e.g., lectin such as ConA (concanavalin A), WGA (wheat germ agglutinin) etc., and the like) and the like.
- cell e.g., monocyte and the like
- protein e.g., lectin such as ConA (concanavalin A), WGA (wheat germ agglutinin) etc., and the like
- lectin such as ConA (concanavalin A), WGA (wheat germ agglutinin) etc., and the like
- the material of the container for the isolation device of the present invention is not particularly limited, inert polymer or a metal material such as a bioaffinity metal or an alloy thereof etc., and the like are used. Alternatively, a material coated or plated with such inert polymer or bioaffinity metal may be used.
- the inert polymer examples include acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like, halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene and the like, polyamide, polysulfone, polycarbonate, polyethylene, polypropylene, vinyl chloride-acrylic copolymer, carbonate-acrylonitrile-butadiene-styrene copolymer, styrene-butadiene copolymer, polystyrene and the like.
- acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like
- halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene
- metal material examples include stainless steel, titanium, platinum, tantalum, gold, and alloys thereof, as well as gold-plated alloy iron, platinum-plated alloy iron, cobalt chromium alloy, titanium nitride-coated stainless steel and the like.
- a germproof or sterile material is particularly preferable.
- Specific examples include glass, polypropylene, polyvinyl chloride, polycarbonate, polysulphone, polymethylpentene and the like coated with silicon.
- a cell harvesting method using the isolation material of the present invention is explained in detail in the following.
- a method of harvesting a cell in the present invention includes contacting the aforementioned isolation material of the present invention with a body fluid, and specifically includes the following steps 1)-3) in this order:
- step for trapping a cell e.g., monocyte and the like
- a cell e.g., monocyte and the like
- the isolation material containing, on at least a part of the surface, a substance having a sugar structure
- the isolation material can also be used in the form of the aforementioned isolation device.
- the “body fluid” encompasses, but is not limited to, blood (e.g., peripheral blood, cord blood, peripheral blood induced by cytokines (e.g., G-CSF and the like) and the like), bone marrow, lymph, pleural fluid, ascites, synovia and the like harvested from a living organism, for example, mammals (human, monkey, rat, mouse, dog, cat, rabbit, bovine, swine, sheep, goat, horse and the like, preferably human) sample, as well as apheresis products, centrifugation treatment liquid, cell suspension (e.g., including cell suspension containing cells subjected to a specific gravity density centrifugation treatment using, when desired, ficoll, percoll, vacutainer tube, lymphoprep, HES (hydroxyethylstarch) and the like) and the like, of these body fluids.
- blood e.g., peripheral blood, cord blood, peripheral blood induced by cytokines (e.g., G
- the method of the present invention is particularly suitable for blood as a body fluid.
- a body fluid can be harvested from a test sample by any method known in the field.
- heparin low molecular weight heparin, nafamostat mesylate, gabexate mesylate, aragatroban, a citric acid-containing anticoagulant such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, and the like may be used as a generally used anticoagulant.
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- citric acid-containing anticoagulant and heparin are most preferable.
- a cell is trapped in an isolation material by contacting a body fluid with an isolation material containing a substance having a sugar structure in at least one part of a surface.
- a target body fluid is injected into the isolation material of the present invention using a petri dish, a flask, a plate, a bag, a cartridge, a cassette and the like as a substrate, and the material is stood or shaken for 5 min-120 min to contact the body fluid with the isolation material, whereby cell is trapped in the isolation material.
- the contact (standing or shaking) time is more preferably 15 min-90 min.
- step 2) the isolation material is washed with a washing liquid to remove untrapped cells.
- a method of removing the untrapped cells is not particularly limited, for example, a method wherein a body fluid is first removed by suction with a pipette, a syringe and the like or decantation and the like, saline, culture medium, buffered solution and the like are injected again in the isolation material to wash away the attached cells, and finally, the supernatant is removed by the aforementioned suction or decantation and the like, and the like can be mentioned.
- the method may be repeated several times.
- the trapped cell is collected from the isolation material.
- the trapped cell can be collected, for example, by contacting a collection liquid containing saline, a medium, a cell preservation solution and the like, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, a sugar-containing cell collection liquid and the like with the isolation material after washing in the above-mentioned step 2).
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material for example, a cell collection liquid containing sugar such as mannose, glucose, galactose, fucose or a mixture thereof is preferably used.
- the sugar concentration of a sugar-containing cell collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1 ⁇ 5 of the saturated solubility.
- the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- the cells are contacted with the above-mentioned cell collection liquid for about 3 min-30 min while standing or shaking them.
- cells can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the trapped cells (for example, flashing and the like) and the like.
- the means for pushing may be, but not limited to, air, inert gas, saline and the like.
- cooling down to 4° C. or heating up to 37° C. may be concurrently performed.
- the above-mentioned collection operation may be repeated.
- step 1) a cell is trapped in an isolation material by contacting a body fluid with a device comprising the above-mentioned isolation material in at least one part of a container having a liquid inlet and/or a liquid outlet.
- “contacting a body fluid with an isolation device” means passing a body fluid through an isolation device.
- passing a liquid means introducing a body fluid from a liquid inlet of an isolation device, transporting the fluid in a given direction and discharging the fluid from a liquid outlet.
- the means for introducing a body fluid into an isolation device may be, but not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like.
- the liquid passage rate is preferably 0.1 ml/min-100 ml/min, and a body fluid may be passed through the device once, or plural times by a circulation treatment.
- step 2) the isolation device is washed with a washing liquid to remove untrapped cells.
- a washing liquid include, but are not limited to, saline, Ringer's solution, buffer such as phosphate buffer and the like, cell culture medium such as RPMI1640 and the like.
- the means for introducing a washing liquid may be, but is not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like.
- the flow rate of liquid passage using a pump is about 0.1 ml/min-100 ml/min. While the amount of the washing liquid varies depending on the isolation material used for an isolation device and the content volume of the isolation device, washing with a volume of about 1- to 5-fold the content volume is preferable.
- the trapped cell is collected from the isolation device.
- the trapped cell is collected, for example, by passing a collection liquid containing saline, a medium, a cell preservation solution and the like, a collection liquid containing a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, a sugar-containing cell collection liquid, and the like through the above-mentioned isolation device.
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material in a separation device for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used.
- the sugar concentration of a collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1 ⁇ 5 of the saturated solubility.
- the sugar-containing cell collection liquid may contain a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- the above-mentioned isolation device is preferably contacted with the collection liquid for about 3 min-30 min and the contact method may be a leaving method, a circulation method and the like.
- the flow rate during circulation is preferably 0.1 ml/min-200 ml/min. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When the cell collection is insufficient, the above-mentioned collection operation may be repeated.
- the method of the present invention is particularly suitable for harvesting a monocyte.
- Monocyte is a monocyte type cell derived from a hematopoietic stem cell, and used for the fields of regenerative medicine and cell medicine such as vascular regeneration, differentiation induction into dendritic cells and the like.
- the obtained monocytes can be used as the cells for vascular regeneration and the like.
- the monocytes harvested by the method of the present invention can also be used as a precursor cell in the below-mentioned “method of preparing a dendritic cell”.
- the present invention also relates to a preparation method of dendritic cell and the dendritic cell obtained the method.
- the method of preparing a dendritic cell of the present invention includes a method including a step wherein the monocytes trapped in the isolation material by the above-mentioned method of the present invention are collected from the isolation material and differentiation induction thereof into dendritic cells is induced, and a method including a step wherein the monocytes trapped in the isolation material are, without collection, induced in situ to differentiate into dendritic cells.
- dendritic cell means immature dendritic cell obtained by inducing monocyte with cytokines such as IL-4, GM-CSF and the like to differentiate thereinto, mature dendritic cell obtained by inducing immature dendritic cell by adding cytokines such as TNF ⁇ , IL1- ⁇ , IL-6, PGE2 and the like to differentiate thereinto, antigen-presenting dendritic cell (e.g., dendritic cell presenting cancer antigen and the like) obtained via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- cytokines such as IL-4, GM-CSF and the like
- mature dendritic cell obtained by inducing immature dendritic cell by adding cytokines such as TNF ⁇ , IL1- ⁇ , IL-6, PGE2 and the like to differentiate thereinto
- antigen-presenting dendritic cell e.g., dendritic cell
- a method of preparing the dendritic cell of the present invention is explained in detail the following.
- dendritic cells can be prepared by harvesting monocytes using the aforementioned method of the present invention, which is followed by induction of differentiation.
- a step for inducing the monocytes to differentiate into dendritic cells can be performed, for example, as in the following.
- Monocytes are placed in a container generally used for cell culture such as petri dish, flask and the like, and a culture medium containing cytokines such as GM-CSF, IL-4 and the like is added. By culturing the cells for about 1 week, the monocytes can be induced to differentiate into immature dendritic cells. By further culturing the cells in a culture medium containing cytokines such as IL-1 ⁇ , PGE2, IL-6, TNF- ⁇ and the like for about 1 week, immature dendritic cells can be induced to differentiate into mature dendritic cells.
- cytokines such as IL-1 ⁇ , PGE2, IL-6, TNF- ⁇ and the like
- the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- antigen-presenting dendritic cells e.g., dendritic cells presenting cancer antigen and the like
- an antigen-presenting capability e.g., addition of cancer antigen
- the obtained dendritic cell can be collected by, for example, a general collection means such as pipetting and the like.
- a preferable embodiment of this method includes the following steps 1)-4) in this order:
- the isolation material can be used in the form of an isolation device as mentioned above.
- steps 1) and 2) can be performed according to steps 1) and 2) of the aforementioned “cell harvesting method”. Steps 3) and 4) are explained in detail in the following.
- step 3 monocytes trapped in the isolation material are further induced to differentiate into dendritic cells.
- untrapped cells are removed by washing in step 2), a culture medium containing cytokines such as GM-CSF, IL-4 and the like is added to monocytes trapped in the isolation material, and the monocytes are cultured for about 1 week to differentiated monocytes trapped in the isolation material into immature dendritic cells. Thereafter, the immature dendritic cells are cultured in a culture medium containing cytokines such as IL-1 ⁇ , PGE2, IL-6, TNF- ⁇ and the like for about 1 week to induce differentiation into mature dendritic cells.
- cytokines such as GM-CSF, IL-4 and the like
- the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- antigen-presenting dendritic cells e.g., dendritic cells presenting cancer antigen and the like
- an antigen-presenting capability e.g., addition of cancer antigen
- the dendritic cell after differentiation induction is collected from the isolation material.
- the dendritic cell can be collected by a pipetting operation, use of a cell collection liquid containing a divalent cation chelating agent such as an acid citrate dextrose liquid (ACD liquid), a citrate phosphate dextrose liquid (CPD liquid) and the like, and the like, which are generally employed therefor.
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- a collection method using a sugar-containing collection liquid is advantageous.
- a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material for example, a cell collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is used.
- the sugar concentration of a sugar-containing collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1 ⁇ 5 of the saturated solubility.
- the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- the dendritic cell is contacted with the above-mentioned cell collection liquid for about 3 min-30 min by leaving or shaking.
- dendritic cells can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like.
- the means for pushing out may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When collection of the dendritic cell is insufficient, the above-mentioned collection operation may be repeated.
- Isolation Device Comprised of a Container Packed with an Isolation Material Comprised of a Structure Having Continuous Pores Such as Non-Woven Fabric, Fiber, Porous Material, Spherical Carrier, Filter and the Like is Used
- step 3 monocytes trapped in the above-mentioned isolation device are further induced to differentiate into dendritic cells.
- a culture medium containing cytokines such as GM-CSF, IL-4 and the like is passed through an isolation device, after which the monocytes are cultured in a culture medium containing cytokines such as GM-CSF, IL-4 and the like for about 1 week, whereby the monocytes are differentiated into immature dendritic cells.
- a culture medium containing cytokines such as IL-1 ⁇ , PGE2, IL-6, TNF- ⁇ and the like is further passed, the cells are cultured in a culture medium containing cytokines such as IL-1 ⁇ , PGE2, IL-6, TNF- ⁇ and the like for about 1 week to induce differentiation of the immature dendritic cells into mature dendritic cells.
- the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability by passing or contacting a culture medium containing an antigen (e.g., cancer antigen).
- antigen-presenting dendritic cells e.g., dendritic cells presenting cancer antigen and the like
- a step of acquiring an antigen-presenting capability by passing or contacting a culture medium containing an antigen (e.g., cancer antigen).
- the dendritic cell after differentiation induction in the above-mentioned step 3) is collected from the isolation device.
- the dendritic cell after differentiation induction can be collected by passing a collection liquid generally used or passing a cell collection liquid containing a divalent cation chelating agent such as an acid citrate dextrose liquid (ACD liquid), a citrate phosphate dextrose liquid (CPD liquid) and the like through the isolation device.
- ACD liquid acid citrate dextrose liquid
- CPD liquid citrate phosphate dextrose liquid
- a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation device for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is used.
- the sugar concentration of a sugar-containing collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1/5 of the saturated solubility.
- the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- the dendritic cell is preferably contacted with the above-mentioned cell collection liquid for about 3 min-30 min.
- the contact method may be a method wherein a collection liquid is passed through an isolation device, and the isolation device is maintained for a given time under leaving or shaking, a method wherein a collection liquid is circulated through an isolation device and the like.
- the flow rate during circulation is preferably 0.1 ml/min-200 ml/min.
- a method of collecting dendritic cells after a contact for a given time may be a method of collecting dendritic cells by application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like.
- the means for pushing out dendritic cells may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When collection of the dendritic cell is insufficient, the above-mentioned collection operation may be repeated.
- a method of harvesting protein using the isolation material or isolation device of the present invention is explained in detail in the following.
- the method of harvesting protein of the present invention includes performing
- a protein-containing liquid is prepared as follows. A material containing protein is disrupted in Tris buffer (pH 7.4), centrifuged and the supernatant is collected. A 45% saturated ammonium sulfate is added thereto and sufficiently dissolved, and the mixture is left standing for 1 hr or longer, centrifuged to collect the precipitate, and dialyzed against 0.01M Tris buffer (pH 7.4). The dialysate is subjected to ion exchange chromatography to collect the object protein fraction, which is then contacted with the isolation material of the present invention, containing, on at least a part of the surface, a substance having a sugar structure.
- Isolation Material or its Substrate has a Form of Petri Dish, Flask, Plate, Bag, Cartridge, Cassette and the Like
- step 1) proteins are trapped in an isolation material by contacting a protein-containing liquid with an isolation material containing a substance having a sugar structure in at least one part of a surface.
- a target protein-containing liquid is injected into the isolation material of the present invention using a petri dish, a flask, a plate, a bag, a cartridge, a cassette and the like as a substrate, and the material is left standing or shaken for 5 min-120 min to contact the protein-containing liquid with the isolation material, whereby proteins are trapped in the isolation material.
- the contact (standing or shaking) time is more preferably 15 min-90 min.
- step 2) the isolation material is washed with a washing liquid to remove untrapped proteins.
- a method of removing the untrapped proteins is not particularly limited, for example, a method wherein a protein-containing liquid is first removed by suction with a pipette, a syringe and the like or decantation and the like, a buffered solution and the like are injected again into the isolation material to wash away the attached proteins, and finally, the supernatant is removed by the aforementioned suction or decantation and the like, and the like can be mentioned.
- the method may be repeated several times.
- step 3 the trapped proteins are collected from the isolation material.
- the trapped proteins can be collected, for example, by contacting a sugar-containing solution and the like with the isolation material after washing in the above-mentioned step 2).
- a solution containing the same kind of sugar as the sugar structure constituting a part of the isolation material for example, a solution containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used.
- the sugar concentration of a sugar-containing solution may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1/5 of the saturated solubility.
- the sugar-containing solution preferably contains a buffer such as a phosphate buffer and the like.
- the protein is contacted with the above-mentioned cell collection liquid for about 3 min-30 min while leaving or shaking them.
- the protein can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like.
- the means for pushing may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. may be concurrently performed. When recovery rate of the protein is insufficient, the above-mentioned collection operation may be repeated.
- Isolation Device Comprised of a Container Having, in at Least One Part Thereof, an Isolation Material Comprised of a Structure Having Continuous Pores Such as Non-Woven Fabric, Fiber, Porous Material, Spherical Carrier, Filter and the Like is Used
- step 1) proteins are trapped in an isolation material by contacting a protein-containing liquid with a device comprising the above-mentioned isolation material in at least one part of a container having a liquid inlet and/or a liquid outlet.
- “contacting a protein-containing liquid with an isolation device” means passing a protein-containing liquid through an isolation device.
- passing a liquid means introducing a protein-containing liquid from a liquid inlet of an isolation device, transporting the liquid in a given direction and discharging the liquid from a liquid outlet.
- the means for introducing a protein-containing liquid into an isolation device may be, but not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like.
- the liquid passage rate is preferably 0.1 ml/min-100 ml/min, and the liquid may be passed through the device once, or plural times by a circulation treatment.
- step 2) the isolation device is washed with a washing liquid to remove untrapped proteins.
- a washing liquid include, but are not limited to, buffers such as Tris buffer, phosphate buffer and the like.
- the means for introducing a washing liquid may be, but is not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like.
- the flow rate of liquid passage using a pump is about 0.1 ml/min-100 ml/min. While the amount of the washing liquid varies depending on the isolation material used for an isolation device and the content volume of the isolation device, washing with a volume of about 1- to 5-fold the content volume is preferable.
- step 3 trapped proteins are collected from an isolation device. Specifically, proteins are collected by passing a sugar-containing solution and the like through the above-mentioned isolation device. Particularly, from the aspects of protein collection efficiency, a collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material in the isolation device, for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used.
- the sugar concentration of a sugar-containing solution may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C.
- the sugar-containing solution preferably contains a buffer such as a phosphate buffer and the like.
- the above-mentioned isolation device is preferably contacted with the collection liquid for about 3 min-30 min, and the contact method may be leaving method, circulation method and the like.
- the flow rate during circulation is preferably 0.1 ml/min-200 ml/min. In this case, to increase collection efficiency, cooling down to 4° C. may be concurrently performed. When collection of the protein is insufficient, the above-mentioned collection operation may be repeated.
- the method of the present invention is particularly suitable for harvesting lectin.
- Lectin is a generic term of proteins that recognize a sugar chain. Lectin specifically binds to a sugar chain having a particular structure, which is present in blood cell, cell surface and the like, and coagulates blood cells and cells.
- Lectin harvested in the present invention can be used as a cell fractionation reagent, a clinical diagnostic reagent, a clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like.
- lectin may be collected from an isolation device by the above-mentioned method and used, or directly used as a lectin-isolation device composition.
- a sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1] a carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2]
- an acid-modified oligosaccharide-containing polyurethane represented by the formula [2-1] an acid-modified sugar residue-modified oligosaccharide represented by the formula [3-1] of the present invention, which are used as sugar chain-containing polymers in the method of the present invention, as well as an oligosaccharide-containing polyurethane represented by the formula [1-3] used as an intermediate in the present invention are each explained in detail hereunder.
- R 1 is a divalent C 1-16 hydrocarbon group optionally having substituent(s).
- a straight chain or branched chain divalent C 1-16 aliphatic hydrocarbon group e.g., a straight chain or branched chain C 1-16 alkylene group (e.g., methylene, ethylene, tetramethylene, pentamethylene, hexamethylene, octamethylene, hexadecamethylene etc.), a straight chain or branched chain C 2-16 alkenylene group (e.g., vinylene, propenylene etc.), C 3-16 cycloalkylene (e.g., cyclohexylene) and the like], (2) a divalent C 6-14 aromatic hydrocarbon group [e.g., a C 6-14 arylene group (e.g., phenylene, naphthylene, biphenylene etc.) and the like], (3) a hydrocarbon group having 7 to 16 carbon atoms, which contains at least one group selected from the aforementioned straight chain or branched chain divalent C 1-16 aliphatic hydrocarbon group and
- a C 1-6 alkyl group e.g., methyl etc.
- a C 3-8 cycloalkyl group e.g., cyclohexyl etc.
- a C 6-14 aryl group e.g., phenyl etc.
- the same or different, 1 to 8, preferably 1 to 4, of these substituents may be present at substitutable position(s) of the above-mentioned “divalent C 1-16 hydrocarbon group”.
- R 1 examples include a tetramethylene group, a pentamethylene group, a hexamethylene group, an octamethylene group, a hexadecamethylene group, a vinylene group, a propenylene group, a phenylene group, a naphthylene group, a phenylmethylene group, a phenylethylene group, a biphenyl group, a bisphenylmethylene group, a bisphenylethylene group, a phenylene group (e.g., paraphenylene group), a xylylene group, a tetramethylxylylene group, a tolylene group, dicyclohexylmethylene group,
- R 2 is a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s).
- Examples thereof include a divalent group containing the same or different 1 to 100 units in total selected from C 2-12 oxyalkylene, a divalent group containing the same or different 1 to 100 units in total selected from divalent C 2-12 hydrocarbon unit optionally having substituent(s), and a divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s).
- divalent group containing the same or different 1 to 100 units in total selected from a C 2-12 oxyalkylene unit and a divalent C 2-12 hydrocarbon unit optionally having substituent(s) is, for example, a divalent group containing the same or different 1 to 100 units in total selected from a unit represented by the formula —(BO) h-1 —B— and a unit represented by the formula -(E) i -, wherein B is at least one kind of C 2-12 alkylene unit, E is at least one kind of the same or different unit selected from a divalent C 2-12 hydrocarbon unit optionally having substituent(s), and h and i are each an integer of 1 ⁇ h ⁇ 100 and 1 ⁇ i ⁇ 100, respectively.
- the “C 2-12 alkylene group” for B may be a straight chain or branched, and when a plurality of B are present in the unit (2 ⁇ h ⁇ 100), B may be one kind or two or more kinds.
- BO include an alkyleneoxy group such as an ethyleneoxy group, a propyleneoxy group, a trimethylenoxy group, a butyleneoxy group, a tetramethyleneoxy group and the like, and specific examples of the unit represented by the formula —(BO) h-1 —B— include a unit represented by the formula —CH 2 —CH 2 —O—CH 2 —CH 2 —CH 2 — and the like.
- the divalent hydrocarbon unit of the “divalent C 2-12 hydrocarbon unit optionally having substituent(s)” for E may be a straight chain or branched, and a saturated group or an unsaturated group and, for example, C 2-12 alkylene (e.g., ethylene, trimethylene, tetramethylene, hexamethylene, nonamethylene etc.), C 2-12 alkenylene (e.g., butadienylene, butenylene etc.) and the like can be mentioned.
- C 2-12 alkylene e.g., ethylene, trimethylene, tetramethylene, hexamethylene, nonamethylene etc.
- C 2-12 alkenylene e.g., butadienylene, butenylene etc.
- Examples of the “substituent” that the “divalent C 2-12 hydrocarbon unit” optionally has include a halogen atom (e.g., fluorine atom etc.), a C 1-6 alkyl group (e.g., methyl etc.) and the like.
- a halogen atom e.g., fluorine atom etc.
- a C 1-6 alkyl group e.g., methyl etc.
- E may be one kind or two or more kinds.
- Such unit represented by the formula -(E) i - include an ethylene group, a trimethylen group, a tetramethylene group, a hexamethylene group, a nonamethylene group, a —CH 2 —CF 2 —CF 2 —CF 2 —CF 2 —CH 2 — group, a butadienylene group, a hydrogenated butadienylene group, a divalent group such as a group derived by eliminating one hydrogen atom from each of the carbon atoms on both chain ends of hydrogenated isoprene and the like, and the like.
- R 2 may further contain, in addition to the unit selected from a unit represented by the above-mentioned formula —(BO) h-1 —B— wherein B and h are as defined above and/or a unit represented by the formula -(E) i - wherein E and i are as defined above, other repeat unit [for example, repeat unit such as alkylene ester groups (e.g., ethyleneadipate group, propyleneadipate group, butyleneadipate group, hexamethyleneadipate group, neopentyladipate group and the like), alkylenecarbonate groups (e.g., hexamethylenecarbonate group and the like), a ring-opening caprolactone group, a poly(dimethylsiloxy)dimethylsilyl group and the like].
- alkylene ester groups e.g., ethyleneadipate group, propyleneadipate group, butyleneadipate group, hexamethyleneadipate group,
- R 2 containing such unit include a divalent group derived by eliminating OH from both ends of polyethylene adipatediol and the like, a poly(dimethylsiloxy)dimethylsilyl-n-propylbisethoxy group and the like.
- R 2 a divalent group having a repeat unit such as an ethyleneoxy group, a propyleneoxy group, an ethyleneadipate group, a propyleneadipate group, a hexamethylenecarbonate group, a ring-opening caprolactone group and the like, a trimethylen group, a tetramethylene group, a —CH 2 —CF 2 —CF 2 —CF 2 —CF 2 —CH 2 — group, a hydrogenated butadienylene group, a divalent group derived by eliminating one hydrogen atom from each of the carbon atoms on both chain ends of hydrogenated isoprene, a polydimethyl siloxy dimethylsilyl-n-propylbisethoxy group and the like are preferable.
- a divalent group having a repeat unit such as an ethyleneoxy group, a propyleneoxy group, an ethyleneadipate group, a propyleneadipate group, a hexamethylenecarbonate group
- R 3 is a C 2-4 alkylene group.
- Specific examples include an ethylene group, a trimethylen group, a tetramethylene group and the like. Of these, an ethylene group and a trimethylen group are preferable, and an ethylene group is more preferable.
- R 4 is a monosaccharide- or disaccharide-derived sugar residue.
- the sugar residue is a residue obtained by removing a certain hydroxyl group from sugar.
- Examples of the monosaccharide and disaccharide usable for R 4 include glucose, mannose, galactose, lactose and the like.
- R 4 is a sugar residue derived from glucose, mannose or galactose, and a sugar residue derived from glucose is more preferable.
- OLS is the skeleton of oligosaccharide.
- the skeleton of oligosaccharide is a residue obtained by removing all hydroxyl group moieties from oligosaccharide.
- the oligosaccharide to be used in the present invention is not particularly limited as long as it is an oligosaccharide having two primary hydroxyl groups, which may be any of disaccharide, trisaccharide and tetrasaccharide.
- disaccharides such as trehalose, maltose, lactose, cellobiose and the like, cyclic tetrasaccharides such as cyclo ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ etc., and the like.
- disaccharides such as trehalose, maltose, lactose and the like are preferable from the aspects of cost and reactivity.
- r shows the total number of secondary hydroxyl groups of oligosaccharide. For example, when OLS is disaccharide, trisaccharide or tetrasaccharide, r is 6, 9 or 12, respectively, and when OLS is cyclic tetrasaccharide, r is 10.
- p shows the number of the secondary hydroxyl groups modified with diacid and amino sugar (group represented by the formula —O 2 C—R 3 —CO—NH—R 4 ; R 3 and R 4 are as defined above) of oligosaccharide, which is an integer within the range of 1 ⁇ p ⁇ r.
- q shows the number of the secondary hydroxyl groups modified with diacid (group represented by the formula HO 2 C—R 3 —CO 2 —; R 3 is as defined above) of oligosaccharide, which is an integer within the range of 0 ⁇ q ⁇ r ⁇ 1.
- p+q shows the number of the secondary hydroxyl groups modified with diacid (group represented by the formula HO 2 C—R 3 —CO 2 —; R 3 is as defined above) of oligosaccharide, which is each an integer within the range of 1 ⁇ p ⁇ r, 0 ⁇ q ⁇ r ⁇ 1.
- m and n are numbers of repeat units, m is an integer of 0-1000 and n is an integer of 1-1000, n/(m+n) is a number within the range of 0.01-1.00, preferably within the range of 0.02-0.80 from the aspects of the balance of water absorbability, polymer strength and polymer formability.
- the arrangement of repeat units in the formulas [1-1], [1-2], [1-3], [2-1] and [3-1] can be either of regular and irregular.
- s shows the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1 ⁇ s ⁇ r.
- the “acid-containing group” is a group represented by the formula XM in the formula [2-1] wherein X and M are as defined above.
- acid-derived moiety for the above-mentioned X may be of any kind as long as polyurethane represented by the formula [2-1] has desired properties, SO 3 or PO 3 is preferable and SO 3 is more preferable.
- alkali metal atom for the above-mentioned M examples include a sodium atom, a potassium atom, a lithium atom and the like, with preference given to a sodium atom and a potassium atom.
- Examples of the organic amino group for the above-mentioned M include an amino group 1 to 3 C 1-6 alkyl groups [for example, mono-C 1-6 alkylamino group (e.g., monomethylamino group, monoethylamino group, monopropylamino group, monobutylamino group, monopentylamino group, monohexylamino group), a di-C 1-6 alkylamino group [for example, dimethylamino group, diethylamino group, dipropylamino group (e.g., di-n-propylamino group, di-iso-propylamino group), dibutylamino group], tri-C 1-6 alkylamino group (e.g., trimethylamino group, triethylamino group)], a C 6-14 aromatic amino group [for example, a C 6-14 aralkylamino group (e.g., benzylamino group), a C 6-14
- p shows the number of the secondary hydroxyl groups modified with an acid-containing group (group represented by the formula —O 2 C—R 3 —CO—NH—R 4 —(XM) s ; R 3 , R 4 , X, M and s are as defined above) of oligosaccharide modified with diacid and amino sugar.
- the “acid-containing group” is a group represented by the formula XMa in the formula [3-1] wherein X and M are as defined above.
- acid-derived moiety for the above-mentioned X may be of any kind as long as polyurethane represented by the formula [3-1] has desired properties, SO 3 or PO 3 is preferable and SO 3 is more preferable.
- alkali metal atom for the above-mentioned M examples include a sodium atom, a potassium atom, a lithium atom and the like, with preference given to a sodium atom and a potassium atom.
- Examples of the organic amino group for the above-mentioned M include an amino group having 1 to 3 C 1-6 alkyl groups [for example, mono-C 1-6 alkylamino group (e.g., monomethylamino group, monoethylamino group, monopropylamino group, monobutylamino group, monopentylamino group, monohexylamino group), di-C 1-6 alkylamino group [for example, dimethylamino group, diethylamino group, dipropylamino group (e.g., di-n-propylamino group, di-iso-propylamino group), dibutylamino group], tri-C 1-6 alkylamino group (e.g., trimethylamino group, triethylamino group)], a C 6-14 aromatic amino group [for example, C 6-14 aralkylamino group (e.g., benzylamino group), C 6-14 aromatic heterocycleamin
- the production methods of the sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1], the carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2], and the oligosaccharide-containing polyurethane (intermediate) represented by the formula [1-3] in the present invention are each explained below.
- the oligosaccharide-containing polyurethane represented by the formula [1-3] can be obtained by reacting an oligosaccharide represented by the formula [1-6]:
- R 2 is as defined above, with a diisocyanate represented by the following formula [1-8]:
- R 2 is as defined above.
- the oligosaccharide represented by the formula [1-6] may be mixed, where necessary, with the diol represented by the formula [1-7] and the mixture is reacted with the diisocyanate represented by the formula [1-8] (one-shot method), or the diisocyanate represented by the formula [1-8] may be reacted, where necessary, with the diol represented by the formula [1-7] to give a prepolymer, which is then reacted with the oligosaccharide represented by the formula [1-6] (prepolymer method 1), or the oligosaccharide represented by the formula [1-6] may be reacted with the diisocyanate represented by the formula [1-8] to give a prepolymer, which is then reacted, where necessary, with the diol represented by the formula [1-7] (prepolymer method 2).
- the oligosaccharide represented by the formula [1-6] the diisocyanate represented by the formula [1-8] and the diol represented by the formula [1-7] each may be one kind or a mixture of two or more kinds.
- diisocyanate of the aforementioned formula [1-8] to be used in the present invention examples include tetramethylenediisocyanate, pentamethylenediisocyanate, hexamethylenediisocyanate, octamethylenediisocyanate, hexadecamethylenediisocyanate, vinylenediisocyanate, propenylenediisocyanate, naphthylenediisocyanate, phenylmethanediisocyanate, diphenylmethanediisocyanate, phenylethanediisocyanate, diphenylethanediisocyanate, phenylenediisocyanate (e.g., paraphenylenediisocyanate), biphenyldiisocyanate, xylylenediisocyanate, tetramethylxylylenediisocyanate, tolylenediisocyanate, isophoronedi
- the diol represented by the formula [1-7] is not particularly limited as long as it has a primary hydroxyl group.
- Specific examples include low molecular weight diols such as ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,9-nonanediol, 2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol and the like; high molecular weight diols, for example, polyether diols such as polyethylene glycol, polytetramethylene ether glycol, polypropylene glycol, ethyleneoxide-propyleneoxide copolymer, tetrahydrofuran-ethylene oxide copolymer, tetrahydrofuran-propylene oxide copolymer and the like, polyester diols such as polyethylene adipate glycol, polydiethylene adipate glycol, polypropy
- the solvent used for producing the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3] may be any as long as it can dissolve the reaction product and the resulting polyurethane.
- Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof.
- the oligosaccharide represented by the aforementioned formula [1-6] and, where necessary, the diol represented by the formula [1-7] are added to a solution containing the diisocyanate represented by the formula [1-8] while passing a dry inert gas such as nitrogen and the like.
- the molar ratio of the above-mentioned reaction components charged is, for example, compound represented by the formula [1-8]: compound represented by the formula [1-7]: compound represented by the formula [1-6] preferably 3:0.01-2.99:0.01-3, more preferably 3:0.2-2.5:0.5-2.8.
- the reaction temperature of the above-mentioned reaction is preferably 10-150° C., more preferably 20-120° C., and the reaction time is preferably 1-10 hr, more preferably 2-6 hr.
- the polyurethane can be purified by, for example, feeding the reaction solution into a single or mixed solvent of methanol, acetone, water and the like, filtration, washing and, where necessary, repeating reprecipitation purification to give a solid content, which is dried under reduced pressure at room temperature ⁇ 100° C. for about 1-24 hr.
- R 1 , R 2 , R 3 , OLS, m, n, p, q and r are as defined above, can be produced by reacting the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3] with an acid anhydride represented by the formula [1-4]
- R 3 is are as defined above, and entirely or partially modifying the secondary hydroxyl group of oligosaccharide.
- the above-mentioned reaction is generally performed in a solvent.
- the solvent for carboxyl group modification may be any as long as it can dissolve the reaction product and the resulting polyurethane.
- Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof.
- a dibasic anhydride such as succinic anhydride, glutaric anhydride, adipic anhydride and the like is preferably used, and succinic anhydride is most preferable.
- the acid anhydride may be used alone or as a mixture of two or more kinds.
- the amount thereof to be used when a hydroxyl group of straight chain oligosaccharide in polyurethane is to be partially modified is 1- to (r ⁇ 1)-fold mol relative to the number of secondary hydroxyl groups (r) of oligosaccharide in polyurethane, and the amount when the aforementioned hydroxyl group is to be completely modified is r- to 2r-fold mol, preferably 1.2r- to 1.5r-fold mol.
- 4-dimethylaminopyridine or imidazole is preferably used in a proportion of 3-10 mol %, more preferably 5 mol %, as a catalyst.
- the reaction temperature of the above-mentioned reaction is 20-100° C., preferably 50-90° C., and the reaction time is 1-24 hr, preferably 2-20 hr.
- a carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2] of the present invention can be obtained.
- the polyurethane can be purified by, for example, feeding the reaction solution into a single or mixed solvent of methanol, acetone, water and the like to allow precipitation of a polymer, filtering, washing and, where necessary, repeating reprecipitation purification to give a solid content, which can be dried under reduced pressure at room temperature ⁇ 100° C. for about 1-24 hr.
- R 1 , R 2 , R 3 , R 4 , p, q, r, m, n and OLS are each as defined above, can be obtained by reacting a carboxyl group-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-2] with an aminated sugar represented by the following formula [1-5]:
- R 4 is as defined above.
- aminated sugar represented by the formula [1-5] for example, glucose amine, mannose amine, lactose amine, galactose amine and the like are preferable. Of these, glucose amine and mannose amine are more preferable, and glucose amine is most preferable from the aspects of cost.
- the aminated sugar may be used alone or as a mixture of two or more kinds. The amount thereof to be used is adjusted according to the object number of aminated sugar modifications relative to the number of carboxyl groups (p+q) in polyurethane represented by [1-2].
- the amount is 1- or 2-fold mol relative to the number of carboxyl groups (p+q), and when the number of aminated sugar modifications is not less than 3, the amount is 3-fold or more relative to the number of carboxyl groups (p+q).
- the above-mentioned reaction is generally performed in a solvent.
- the solvent may be any as long as it can dissolve the reaction product and the resulting polyurethane.
- Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof, and further, a mixed solvent thereof with methanol, ethanol, water.
- DMSO dimethyl sulfoxide
- NMP N-methyl-2-pyrrolidone
- DMF N,N-dimethylformamide
- DMAc N,N-dimethylacetamide
- the above-mentioned reaction is preferably performed in the presence of a condensation agent.
- a condensation agent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide (NHS) mixture, dicyclohexylcarbodiimide (DCC), 4(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) and the like are used.
- EDC/NHS mixture and DMT-MM are most preferable.
- the amount thereof to be used is 0.5- to 1.5-fold mol, preferably 0.8- to 1.2-fold mol, relative to the aminated sugar.
- the reaction temperature of the above-mentioned reaction is 20-60° C., preferably 30-50° C., and the reaction time is 5-36 hr, preferably 10-20 hr.
- a sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1] of the present invention can be obtained.
- the polyurethane can be purified by, for example, evaporating the reaction solvent, feeding a single or mixed solvent of methanol, water and the like to the concentrate to wash the polymer, filtering, and, where necessary, repeating reprecipitation purification to give a solid content, which can be dried under reduced pressure at room temperature ⁇ 100° C. for about 1-24 hr.
- the sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-1] and the carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping monocyte, lymphocyte, granulocyte, stem cell, virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials.
- physiological functions e.g., function of trapping monocyte, lymphocyte, granulocyte, stem cell, virus, protein and the like, and the like
- the physiological material here is, for example, a composition containing a polyurethane represented by the above-mentioned formula [1-1] or a polyurethane represented by the formula [1-2] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material.
- a solution or suspension wherein polyurethane is dissolved or suspended in an organic solvent (DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- the physiological material of the present invention can be used for various applications such as for contact with a body fluid such as blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- a body fluid such as blood and the like
- an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid
- an isolation device and an isolation filter e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like)
- acid modifying reagent for example, when X is SO 3 , trimethylaminesulfur trioxide complex, triethylaminesulfur trioxide complex, dimethylformamidesulfur trioxide complex, pyridinesulfur trioxide complex, chlorosulfonate and the like are used, and when X is PO 3 , orthophosphoric acid, polyphosphoric acid, diphosphorus pentoxide, phosphorus oxychloride and the like are used.
- the above-mentioned reaction is generally performed in a solvent.
- a solvent dimethylformamide, pyridine, dimethyl sulfoxide (DMSO) and the like are generally used.
- the reaction temperature is generally 0° C.-80° C., and the reaction time is generally 5 min-24 hr.
- the obtained compound is treated with an ion exchange resin (Na + type and the like) to convert M to an alkali metal atom (e.g., sodium atom and the like) and the like.
- the sulfated oligosaccharide-containing polyurethane represented by the above-mentioned formula [2-1] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials.
- physiological functions e.g., function of trapping virus, protein and the like, and the like
- the physiological material here is, for example, a composition containing a sulfated oligosaccharide-containing polyurethane represented by the above-mentioned formula [2-1] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material.
- examples thereof include, but are not limited to, a solution or suspension wherein polyurethane is dissolved or suspended in an organic solvent (DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- the physiological material of the present invention can be used for applications such as for contact with blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid
- an isolation device and an isolation filter e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- each symbol is as defined above, can be obtained by reacting the sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-1] with an acid modifying reagent.
- acid modifying reagent for example, when X is SO 3 , trimethylaminesulfur trioxide complex, triethylaminesulfur trioxide complex, dimethylformamidesulfur trioxide complex, pyridinesulfur trioxide complex, chlorosulfonic acid and the like are used, and when X is PO 3 , orthophosphoric acid, polyphosphoric acid, diphosphorus pentoxide, phosphorus oxychloride and the like are used.
- the above-mentioned reaction is generally performed in a solvent.
- a solvent dimethylformamide, pyridine, dimethyl sulfoxide (DMSO) and the like are generally used.
- the reaction temperature is generally 0° C.-80° C., and the reaction time is generally 5 min-24 hr.
- the obtained compound is treated with an ion exchange resin (Na + type and the like) to convert M to an alkali metal atom (e.g., sodium atom and the like) and the like.
- the acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [3-1] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials.
- physiological functions e.g., function of trapping virus, protein and the like, and the like
- the physiological material here is, for example, a composition containing an acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [3-1] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material.
- a solution or suspension wherein polyurethane is dissolved or suspended in a solvent (organic solvent such as DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- the physiological material of the present invention can be used for applications such as for contact with blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid
- an isolation device and an isolation filter e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- a mannobiose-bound polystyrene derivative (Poly[N-p-vinylbenzyl-O- ⁇ -D-mannopyranosyl-(1 ⁇ 4)-D-mannamide], manufactured by SEIKAGAKU CORPORATION) was dissolved in distilled water at a concentration of 0.1% (W/V). The solution (1 ml) was added to a commercially available 1 ml polystyrene petri dish (diameter 35 mm), and left standing at room temperature for about 1 hr. Then, the supernatant polymer was removed, and saline (1 ml) was added. Excess mannobiose-bound polystyrene derivative was washed, and the supernatant was removed. This operation was repeated 3 times to give a mannobiose-bound polystyrene derivative coated petri dish.
- a lymphocyte isolation tube vacutainer tube, manufactured by Becton, Dickinson and Company.
- the prepared mononuclear cell suspension (1 ml, number of nuclear cells 2.0 ⁇ 10 6 cells) were added to the mannobiose-bound polystyrene derivative coating petri dish of (1), and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 30 min. After a predetermined time, the supernatant was collected, and the petri dish was washed 3 times with saline (1 ml). Then, 10% mannose solution (1 ml) was added, and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 15 min. The monocytes attached to the petri dish were collected by pipetting. The collection rate of the monocytes was determined by the following formula.
- Monocyte collection rate(%) (number of monocytes collected from the petri dish/number of monocytes before inoculation) ⁇ 100 formula (1)
- the number of monocytes was determined by measuring the number of leukocytes in the cell suspension collected from the petri dish by a blood cell counter (KX-21NV, manufactured by Sysmex Corporation), labeling the cell suspension with CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), determining the monocyte ratio by a flow cytometer (BD FACS Canto, manufactured by Japan Becton, Dickinson and Company), and multiplying the number of leukocytes by the monocyte ratio.
- the number of monocytes before inoculation was also determined by performing a similar operation for a cell suspension before inoculation as a target.
- the purity of the monocyte was determined by labeling the cell suspension collected from the petri dish with a CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), and measuring by a flow cytometer (BD FACS Canto, manufactured by Japan Becton, Dickinson and Company). As a result, the monocyte recovery rate was 78% and the purity was 96%, and the monocyte was found to have been selectively isolated and collected.
- Example A1 In the same manner as in Example A1 except that a lactose-bound polystyrene derivative (nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION) was used instead of the mannobiose-bound polystyrene derivative, the recovery rate and purity of the monocyte were measured. As a result, the recovery rate of monocyte was 81% and the purity thereof was 73%, and the monocyte was found to have been selectively isolated and collected.
- a lactose-bound polystyrene derivative nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION
- Example A1 In the same manner as in Example A1 except that a maltose-bind polystyrene derivative (nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION) was used instead of the mannobiose-bound polystyrene derivative, the recovery rate and purity of the monocyte were measured. As a result, the recovery rate of monocyte was 76% and the purity thereof was 71%, and the monocyte was found to have been selectively isolated and collected.
- a maltose-bind polystyrene derivative nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION
- Example A1 In the same manner as in Example A1 except that a polystyrene petri dish free of polymer coating was used, the collection rate and purity of the monocyte and the recovery rate of the dendritic cell were measured. As a result, the recovery rate of monocyte was 56% and the purity thereof was 46%.
- a mononuclear cell suspension (1 ml, the number of nuclear cells 2.0 ⁇ 10 6 cells) prepared according to the method of Example A1(1) was added to a mannobiose-bound polystyrene derivative coated petri dish prepared according to the method of Example A1(1), and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 30 min. After 30 min, the supernatant was removed, saline (1 ml) was added, the petri dish was stirred slowly, and the supernatant was removed. Untrapped cells were washed by repeating the washing operation 5 times. Then AIM-V (manufactured by GIBCO) medium (1.5 ml) prepared to IL-4: 500 IU/ml, GM-CSF: 500 IU/ml was added, and the cells were cultured for 6 days.
- GIBCO GIBCO
- the cells floating in the petri dish supernatant were collected, 10% mannose solution (1 ml) was further added to the petri dish, and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 15 min. After 15 min, the cells trapped in the petri dish were collected by a pipetting operation, combined with the cells collected earlier, and the total number of the collected cells was determined by a blood cell counting chamber.
- the cell suspension obtained by a dendritic cell collection operation were taken by 200 ⁇ l in a polypropylene test tube, 10 ⁇ l each of anti-CD14 antibody (PE-labeled), and anti-HLA-DR antibody (FITC-labeled, manufactured by Becton, Dickinson and Company) was added, and the mixture was left standing in a dark and cold place for 20 min. After a predetermined time, the mixture was centrifuged at 1500 rpm for 5 min, and the supernatant was removed. Then phosphate buffer (1 ml) was added, and the measurement was performed by a flow cytometer. As a result of the measurement, surface antigen CD14+and HLA-DR+ was taken as monocyte, CD14- and HLA-DR+ was taken as dendritic cell, and the positive rate of each cell was determined.
- PE-labeled anti-CD14 antibody
- FITC-labeled anti-HLA-DR antibody
- the recovery rate of the dendritic cell was measured by the following formulas (2) and (3).
- the recovery rate of the dendritic cell was 47.6%.
- Example A4 In the same manner as in Example A4 except that a polystyrene petri dish free of coating with a mannobiose-bound polystyrene derivative polymer was used, the recovery rate of dendritic cell was measured. As a result, the recovery rate of dendritic cell was 23.6%.
- Cellulose acetate was dissolved in a mixed solvent of dimethyl sulfoxide and propylene glycol, the solution was prepared into droplets by the method (vibration method) described in JP-A-63-117039, coagulated to give cellulose acetate spherical particles.
- the obtained spherical particles had a particle size of about 400 ⁇ m.
- the particles were mixed with 4N aqueous sodium hydroxide solution at a sedimentation volume ratio of 1:1 (V/V) to allow contact at 10° C.-15° C. for 120 min for hydrolysis.
- the obtained porous cellulose carrier (40 ml by sedimentation volume) was separated, 40 ml of reverse osmosis water (Yamato Pure line RO21, manufactured by Yamato Scientific Co., Ltd.) was added, and the inside temperature was raised to 40° C. 2N NaOH (24 ml) was added, and the mixture was shaken at 40° C. for 30 min. Then, epichlorohydrin (8.2 ml) was added, and the mixture was reacted at 40° C. for 2 hr. After completion of the reaction, carrier was washed with water (about 4 L) to give an epoxydized carrier (epoxy introduction amount; 32.9 ⁇ mol/g).
- mannose amine manufactured by Sigma Ltd., molecular weight about 215, 0.783 g
- 0.5M sodium hydrogen carbonate buffer 51 ml
- the epoxydized carrier 51 ml by sediment volume
- the carrier was washed until the washing liquid was neutralized to give a mannose amine-immobilized carrier.
- Reverse osmosis water was added to the mannose amine-immobilized carrier (51 ml by sedimentation volume) to the total amount of 102 ml.
- mannose amine-immobilized carrier was washed with heparin (heparin sodium injection, manufactured by Mitsubishi Tanabe Pharma Corporation) added saline (prepared to the heparin final concentration of 5 IU/ml) for heparin equilibration. Then mannose amine-immobilized carrier was defoamed, and 1.0 ml by sedimentation volume was filled in a mini column (acrylic, inner diameter 10 mm, height 10 mm). A polyvinyl chloride tube (inner diameter 1 mm, outer diameter 3 mm, length 50 cm) was mounted on the column entry side, and a similar polyvinyl chloride tube (length 20 cm) was mounted on the column exit side.
- heparin heparin sodium injection, manufactured by Mitsubishi Tanabe Pharma Corporation
- saline prepared to the heparin final concentration of 5 IU/ml
- mannose amine-immobilized carrier was defoamed, and 1.0 ml by sedimentation volume was filled in a mini column
- the mononuclear cell suspension (5 ml, total number of nuclear cells 6.0 ⁇ 10 5 cells) prepared according to the method described in Example A1(1) was passed through the mini column at a flow rate of 0.2 ml/min. The time point when the mononuclear cell suspension was discharged from the column exit side was taken as the start point, and the tip of the tube on the column exit side was returned to the cell pool container and the perfusion was performed for 60 min.
- the cell suspension on the column exit side was harvested, the number of leukocytes was measured by a blood cell counting apparatus (KX-21NV manufactured by SYSMEX CORPORATION), and the monocyte ratio was determined by a flow cytometer (FACSCanto, Becton, Dickinson and Company). The results are shown in Table 3.
- the monomer compounds to be used for polymerization are abbreviated as follows.
- OLS oligosaccharide skeleton
- CTS cyclic tetrasaccharide: cyclo ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ 6)- ⁇ -D-glucopyranosyl-(1 ⁇ 3)- ⁇ -D-glucopyranosyl-(1 ⁇ )
- PPG4 polypropylene glycol (molecular weight 400)
- PPG7 polypropylene glycol (molecular weight 700)
- Methane diphenyl diisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was concentrated and poured into water (500 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 81%).
- the product was confirmed to be the object product by proton NMR.
- Methane diphenyl diisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (3.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was concentrated and poured into water (500 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 87%).
- the product was confirmed to be the object product by proton NMR.
- Methane diphenyl diisocyanate (11.59 g) and dimethylacetamide (150 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 400, 9.26 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- cyclic tetrasaccharide (15.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 6 hr.
- the reaction solution was concentrated and poured into water (1000 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 70%).
- the product was confirmed to be the object product by proton NMR.
- Methane diphenyl diisocyanate (7.7 g) and dimethylacetamide (175 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 700, 10.80 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- cyclic tetrasaccharide (10.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 6 hr.
- the reaction solution was concentrated and poured into water (1000 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 73%).
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- Example B17 Polyurethane (10.00 g) in Example B17 and dimethylformamide (300 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (10.83 g), N-hydroxysuccinimide (6.49 g) and triethylamine (11.28 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr.
- D-glucose amine hydrochloride (12.16 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr.
- the reaction solution was filtered, concentrated and poured into acetone (900 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 90%).
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the properties of the carboxyl group-modified oligosaccharide-containing polyurethane and the sugar residue-modified oligosaccharide-containing polyurethane of the present invention were evaluated by the following methods (1)-(3).
- the above-mentioned adapter was connected to a winged intravenous injection needle, and a holder was connected to the other end of the adapter.
- the needle was punctured into an upper arm of a healthy subject, and the blood (about 7.5 ml) was drawn in a lymphocyte isolation tube (vacutainer tube, manufactured by Becton, Dickinson and Company).
- a lymphocyte isolation tube vacutainer tube, manufactured by Becton, Dickinson and Company.
- the plasma component was collected, and the mononuclear cell layer was separately collected in a container.
- the monocyte collection rate was determined by the following formula.
- monocyte ⁇ ⁇ collection ⁇ ⁇ rate ⁇ ⁇ ( % ) number ⁇ ⁇ of ⁇ ⁇ monocytes collected ⁇ ⁇ from ⁇ ⁇ petri ⁇ ⁇ dish number ⁇ ⁇ of ⁇ ⁇ monocytes on ⁇ ⁇ inoculation ⁇ 100 formula ⁇ ⁇ ( 1 )
- the number of monocytes was obtained by measuring the number of leukocytes in the cell suspension collected from the petri dish by a blood cell counter (KX-21NV, Sysmex Corporation), labeling the cell suspension with a CD14-PE fluorescence antibody (Japan Becton, Dickinson and Company), determining the monocyte ratio by a flow cytometer (BD FACS Canto, Japan Becton, Dickinson and Company), and multiplying the above-mentioned number of leukocytes by the monocyte ratio to be mentioned below.
- the number of monocytes on inoculation was also determined in the same manner using a cell suspension on inoculation as a target.
- the purity of the monocyte was determined by labeling the cell-containing liquid collected from the petri dish with a CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), and measuring the positive rate of monocyte by a flow cytometer (BD FACS Canto, Japan Becton, Dickinson and Company), which was taken as the purity.
- a mononuclear cell suspension (1 ml, the number of nuclear cells 2.0 ⁇ 10 6 cells) prepared according to the method of Example A1(1) was added to a mannose-bound polyurethane derivative (Example B20)-coated petri dish prepared according to the method of Example A1(1), and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 30 min. After 30 min, the supernatant was removed, saline (1 ml) was added, the petri dish was stirred slowly, and the supernatant was removed. Untrapped cells were washed by repeating the washing operation 5 times. Then AIM-V (manufactured by GIBCO) medium (1.5 ml) prepared to IL-4: 500 IU/ml, GM-CSF: 500 IU/ml was added, and the cells were cultured for 6 days.
- GIBCO mannose-bound polyurethane derivative
- the cells floating in the petri dish supernatant were collected, 10% mannose solution (1 ml) was further added to the petri dish, and the mixture was left standing in an incubator at 37° C., 5% CO 2 for 15 min. After 15 min, the cells trapped in the petri dish were collected by a pipetting operation, combined with the cells collected earlier, and the total number of the collected cells was determined by a blood cell counting chamber.
- the cell suspension obtained by a dendritic cell collection operation were taken by 200 ⁇ l in a polypropylene test tube, 10 ⁇ l each of anti-CD14 antibody (PE-labeled), and anti-HLA-DR antibody (FITC-labeled, manufactured by Becton, Dickinson and Company) was added, and the mixture was left standing in a dark and cold place for 20 min. After a predetermined time, the mixture was centrifuged at 1500 rpm for 5 min, and the supernatant was removed. Then phosphate buffer (1 ml) was added, and the measurement was performed by a flow cytometer. As a result of the measurement, surface antigen CD14+and HLA-DR+ was taken as monocyte, CD14- and HLA-DR+ was taken as dendritic cell, and the positive rate of each cell was determined.
- PE-labeled anti-CD14 antibody
- FITC-labeled anti-HLA-DR antibody
- the recovery rate of the dendritic cell was determined by the following formulas (A) and (B).
- dendritic cell recovery rate(%) (number of dendritic cells collected from the petri dish/number of monocytes trapped in petri dish) ⁇ 100 formula (B)
- the dendritic cell recovery rate was 37.2%.
- the monomer compounds and the like to be used for polymerization are abbreviated as follows.
- OLS oligosaccharide skeleton
- LAC lactose
- PPG4 polypropylene glycol (molecular weight 400)
- PPG7 polypropylene glycol (molecular weight 700)
- Diphenylmethanediisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 700, 10.23 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (1.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 86%).
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- Diphenylmethanediisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (weight average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 81%).
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the integration value of pyridyl group in proton NMR it was found that two sulfuric acid groups were introduced per one oligosaccharide.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the integration value of pyridyl group in proton NMR it was found that two sulfuric acid groups were introduced per one oligosaccharide.
- solvent solubility Whether or not various polyurethanes (0.1 g) obtained in the Examples can be dissolved in dimethylacetamide (1 ml) was examined.
- softening point The softening point of polyurethane produced in the Examples was measured using a melting point measurement apparatus by starting heating from room temperature (5° C./min) and at the temperature at which the sample was dissolved.
- the acid-modified oligosaccharide-containing polyurethane of the present invention was shown to have thermoplasticity and solvent solubility.
- the monomer compounds to be used for polymerization are abbreviated as follows.
- OLS oligosaccharide skeleton
- PPG4 polypropylene glycol (molecular weight 400)
- PPG7 polypropylene glycol (molecular weight 700)
- Diphenylmethanediisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (weight average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 81%).
- the product was confirmed to be the object product by proton NMR.
- Diphenylmethanediisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (weight average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (3.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 87%).
- the product was confirmed to be the object product by proton NMR.
- Methane diphenyl diisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer.
- Polypropylene glycol (average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr.
- trehalose (1.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr.
- the reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 86%).
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- the product was confirmed to be the object product by proton NMR and IR spectrum.
- molecular weight The weight average molecular weight (Mw) of the polyurethane derivatives produced in the Examples was measured using DMF (dimethylformamide) as an eluent and standard polyethylene glycol (PEG) as the standard.
- softening point The softening point of polyurethane produced in the Examples was measured using a melting point measurement apparatus by starting heating from room temperature (5° C./min) and at the temperature at which the sample was dissolved.
- solvent solubility Whether or not various polyurethanes (0.1 g) obtained in the Examples can be dissolved in dimethylacetamide (1 ml) was examined.
- the sugar residue-modified oligosaccharide-containing polyurethane was shown to have thermoplasticity and solvent solubility.
- FITC-labeled two kinds of lectin ConA-FITC manufactured by SEIKAGAKU CORPORATION
- WGA-FITC manufactured by SEIKAGAKU CORPORATION
- Phosphate buffer pH 7.2, 1 ml was added to a petri dish coated with the polyurethane obtained in Example B18, and the supernatant was removed. This operation was repeated 3 times to wash the petri dish.
- the lectin trap rate was determined by the following formula.
- MDI-PPG7-CTS (Molar Ratio 2/1/1)-5SUC-2GluA Polyurethane
- the sugar residue-modified oligosaccharide-containing polyurethane of the present invention was found to have a superior lectin trapping capability.
- the lectin harvested in the present invention can be used as a cell fractionation reagent, a clinical diagnostic reagent, a clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like.
- lectin may be directly used as a lectin-isolation device composition.
- a cell such as monocyte and the like or a protein such as lectin and the like can be collected conveniently at high purity and in a high collection rate.
- monocytes to further differentiate into dendritic cells according to the method of the present invention, dendritic cells can be prepared conveniently and highly efficiently.
- sugar residue-modified oligosaccharide-containing polyurethane, carboxyl group-modified oligosaccharide-containing polyurethane, acid-modified oligosaccharide-containing polyurethane and acid-modified sugar residue-modified oligosaccharide-containing polyurethane of the present invention are solvent soluble and thermoplastic, and superior in film forming capability.
- polyurethanes are particularly superior in trapping capability of cell (e.g., monocyte and the like), protein, virus and the like, they are useful as highly functional materials used in the fields of isolation, analysis and the like of cells, proteins and viruses, particularly, for use involving contact with blood (e.g., various isolation devices, isolation filters and the like for harvesting blood, cell, monocyte, protein and the like) and the like.
- the acid-modified oligosaccharide-containing polyurethane and acid-modified sugar residue-modified oligosaccharide-containing polyurethane of the present invention are expected to have affinity for particular cells, proteins and viruses, since oligosaccharide or sugar residue is further modified with an acid. Therefore, these polyurethanes are useful as highly functional materials for use in the fields of medicine and livingwares.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Botany (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a novel material useful for selectively isolating a cell such as monocyte and the like or a protein from a body fluid and a production method thereof, a physiological material using the material and an isolation material using the physiological material, as well as a method of harvesting a cell such as monocyte and the like using the isolation material, a method of harvesting a protein and a method of preparing a dendritic cell.
Description
- This application is a divisional of U.S. application Ser. No. 12/302,881, filed Jun. 9, 2009, which is a National Stage application of PCT/JP2007/060721 filed May 25, 2001.
- The present invention relates to a novel material useful for selectively isolating a cell such as monocyte and the like from a body fluid or a protein contained in an animal or plant and a production method thereof, a physiological material using the material and an isolation material using the same, as well as a method of harvesting a cell such as monocyte and the like, a method of harvesting a protein by the use of the isolation material, and a method of preparing a dendritic cell.
- In recent years, it has been clarified that sugar chain present in the cell surface is deeply involved in various vital phenomena (cell recognition, transduction of information, cell adhesion, differentiation and proliferation, canceration, virus infection, blood coagulation, immune reaction and the like). When the target molecule in the phenomenon is a sugar chain, the interaction is classified into a “sugar chain-sugar chain” interaction, and when the target molecule is a protein, it is classified into a “sugar chain-protein” interaction. In the former, cell surface sugar chains in a particular sugar chain structure combinatory relationship are bound to each other. In the latter, one of the cell surface sugar chains recognizes and binds to a sugar chain recognition protein on the other cell surface, where lectin, glycosyltransferase and glycohydrolase are said to be involved as the sugar chain recognition protein. Inspired by such vital phenomenon, the development and research of a physiological material (cell or protein isolation material, device, sensor), pharmaceutical products and the like, incorporating a sugar chain, has been actively performed (e.g., non-patent documents 1, 2 and 3).
- For the development of a sugar chain-containing functional material that expresses a desired physiological function, the correlation between the structure and physiological activity of a sugar chain needs to be studied at molecular and functional group levels, as well as a technique to freely modify a sugar chain molecule and introduce same into a polymer is required.
- With these backgrounds, various sugar chain-containing polymers have been reported. For example, as polymers incorporating a sugar chain such as monosaccharide, disaccharide, oligosaccharide and the like (hereinafter sugar chain polymer),
- 1. polyvinyl alcohol type (e.g., patent document 1)
2. polyacrylate type (e.g., patent document 2)
3. polystyrene type (e.g., patent documents 3-8)
4. polyether type (e.g., patent document 9)
5. polyethyleneimine type (e.g., patent documents 10 and 11)
6. polyamino acid type (e.g., patent documents 12-16)
7. polyurethane type (e.g., patent document 17)
and the like are known. Among these, patent document 5 discloses selective adhesion and collection of hepatocytes as well as cancer cell recognition using a sugar chain polymer-coated substrate. - In recent years, a cell treatment has been practiced wherein cells contained in body fluids such as blood, bone marrow and the like are isolated and transplanted for the purpose of regeneration of tissues such as blood vessel and the like as well as immunomodulation of cancer patients. Along therewith, various materials, devices and the like for selectively isolating cells useful for the treatment have been developed. Among the cells present in body fluids represented by blood, monocyte has blood vessel regeneration capability (non-patent documents 4, 5), and is drawing attention as a precursor cell of a dendritic cell to be used for a dendritic cell therapy, which is one of the cell immunity therapies (non-patent document 6). As a method for isolating monocytes from a body fluid such as blood and the like, the following have been reported.
- Examples of a method of isolating peripheral blood monocytes include a density-gradient centrifugation method wherein the difference in the specific gravity of the cells is utilized for isolation, a method wherein a blood component containing monocytes is isolated from the peripheral blood by apheresis and the like, highly adhesive monocytes are attached to a physical and chemical instrument such as a polystyrene flask and the like, and non-adhesive cells are removed to isolate the monocytes, a method wherein monocytes are selectively isolated by utilizing magnetic beads bound with an antibody to the monocyte and the like. The isolated monocytes are cultured with cytokine such as IL-4, GM-CSF and the like to induce differentiation into dendritic cells, which are used as cancer treatment cells.
- However, the method of isolating monocytes by the density-gradient centrifugation method is associated with many problems yet to be solved, such as a safety problem of the liquid to be used for density gradient (cytotoxicity and the like), an operability problem because of a long time required for centrifugation, washing operation and the like, much loss of cells, an open system operation allowing easy contamination and the like, isolation efficiency (insufficient removal of non-adhesive cells, contamination with lymphocytes) and the like.
- Moreover, a method including isolation of mononuclear cells by the density-gradient centrifugation method, and selective attachment of monocytes to a physical and chemical instrument such as plastic dish and the like by utilizing the difference in the adhesion of monocytes and lymphocytes to a substrate is known. However, this method requires complicated operation, and the recovery rate and purity of the isolated monocytes are not sufficient.
- The isolation method using magnetic beads with antibody can isolate monocytes at a comparatively high purity, but the cell treatment requires a long time, and also, is expensive.
- In the elutriation method, a cell suspension is centrifuged in a chamber having a slope, while flowing a buffer in an opposite direction from the centrifugation to form a particular cell layer. This method affords high purity monocytes, but the apparatus is expensive, and requires a skillful operation technique. In addition, the cell isolation problematically requires a long time.
- In recent years, moreover, a monocyte isolation method using a cell isolation filter has been reported.
- For example, patent document 18 discloses a method of collecting nuclear cells by trapping nuclear cells on a filter that traps nuclear cells but passes red blood cells, and inducing a liquid current in the opposite direction from the first liquid flow direction. However, this document is directed to a filter for collecting nuclear cells, where selectivity to monocyte is absent.
- In addition, patent document 19 discloses monocyte and/or monocyte-derived macrophage selective removal filter apparatus. However, this document is directed to a physical filtration filter wherein the average pore cross sectional area and bulk density of the filter were defined in consideration of the particle size of macrophage, which is clearly different from the present invention wherein monocytes are selectively isolated utilizing the affinity for the monocytes.
- Patent document 20 also discloses that the monocyte trap rate increases by defining the packing density and fiber diameter of the filter. For the same reasons as mentioned above, it is clearly different from the present invention. In addition, the property is not sufficient because the monocyte recovery rate is about 50% and the purity is about 40%.
- Lectin widely present in the biological world including animals, plants, microorganisms etc. is a generic term of proteins that recognize a sugar chain. Lectin specifically binds to a sugar chain having a particular structure, which is present in blood cell, cell surface and the like, and has an activity to aggregate blood cells and cells. For example, sword bean-derived concanavalin A (ConA) and wheat germ agglutinin (WGA) are known to aggregate malignant cells. As mentioned above, lectin is medically highly useful as a cell fractionation reagent, clinical diagnostic reagent, clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like. At present, a wide variety of lectins are isolated from various individuals, and their functions are being strenuously examined. To further clarify the property of undeveloped lectin and develop practical use, a technique for efficient isolation and purification of useful lectin at a low cost is required (non-patent documents 7, 8).
- As a conventional protein isolation method, a fractionation method utilizing difference in solubilities (salting out, fractional precipitation by organic solvent, acidic precipitation and isoelectric point precipitation), and fractionation by column chromatography (ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, affinity chromatography) are known. For isolation and purification of lectin, one kind of protein, from a naturally occurring substance such as pulse and the like, isolation from contaminating protein, fat, sugar, amino acid etc. is required, and as a method therefor, a combination of the above-mentioned methods (ion exchange and gel filtration chromatography after salting out) has been employed. However, such method cannot isolate lectin sufficiently, and high purity lectin cannot be obtained problematically. Therefore, for example, affinity chromatography using a carrier having a sugar such as maltose, lactose and the like immobilized thereon as a ligand (patent documents 21-24), and affinity chromatography using a methacrylate polymer bound with a sugar such as maltose, lactose (patent document 25), albumen-derived sugar chain (patent document 26) and the like have been utilized. As shown, various materials and methods for isolating lectin have been disclosed.
- Nevertheless, since this method requires chemically binding a sugar ligand onto the carrier surface, the sugar density is not sufficient, lectin is not sufficiently isolated, and high purity lectin cannot be obtained problematically.
- Sulfated sugar is known to have affinity for influenza virus and AIDS virus, and development of a new material capable of trapping viruses utilizing the principle and its production method is desired. With such backgrounds, various sulfated sugar chain-containing polymers have been reported. For example, a sulfated galactose-inducing polyacrylate type (e.g., patent document 27), sulfated sugar-inducing polyethylene type (e.g., patent document 28), sulfated glucosamine-inducing polyethylene type (e.g., patent document 29) and the like are known.
- The biological functions such as recognition, adhesion and the like of cell, protein containing lectin or virus are expressed due to a “sugar chain-sugar chain interaction” or a “sugar chain-protein interaction” between a sugar chain aggregate (cluster) on the cell surface and a sugar chain aggregate complementary thereto, and the strength of the interaction is known to correlate with the sugar chain density. Since only one sugar chain such as monosaccharide, disaccharide, oligosaccharide and the like can be linearly introduced per repeat unit into the sugar chain polymers disclosed in the above-mentioned patent documents 1-17 and 25-29, the number of repeat units having a sugar chain introduced thereinto in a polymer chain needs to be increased so as to sufficiently express the biological function (recognition, adhesion and the like to cell, protein containing lectin and virus) of sugar chain by increasing the sugar chain density in the sugar chain cluster. On the other hand, this may result in the degradation of the film forming capability, mechanical intensity and the like that skeleton polymers inherently show.
- From the aspects of biocompatibility and blood compatibility, the polyurethane type sugar chain polymer disclosed in patent document 17 is preferable. However, since the production step for introducing a sugar chain into the side chain requires complicated protection and deprotection operations, the production cost may problematically increase.
- patent document 1: JP-A-63-238105
- patent document 2: JP-A-63-68603
- patent document 3: JP-A-7-304788
- patent document 4: JP-A-8-253495
- patent document 5: JP-A-8-319317 (JP-B-3053764)
- patent document 6: JP-A-8-253495
- patent document 7: JP-A-2002-88094
- patent document 8: JP-A-2005-112987
- patent document 9: JP-A-5-140294
- patent document 10: JP-A-5-140213
- patent document 11: JP-A-2002-302511
- patent document 12: JP-A-5-178986
- patent document 13: JP-A-8-337566
- patent document 14: JP-A-9-227600
- patent document 15: JP-A-11-60603
- patent document 16: JP-A-2003-73397
- patent document 17: JP-A-11-71391
- patent document 18: WO98/32840
- patent document 19: JP-A-9-75076 (JP-B-3812909)
- patent document 20: JP-A-2004-129550
- patent document 21: JP-A-62-201641
- patent document 22: JP-B-2660175
- patent document 23: JP-A-10-504287
- patent document 24: JP-B-3711356
- patent document 25: JP-A-63-68603
- patent document 26: JP-B-1995189
- patent document 27: JP-A-11-315091
- patent document 28: JP-A-2004-526691
- patent document 29: JP-A-2005-15451
- non-patent document 1: Design and Physiology of Sugar Chain Molecule, 2001, Japan Scientific Societies Press
- non-patent document 2: Method of Studying Physiologically Active Sugar Chain, 1999, Japan Scientific Societies Press
- non-patent document 3: Carbohydrate Engineering and Production Technique, 1993, Science Forum Inc.
- non-patent document 4: Proc. Natl. Acad. Sci., vol. 100, No. 5: 2, 426-2431, 2003
- non-patent document 5: Cardiovasc. Reserch, 49(3): 671-680, 2001
- non-patent document 6: Cancer Res., vol. 59: 56-58. 1999
- non-patent document 7: New Biochemical Experiment Course 1 Protein isolation, purification, properties, 1993, Ed. The Japanese Biochemical Society, Tokyo Kagaku Dozin Co., Ltd.
- non-patent document 8: Lectin, N. Sharon • H. L is ed., translated by Toshiaki Ohsawa • Yukiko Konami, 1989, Japan Scientific Societies Press
- An object of the present invention is to provide a novel material having superior film forming capability, which is expected to show various physiological functions such as biocompatibility, blood compatibility, affinity for cell or protein, and the like, and a convenient and low cost production method thereof, provide a physiological material containing the material and an isolation material using the same, and to provide a convenient and efficient method of harvesting a cell such as monocyte and the like or a protein as well as a convenient and efficient method of preparing a dendritic cell, using the isolation material.
- The present inventors have conducted intensive studies in an attempt to solve the above-mentioned problems and found that a cell such as monocyte and the like or a protein can be isolated conveniently and efficiently by the use of an isolation material containing, on at least a part of the surface, a substance having a sugar structure, and that a dendritic cell can be prepared conveniently and efficiently from a monocyte.
- Furthermore, the present inventors have also found that, as the above-mentioned substance having a sugar structure, a sugar chain-containing polymer having a particular structure defined below particularly has superior film forming capability, is expected to have various physiological functions such as biocompatibility, blood compatibility, affinity for a cell or a protein and the like, and is useful for harvesting a cell such as monocyte and the like or a protein, and that the sugar chain-containing polymer can be produced by a convenient method at a low cost.
- Accordingly, the present invention provides the following.
- [1] A method of harvesting a monocyte, comprising performing
- 1) a step for trapping a monocyte in an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- 2) a step for removing untrapped monocytes by washing the isolation material with a washing liquid, and
- 3) a step for collecting a trapped monocyte from the isolation material, in this order.
- [2] The method of the above-mentioned [1], wherein the monocyte is collected using a solution for cell collection, comprising one or more kinds of sugars selected from the group consisting of mannose, glucose, galactose and fucose, in the aforementioned step 3).
- [3] A method of preparing a dendritic cell, comprising inducing further differentiation of a monocyte collected by the method of the above-mentioned [1] or [2] into a dendritic cell.
[4] A method of preparing a dendritic cell, comprising performing - 1) a step for trapping a monocyte in an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- 2) a step for removing untrapped monocytes by washing the isolation material with a washing liquid,
- 3) a step for inducing further differentiation of a monocyte trapped by the isolation material to give a dendritic cell, and
- 4) a step for collecting the dendritic cell after differentiation induction from the isolation material, in this order.
- [5] A composition comprising a dendritic cell obtained by the method of the above-mentioned [3] or [4].
[6] A method of harvesting a protein, comprising performing - 1) a step for trapping a protein in an isolation material by contacting a protein-containing liquid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- 2) a step for removing untrapped proteins by washing the isolation material with a washing liquid, and
- 3) a step for collecting a trapped protein from the isolation material, in this order.
- [7] The method of the above-mentioned [6], wherein the protein is lectin.
[8] The method of the above-mentioned [7], wherein the lectin is concanavalin A (ConA) or wheat germ agglutinin (WGA).
[9] A lectin-containing composition obtained by the method of the above-mentioned [6].
[10] The method of any one of the above-mentioned [1]-[4] and [6]-[8], wherein the substance having a sugar structure is a sugar chain-containing polymer having, as a partial structure, (i) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group, or (ii) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative.
[11] The method of the above-mentioned [10], wherein the sugar constituting the substance having a sugar structure is at least one sugar selected from the group consisting of mannose, glucose, galactose, lactose, fucose, trehalose, maltose and cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→1.
[12] The method of the above-mentioned [10], wherein the substance having a sugar structure is a sugar chain-containing polymer having, as a partial structure, a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative.
[13] The method of the above-mentioned [12], wherein the sugar chain-containing polymer is a sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [1-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue, OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00. - [14] The method of the above-mentioned [12], wherein the sugar chain-containing polymer is a carboxyl group-modified oligosaccharide-containing polyurethane represented by the following formula [1-2]:
- wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[15] The method of the above-mentioned [12], wherein the sugar chain-containing polymer is an acid-modified oligosaccharide-containing polyurethane represented by the following formula [2-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s shows the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1≦s≦r, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00. - [16] The method of the above-mentioned [12], wherein the sugar chain-containing polymer is an acid-modified sugar residue-modified oligosaccharide represented by the following formula [3-1]:
- wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s shows the number of hydroxyl groups of a sugar residue R4 modified with an acid-containing group, which is an integer within the range of 1≦s≦4,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[17] A sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [1-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[18] The polyurethane of the above-mentioned [17], wherein R3 is an ethylene group.
[19] The polyurethane of the above-mentioned [17], wherein R4 is a sugar residue derived from glucose, mannose or galactose.
[20] The polyurethane of the above-mentioned [17], wherein the oligosaccharide is trehalose, maltose or lactose.
[21] The polyurethane of the above-mentioned [17], wherein the oligosaccharide is cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}.
[22] A carboxyl group-modified oligosaccharide-containing polyurethane represented by the following formula [1-2]: - wherein
R1 is a divalent C2-26 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-22 oxyalkylene unit and a divalent C2-22 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[23] The polyurethane of the above-mentioned [22], wherein R3 is an ethylene group.
[24] The polyurethane of the above-mentioned [22], wherein R4 is derived from glucose, mannose or galactose sugar residue.
[25] The polyurethane of the above-mentioned [22], wherein the oligosaccharide is trehalose, maltose or lactose.
[26] The polyurethane of the above-mentioned [22], wherein the oligosaccharide is cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}.
[27] An acid-modified oligosaccharide-containing polyurethane represented by the following formula [2-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s is the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1≦s≦r, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[28] The polyurethane of the above-mentioned [27], wherein X is SO3 or PO3.
[29] The polyurethane of the above-mentioned [27], wherein X is SO3.
[30] The polyurethane of the above-mentioned [27], wherein R3 is an ethylene group.
[31] The polyurethane of the above-mentioned [27], wherein R4 is glucose, mannose or galactose.
[32] The polyurethane of the above-mentioned [27], wherein the oligosaccharide is trehalose, maltose or lactose.
[33] The polyurethane of the above-mentioned [27], wherein the oligosaccharide is cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}.
[34] An acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [3-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s is the number of hydroxyl groups of a sugar residue R4 modified with an acid-containing group, which is an integer within the range of 1≦s≦4,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
[35] The polyurethane of the above-mentioned [34], wherein X is SO3 or PO3.
[36] The polyurethane of the above-mentioned [34], wherein X is SO3.
[37] The polyurethane of the above-mentioned [34], wherein R3 is an ethylene group.
[38] The polyurethane of the above-mentioned [34], wherein R4 is glucose, mannose or galactose.
[39] The polyurethane of the above-mentioned [34], wherein the oligosaccharide is trehalose, maltose or lactose.
[40] The polyurethane of the above-mentioned [34], wherein the oligosaccharide is cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}.
[41] A method of harvesting a cell comprising performing - 1) a step for trapping a cell on an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
- 2) a step for removing untrapped cells by washing the isolation material with a washing liquid, and
- 3) a step for collecting a trapped cell from the isolation material, in this order, wherein the substance having a sugar structure is a polyurethane of any one of the above-mentioned [17]-[40].
- [42] A monocyte isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure, wherein the substance having a sugar structure is a sugar chain-containing polymer having, as a partial structure, (i) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group, or (ii) a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative.
[43] The monocyte isolation material of the above-mentioned [42], wherein the sugar constituting the substance having a sugar structure is at least one sugar selected from the group consisting of mannose, glucose, galactose, lactose, fucose, trehalose, maltose and cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}.
[44] The monocyte isolation material of the above-mentioned [43], wherein the sugar constituting the substance having a sugar structure is at least one sugar selected from the group consisting of mannose, glucose, galactose, lactose and fucose.
[45] The monocyte isolation material of any one of the above-mentioned [42]-[44], having the form of a filter. - [46] A monocyte isolation device comprising a container provided with a liquid inlet and/or a liquid outlet, wherein the container comprises a monocyte isolation material of any one of the above-mentioned [42]-[45] in at least one part thereof.
- [47] A physiological material comprising a polyurethane of any one of the above-mentioned [17]-[40].
[48] An isolation material comprising a polyurethane of any one of the above-mentioned [17]-[40] at least on a part of a surface thereof.
[49] The isolation material of the above-mentioned [48], which is a cell isolation material.
[50] The isolation material of the above-mentioned [49], which is a monocyte isolation material.
[51] The isolation material of the above-mentioned [48], which is a protein isolation material.
[52] The isolation material of the above-mentioned [51], which is a lectin isolation material.
[53] The isolation material of the above-mentioned [52], which is a concanavalin A (ConA) or wheat germ agglutinin (WGA) isolation material.
[54] The isolation material of the above-mentioned [48], which is a blood isolation material.
[55] The isolation material of any one of the above-mentioned [48]-[54], having the form of a filter.
[56] An isolation device comprising a container provided with a liquid inlet and/or a liquid outlet, wherein the container comprises an isolation material of the above-mentioned [48]-[55] in at least one part thereof.
[57] The isolation device of the above-mentioned [56], which is a cell isolation device.
[58] The isolation device of the above-mentioned [57], which is a monocyte isolation device.
[59] The isolation device of the above-mentioned [56], which is a protein isolation device.
[60] The isolation device of the above-mentioned [59], which is a lectin isolation device.
[61] The isolation device of the above-mentioned [60], which is a concanavalin A (ConA) or wheat germ agglutinin (WGA) isolation device. - [62] A method of producing a carboxyl group-modified oligosaccharide-containing polyurethane represented by the following formula [1-2]:
- wherein
R1 is a divalent C2-26 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-22 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide, and
p and q are as defined above, comprising reacting an oligosaccharide-containing polyurethane represented by the following formula [1-3]: - wherein R1, R2, m, n, r and OLS are each as defined above, with an acid anhydride represented by the following formula [1-4]:
- wherein R3 is as defined above.
[63] A method of producing a sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [1-1] - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00, comprising reacting a carboxyl group-modified oligosaccharide-containing polyurethane represented by the following formula [1-2]: - wherein R1, R2, R3, p, q, r, m, n and OLS are each as defined above, with an aminated sugar represented by the following formula [1-5]:
-
R4—NH2 [1-5] - wherein R4 is as defined above.
[64] A method of producing an acid-modified oligosaccharide-containing polyurethane represented by the following formula [2-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
s is as defined above,
X is an acid-derived moiety, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00, comprising reacting an oligosaccharide-containing polyurethane represented by the following formula [1-3]: - wherein R1, R2, OLS, r, m and n are as defined above, with an acid modifying reagent.
[65] The production method of the above-mentioned [64], wherein the acid modifying reagent is a sulfating reagent or a phosphorylation reagent.
[66] The production method of the above-mentioned [65], wherein the acid modifying reagent is a sulfating reagent.
[67] A method of producing an acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [3-1]: - wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s is the number of hydroxyl groups of a sugar residue R4 modified with an acid-containing group, which is an integer within the range of 1≦s≦4,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, - m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, n/(m+n) is a number within the range of 0.01-1.00, comprising reacting a sugar residue-modified oligosaccharide-containing polyurethane represented by the following formula [1-1]:
- wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s), R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1,
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, n/(m+n) is a number within the range of 0.01-1.00, with an acid modifying reagent.
[68] The production method of the above-mentioned [67], wherein the acid modifying reagent is a sulfating reagent or a phosphorylation reagent.
[69] The production method of the above-mentioned [68], wherein the acid modifying reagent is a sulfating reagent. - The present invention is specifically explained in the following.
- The isolation material to be used for the method of the present invention characteristically contains a substance having a sugar structure on at least a part of the surface. In the present invention, “contains a substance having a sugar structure on at least a part of the surface” encompasses both cases where 1) the isolation material itself is constituted with a substance having a sugar structure, and 2) the substrate of the isolation material is different from the substance having a sugar structure, and the entirety or a part of the surface of the isolation material is constituted with a substance having a sugar structure.
- The “substance having a sugar structure” to be used in the method of the present invention is not particularly limited as long as it contains monosaccharide, oligosaccharide and/or polysaccharide structures as a partial structure, which can be formed into an isolation material by itself, or immobilized or coated on the surface of a substrate of the isolation material. For example, a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group, a sugar chain-containing polymer having, as a partial structure, a monosaccharide, an oligosaccharide and/or a polysaccharide, and the like can be mentioned.
- While the kind of sugar in a substance having a sugar structure is not particularly limited, monosaccharides such as mannose, glucose, galactose, fucose and the like, and oligosaccharide or polysaccharide containing these sugar units are preferable. Examples thereof include mannose, glucose, galactose, lactose, fucose, trehalose, maltose, cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→} and the like.
- The kind of sugar may be single or plural. The sugar structure means a partial structure or derivative of these sugars. When the sugar of the sugar structure is oligosaccharide or polysaccharide, it may have a straight chain structure or a branched structure. The terminal sugar of a sugar structure preferably has a structure selected from glucose, galactose and fucose. The terminal sugar here means a sugar on the terminal at the nonreducing terminal side.
- In the isolation material of the present invention, when a substance having a sugar structure is immobilized on a substrate of the isolation material, the immobilizing method includes an ion bond method, a covalent bond method and the like. As the immobilization method, various known methods can be used without any particular limitation. In this case, a monosaccharide derivative, an oligosaccharide derivative and a polysaccharide derivative, each having a reactive functional group, are preferably used as substances having a sugar structure. The reactive functional group of a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative is not particularly limited as long as it can chemically bind to a substrate of the isolation material directly or via a spacer. For example, a hydroxyl group, an amino group, an aldehyde group, a carboxyl group, a thiol group, a silanol group, an amide group, an epoxy group, a halogen group, a succinoylimide group, an acid anhydride group and the like can be mentioned. When a monosaccharide derivative, an oligosaccharide derivative and/or a polysaccharide derivative, each having a reactive functional group is immobilized on an isolation material, a reactive group may be introduced onto the surface of a substrate of the isolation material. For introduction of a reactive group, for example, immobilization of halogen or pseudohalogen as disclosed in JP-A-2-261833, introduction of an epoxy group as disclosed in JP-A-6-219051 and JP-B-1887096, and the like are preferably utilized. In addition, a substance having a sugar structure or a precursor thereof can also be immobilized by graft polymerization onto a substrate of the isolation material. In this case, monosaccharide, oligosaccharide and/or polysaccharide derivative, having, as a reactive functional group, a styrene group, a methacryl group, a vinyl group, an acrylic group and the like capable of graft polymerization can be used as a substance having a sugar structure. As an immobilization method therefor, known methods using radiation or electron beam can be employed without any particular limitation.
- In the isolation material to be used in the present invention, when a substrate of the isolation material is coated with a substance having a sugar structure, a sugar chain-containing polymer having monosaccharide, oligosaccharide and/or polysaccharide as a partial structure is preferably used as the substance having a sugar structure. Examples of such sugar chain-containing polymer include synthetic polymers represented by polyurethane, polystyrene, polyethylene, polyolefin, polyacrylamide, polyester, nylon, polyimide, aramid, polyamide, acrylic resin and the like, natural polymers represented by chitin, chitosan, acetyl cellulose, cellulose, rayon, agarose, alginic acid and the like, into which at least one kind of monosaccharide, oligosaccharide and/or polysaccharide structure has been introduced, and the like.
- While the method of coating a substrate of the isolation material with a substance having a sugar structure is not particularly limited, for example, coating methods including immersing a substrate of the isolation material into a liquid containing a substance having a sugar structure which forms a coating layer, spraying the solution on a substrate of the isolation material, injecting the solution on a substrate of the isolation material and the like can be mentioned. The substrate after a coating treatment may be used after removing the remaining solution by washing, or used after drying without washing. Alternatively, the substrate may be used after washing but without drying, and known methods can be used without any particular limitation. Moreover, a coating layer may be formed by applying a solution containing a substance having a sugar structure and a polymerizable compound in combination, and crosslinking the solution.
- The form of the isolation material of the present invention is not particularly limited and may be, for example, a tool having a flat plate structure such as petri dish, flask, plate, bag, cartridge, cassette and the like, a structure having continuous pores (e.g., filter) such as non-woven fabric, fiber, porous material, spherical carrier and the like, and the like.
- When a substrate of the isolation material to be used in the present invention is petri dish, flask, plate, bag, cartridge, cassette and the like, its form and size are not particularly limited. The materials thereof are not particularly limited. However, an inert polymer, or a metal material such as bioaffinity metal, alloy thereof and the like, and the like are preferably used. Alternatively, a material coated or plated with such inert polymer, bioaffinity metal and the like may be used.
- Examples of the inert polymer include acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like, halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene and the like, polyamide, polysulfone, polycarbonate, polyethylene, polypropylene, vinyl chloride-acrylic copolymer, carbonate-acrylonitrile-butadiene-styrene copolymer, styrene-butadiene copolymer, polystyrene and the like.
- Examples of the metal material include stainless steel, titanium, platinum, tantalum, gold, alloys thereof, as well as gold-plated alloy iron, platinum-plated alloy iron, cobalt chromium alloy, titanium nitride-coated stainless steel and the like.
- Among these, a germproof or sterile material is particularly preferable. Specifically, glass, polypropylene, polyvinyl chloride, polycarbonate, polysulphone, polymethylpentene and the like coated with silicon can be mentioned.
- When a substrate of the isolation material to be used in the present invention is petri dish, flask, plate, bag, cartridge, cassette and the like, a material having a gas permeable structure is also used preferably. Examples of the material having a gas permeable structure include a material having an ultrafine pore structure or a slit structure of the level permitting suppression of contamination, a material inherently having high gas permeability and the like. Examples of the material inherently having high gas permeability include, but are not limited to, polymethylpentene, cyclic polyolefin, olefin type thermoplastic elastomer, styrene type thermoplastic elastomer, polyamide type thermoplastic elastomer and the like.
- A substrate of the isolation material to be used in the present invention may be a non-woven fabric or a porous material. In this case, an average pore size of the substrate is, for example, preferably within the range of 9 μm-80 μm. While the material of the substrate is not particularly limited, it is, for example, a synthetic polymer such as polyurethane, polystyrene, polyethylene, polyolefin, polyacrylamide, polyester, nylon, polyimide, aramid, polyamide, acrylic resin and the like, a natural polymer such as chitin, chitosan, acetyl cellulose, cellulose, rayon, agarose, alginic acid and the like, an inorganic material such as hydroxyapatite, glass, alumina and the like, a metal such as stainless, titanium and the like, and the like.
- The porous state form may be any form such as sponge-like, felt-like, cotton-like, fiber-like, particles-like, pipy, discotic and cylindrical shape forms and the like. When a substrate of the isolation material is a spherical carrier, its particle size is preferably 10 μm-2000 μm, more preferably 70 μm-1000 μm, from treatment efficiency. Examples of the material of the spherical carrier include, but are not limited to, inorganic carriers such as glass beads, silica gel and the like, synthetic polymer compounds such as crosslinked polyvinyl alcohol, crosslinked polyacrylate, crosslinked polyacrylamide, crosslinked polystyrene, ethylene-vinyl acetate copolymer saponifiable substance, crosslinked polyacrylic acid, crosslinked polymethacrylic acid, polymethyl methacrylate, polyacrylamide grafted polyethylene and the like, organic carrier comprised of polysaccharides such as crystalline cellulose, crosslinked cellulose, cellulose derivatives, crosslinked agarose, crosslinked dextrin, chitin, chitosan and the like, composite carriers obtained by combining them, such as organic-organic, organic-inorganic composite carriers and the like, and the like.
- The above-mentioned isolation material may be directly used as a harvesting method of cell, protein and the like, or can also be used in the form of an isolation device.
- In the present invention, the “isolation device” means a device wherein the aforementioned isolation material is contained at least in one part of a container having a liquid inlet and/or a liquid outlet. The isolation material preferably used for the isolation device of the present invention is a structure having continuous pores, such as non-woven fabric, fiber, porous material, spherical carrier, filter and the like. The isolation device of the present invention refers to a device wherein such isolation material structure is mounted on or filled in a container suitable for the form thereof, such as column, bag, cassette and the like, or housed in an incubator such as flask, bag and the like, and the like. Preferably, the aforementioned isolation material is filled in the aforementioned container.
- The form, material and size of the container are not particularly limited, and any form such as dish/bottle, bag, tube, column, cassette, flask and the like may be employed. Examples of the isolation device of the present invention include an isolation device in the form of a column of an about 0.1-500 ml transparent or translucent cylindrical container having a diameter of about 0.1-10 cm filled with a structure having continuous pores such as spherical carrier etc., and the like.
- The device is preferably mounted on or filled in a container having a body fluid inlet and a body fluid outlet to divide the body fluid inlet from the body fluid outlet to give a filter or a cross-flow module. When a non-woven fabric or a porous material is mounted on or filled in a container, it may form a single layer or a laminate of a plurality thereof, or it may also be combined with a material having a surface not constituted with a substance having a sugar structure and then mounted on or filled in a container.
- Such isolation device is useful for harvesting, for example, cell (e.g., monocyte and the like), protein (e.g., lectin such as ConA (concanavalin A), WGA (wheat germ agglutinin) etc., and the like) and the like.
- While the material of the container for the isolation device of the present invention is not particularly limited, inert polymer or a metal material such as a bioaffinity metal or an alloy thereof etc., and the like are used. Alternatively, a material coated or plated with such inert polymer or bioaffinity metal may be used.
- Examples of the inert polymer include acrylonitrile polymers such as acrylonitrile-butadiene-styrene copolymer and the like, halogenated polymers such as polytetrafluoroethylene, polychlorotrifluoroethylene, tetrafluoroethylene, polyhexafluoropropylene and the like, polyamide, polysulfone, polycarbonate, polyethylene, polypropylene, vinyl chloride-acrylic copolymer, carbonate-acrylonitrile-butadiene-styrene copolymer, styrene-butadiene copolymer, polystyrene and the like.
- Examples of the metal material include stainless steel, titanium, platinum, tantalum, gold, and alloys thereof, as well as gold-plated alloy iron, platinum-plated alloy iron, cobalt chromium alloy, titanium nitride-coated stainless steel and the like.
- Among these, a germproof or sterile material is particularly preferable. Specific examples include glass, polypropylene, polyvinyl chloride, polycarbonate, polysulphone, polymethylpentene and the like coated with silicon.
- A cell harvesting method using the isolation material of the present invention is explained in detail in the following.
- A method of harvesting a cell in the present invention includes contacting the aforementioned isolation material of the present invention with a body fluid, and specifically includes the following steps 1)-3) in this order:
- 1) step for trapping a cell (e.g., monocyte and the like) in an isolation material by contacting a body fluid with the isolation material containing, on at least a part of the surface, a substance having a sugar structure,
- 2) a step for removing untrapped cells by washing the isolation material with a washing liquid, and
- 3) a step for collecting a trapped cell from the isolation material.
- In the above-mentioned method, the isolation material can also be used in the form of the aforementioned isolation device.
- In the method of the present invention, the “body fluid” encompasses, but is not limited to, blood (e.g., peripheral blood, cord blood, peripheral blood induced by cytokines (e.g., G-CSF and the like) and the like), bone marrow, lymph, pleural fluid, ascites, synovia and the like harvested from a living organism, for example, mammals (human, monkey, rat, mouse, dog, cat, rabbit, bovine, swine, sheep, goat, horse and the like, preferably human) sample, as well as apheresis products, centrifugation treatment liquid, cell suspension (e.g., including cell suspension containing cells subjected to a specific gravity density centrifugation treatment using, when desired, ficoll, percoll, vacutainer tube, lymphoprep, HES (hydroxyethylstarch) and the like) and the like, of these body fluids.
- The method of the present invention is particularly suitable for blood as a body fluid.
- A body fluid can be harvested from a test sample by any method known in the field. For collection of a body fluid, heparin, low molecular weight heparin, nafamostat mesylate, gabexate mesylate, aragatroban, a citric acid-containing anticoagulant such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, and the like may be used as a generally used anticoagulant. Among these, citric acid-containing anticoagulant and heparin are most preferable.
- Each step of the method of the present invention is explained in detail in the following by referring to each representative embodiment using an isolation material and an isolation device.
- In step 1), a cell is trapped in an isolation material by contacting a body fluid with an isolation material containing a substance having a sugar structure in at least one part of a surface. To be specific, a target body fluid is injected into the isolation material of the present invention using a petri dish, a flask, a plate, a bag, a cartridge, a cassette and the like as a substrate, and the material is stood or shaken for 5 min-120 min to contact the body fluid with the isolation material, whereby cell is trapped in the isolation material. For stable trapping of the cell and reduced damage on the cell, the contact (standing or shaking) time is more preferably 15 min-90 min.
- In step 2), the isolation material is washed with a washing liquid to remove untrapped cells. While a method of removing the untrapped cells is not particularly limited, for example, a method wherein a body fluid is first removed by suction with a pipette, a syringe and the like or decantation and the like, saline, culture medium, buffered solution and the like are injected again in the isolation material to wash away the attached cells, and finally, the supernatant is removed by the aforementioned suction or decantation and the like, and the like can be mentioned. When removal of the untrapped cells is insufficient, the method may be repeated several times.
- In step 3), the trapped cell is collected from the isolation material. The trapped cell can be collected, for example, by contacting a collection liquid containing saline, a medium, a cell preservation solution and the like, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, a sugar-containing cell collection liquid and the like with the isolation material after washing in the above-mentioned step 2).
- While the kind of the collection liquid is not particularly limited, from the aspects of cell recovery rate, a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material, for example, a cell collection liquid containing sugar such as mannose, glucose, galactose, fucose or a mixture thereof is preferably used. The sugar concentration of a sugar-containing cell collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-⅕ of the saturated solubility. In addition, the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- The cells are contacted with the above-mentioned cell collection liquid for about 3 min-30 min while standing or shaking them. After contact for a given time, cells can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the trapped cells (for example, flashing and the like) and the like. The means for pushing may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When the cell recovery rate is insufficient, the above-mentioned collection operation may be repeated.
- <When an Isolation Device Comprising an Isolation Material Having a Structure with Continuous Pores Such as Non-Woven Fabric, Fiber, Porous Material, Spherical Carrier, Filter and the Like in at Least One Part of a Container is Used>
- Here, a case using an isolation material in the form of an isolation device is particularly explained.
- In step 1), a cell is trapped in an isolation material by contacting a body fluid with a device comprising the above-mentioned isolation material in at least one part of a container having a liquid inlet and/or a liquid outlet.
- When the above-mentioned isolation device is used, “contacting a body fluid with an isolation device” means passing a body fluid through an isolation device. Here, passing a liquid means introducing a body fluid from a liquid inlet of an isolation device, transporting the fluid in a given direction and discharging the fluid from a liquid outlet. The means for introducing a body fluid into an isolation device may be, but not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like. The liquid passage rate is preferably 0.1 ml/min-100 ml/min, and a body fluid may be passed through the device once, or plural times by a circulation treatment.
- In step 2), the isolation device is washed with a washing liquid to remove untrapped cells. When the above-mentioned isolation device is used, untrapped cells are removed from the isolation material by passing a washing liquid through the isolation device from a liquid inlet (same direction as body fluid flow entry direction) or a liquid outlet (opposite direction to body fluid flow entry direction). Specific examples of the washing liquid include, but are not limited to, saline, Ringer's solution, buffer such as phosphate buffer and the like, cell culture medium such as RPMI1640 and the like. The means for introducing a washing liquid may be, but is not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like. The flow rate of liquid passage using a pump is about 0.1 ml/min-100 ml/min. While the amount of the washing liquid varies depending on the isolation material used for an isolation device and the content volume of the isolation device, washing with a volume of about 1- to 5-fold the content volume is preferable.
- In step 3), the trapped cell is collected from the isolation device. To be specific, the trapped cell is collected, for example, by passing a collection liquid containing saline, a medium, a cell preservation solution and the like, a collection liquid containing a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like, a sugar-containing cell collection liquid, and the like through the above-mentioned isolation device.
- Particularly, in view of cell collection efficiency, a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material in a separation device, for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used. When a sugar-containing cell collection liquid is used as a collection liquid, the sugar concentration of a collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-⅕ of the saturated solubility. In addition, the sugar-containing cell collection liquid may contain a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like. The above-mentioned isolation device is preferably contacted with the collection liquid for about 3 min-30 min and the contact method may be a leaving method, a circulation method and the like. The flow rate during circulation is preferably 0.1 ml/min-200 ml/min. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When the cell collection is insufficient, the above-mentioned collection operation may be repeated.
- The method of the present invention is particularly suitable for harvesting a monocyte. Monocyte is a monocyte type cell derived from a hematopoietic stem cell, and used for the fields of regenerative medicine and cell medicine such as vascular regeneration, differentiation induction into dendritic cells and the like.
- When monocytes are collected by the method of the present invention, the obtained monocytes can be used as the cells for vascular regeneration and the like. Alternatively, the monocytes harvested by the method of the present invention can also be used as a precursor cell in the below-mentioned “method of preparing a dendritic cell”.
- The present invention also relates to a preparation method of dendritic cell and the dendritic cell obtained the method.
- The method of preparing a dendritic cell of the present invention includes a method including a step wherein the monocytes trapped in the isolation material by the above-mentioned method of the present invention are collected from the isolation material and differentiation induction thereof into dendritic cells is induced, and a method including a step wherein the monocytes trapped in the isolation material are, without collection, induced in situ to differentiate into dendritic cells.
- In the present invention, dendritic cell means immature dendritic cell obtained by inducing monocyte with cytokines such as IL-4, GM-CSF and the like to differentiate thereinto, mature dendritic cell obtained by inducing immature dendritic cell by adding cytokines such as TNFα, IL1-β, IL-6, PGE2 and the like to differentiate thereinto, antigen-presenting dendritic cell (e.g., dendritic cell presenting cancer antigen and the like) obtained via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- A method of preparing the dendritic cell of the present invention is explained in detail the following.
- <Method of Collecting Trapped Monocytes from the Isolation Material of the Present Invention and Inducing them to Differentiate into Dendritic Cells>
- In this method, dendritic cells can be prepared by harvesting monocytes using the aforementioned method of the present invention, which is followed by induction of differentiation.
- A step for inducing the monocytes to differentiate into dendritic cells can be performed, for example, as in the following.
- Monocytes are placed in a container generally used for cell culture such as petri dish, flask and the like, and a culture medium containing cytokines such as GM-CSF, IL-4 and the like is added. By culturing the cells for about 1 week, the monocytes can be induced to differentiate into immature dendritic cells. By further culturing the cells in a culture medium containing cytokines such as IL-1β, PGE2, IL-6, TNF-α and the like for about 1 week, immature dendritic cells can be induced to differentiate into mature dendritic cells.
- Where necessary, the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- The obtained dendritic cell can be collected by, for example, a general collection means such as pipetting and the like.
- <Method of Inducing In Situ the Monocytes Trapped in the Isolation Material to Differentiate into Dendritic Cells without Collection>
- A preferable embodiment of this method includes the following steps 1)-4) in this order:
- 1) a step for trapping monocytes in an isolation material by contacting a body fluid with an isolation material containing, on at least a part of the surface, a substance having a sugar structure,
- 2) a step for removing untrapped monocytes by washing the isolation material with a washing liquid,
- 3) a step for inducing further differentiation of the monocytes trapped by the isolation material to give dendritic cells, and
- 4) a step for collecting the dendritic cells after induced to differentiate into from the isolation material.
- Also in this method, the isolation material can be used in the form of an isolation device as mentioned above.
- The above-mentioned steps 1) and 2) can be performed according to steps 1) and 2) of the aforementioned “cell harvesting method”. Steps 3) and 4) are explained in detail in the following.
- In step 3), monocytes trapped in the isolation material are further induced to differentiate into dendritic cells.
- To be specific, untrapped cells are removed by washing in step 2), a culture medium containing cytokines such as GM-CSF, IL-4 and the like is added to monocytes trapped in the isolation material, and the monocytes are cultured for about 1 week to differentiated monocytes trapped in the isolation material into immature dendritic cells. Thereafter, the immature dendritic cells are cultured in a culture medium containing cytokines such as IL-1β, PGE2, IL-6, TNF-α and the like for about 1 week to induce differentiation into mature dendritic cells.
- Where necessary, the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability (e.g., addition of cancer antigen), and the like.
- In step 4), the dendritic cell after differentiation induction is collected from the isolation material. The dendritic cell can be collected by a pipetting operation, use of a cell collection liquid containing a divalent cation chelating agent such as an acid citrate dextrose liquid (ACD liquid), a citrate phosphate dextrose liquid (CPD liquid) and the like, and the like, which are generally employed therefor. To realize a higher recovery rate, a collection method using a sugar-containing collection liquid is advantageous. As a preferable sugar-containing collection liquid, a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material, for example, a cell collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is used. The sugar concentration of a sugar-containing collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-⅕ of the saturated solubility. In addition, the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- The dendritic cell is contacted with the above-mentioned cell collection liquid for about 3 min-30 min by leaving or shaking. After contact for a given time, dendritic cells can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like. The means for pushing out may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When collection of the dendritic cell is insufficient, the above-mentioned collection operation may be repeated.
- When Isolation Device Comprised of a Container Packed with an Isolation Material Comprised of a Structure Having Continuous Pores Such as Non-Woven Fabric, Fiber, Porous Material, Spherical Carrier, Filter and the Like is Used
- In step 3), monocytes trapped in the above-mentioned isolation device are further induced to differentiate into dendritic cells. After removing the untrapped monocytes in step 2), a culture medium containing cytokines such as GM-CSF, IL-4 and the like is passed through an isolation device, after which the monocytes are cultured in a culture medium containing cytokines such as GM-CSF, IL-4 and the like for about 1 week, whereby the monocytes are differentiated into immature dendritic cells. Thereafter, a culture medium containing cytokines such as IL-1β, PGE2, IL-6, TNF-α and the like is further passed, the cells are cultured in a culture medium containing cytokines such as IL-1β, PGE2, IL-6, TNF-α and the like for about 1 week to induce differentiation of the immature dendritic cells into mature dendritic cells.
- Where necessary, the cells may be induced to differentiate into antigen-presenting dendritic cells (e.g., dendritic cells presenting cancer antigen and the like) via a step of acquiring an antigen-presenting capability by passing or contacting a culture medium containing an antigen (e.g., cancer antigen).
- In step 4), the dendritic cell after differentiation induction in the above-mentioned step 3) is collected from the isolation device. The dendritic cell after differentiation induction can be collected by passing a collection liquid generally used or passing a cell collection liquid containing a divalent cation chelating agent such as an acid citrate dextrose liquid (ACD liquid), a citrate phosphate dextrose liquid (CPD liquid) and the like through the isolation device. To realize a higher recovery rate, a collection method using a sugar-containing collection liquid is advantageous. As a preferable sugar-containing collection liquid, a cell collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation device, for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is used. The sugar concentration of a sugar-containing collection liquid may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1/5 of the saturated solubility. In addition, the sugar-containing cell collection liquid may contain, where necessary, a divalent cation chelating agent such as acid citrate dextrose liquid (ACD liquid), citrate phosphate dextrose liquid (CPD liquid) and the like.
- The dendritic cell is preferably contacted with the above-mentioned cell collection liquid for about 3 min-30 min. The contact method may be a method wherein a collection liquid is passed through an isolation device, and the isolation device is maintained for a given time under leaving or shaking, a method wherein a collection liquid is circulated through an isolation device and the like. The flow rate during circulation is preferably 0.1 ml/min-200 ml/min. A method of collecting dendritic cells after a contact for a given time may be a method of collecting dendritic cells by application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like. The means for pushing out dendritic cells may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. or heating up to 37° C. may be concurrently performed. When collection of the dendritic cell is insufficient, the above-mentioned collection operation may be repeated.
- A method of harvesting protein using the isolation material or isolation device of the present invention is explained in detail in the following.
- The method of harvesting protein of the present invention includes performing
- 1) a step for trapping a protein in an isolation material by contacting a protein-containing liquid with an isolation material containing, on at least a part of the surface, a substance having a sugar structure,
- 2) a step for removing untrapped proteins and substances other than proteins by washing the isolation material with a washing liquid, and
- 3) a step for collecting the trapped protein from the isolation material, in this order.
- First, a protein-containing liquid is prepared as follows. A material containing protein is disrupted in Tris buffer (pH 7.4), centrifuged and the supernatant is collected. A 45% saturated ammonium sulfate is added thereto and sufficiently dissolved, and the mixture is left standing for 1 hr or longer, centrifuged to collect the precipitate, and dialyzed against 0.01M Tris buffer (pH 7.4). The dialysate is subjected to ion exchange chromatography to collect the object protein fraction, which is then contacted with the isolation material of the present invention, containing, on at least a part of the surface, a substance having a sugar structure.
- In step 1), proteins are trapped in an isolation material by contacting a protein-containing liquid with an isolation material containing a substance having a sugar structure in at least one part of a surface. To be specific, a target protein-containing liquid is injected into the isolation material of the present invention using a petri dish, a flask, a plate, a bag, a cartridge, a cassette and the like as a substrate, and the material is left standing or shaken for 5 min-120 min to contact the protein-containing liquid with the isolation material, whereby proteins are trapped in the isolation material. For stable trapping of the protein and reduced damage on the protein, the contact (standing or shaking) time is more preferably 15 min-90 min.
- In step 2), the isolation material is washed with a washing liquid to remove untrapped proteins. While a method of removing the untrapped proteins is not particularly limited, for example, a method wherein a protein-containing liquid is first removed by suction with a pipette, a syringe and the like or decantation and the like, a buffered solution and the like are injected again into the isolation material to wash away the attached proteins, and finally, the supernatant is removed by the aforementioned suction or decantation and the like, and the like can be mentioned. When removal of the untrapped proteins is insufficient, the method may be repeated several times.
- In step 3), the trapped proteins are collected from the isolation material. The trapped proteins can be collected, for example, by contacting a sugar-containing solution and the like with the isolation material after washing in the above-mentioned step 2).
- While the kind of the collection liquid is not particularly limited, from the aspects of protein recovery rate, a solution containing the same kind of sugar as the sugar structure constituting a part of the isolation material, for example, a solution containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used. The sugar concentration of a sugar-containing solution may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1/5 of the saturated solubility. In addition, the sugar-containing solution preferably contains a buffer such as a phosphate buffer and the like.
- The protein is contacted with the above-mentioned cell collection liquid for about 3 min-30 min while leaving or shaking them. After contact for a given time, the protein can be collected by pipetting, application of vibration, pushing the collection liquid swiftly while preventing damage on the dendritic cells (for example, flashing and the like) and the like. The means for pushing may be, but not limited to, air, inert gas, saline and the like. In this case, to increase collection efficiency, cooling down to 4° C. may be concurrently performed. When recovery rate of the protein is insufficient, the above-mentioned collection operation may be repeated.
- When Isolation Device Comprised of a Container Having, in at Least One Part Thereof, an Isolation Material Comprised of a Structure Having Continuous Pores Such as Non-Woven Fabric, Fiber, Porous Material, Spherical Carrier, Filter and the Like is Used
- Use of an isolation material in the form of an isolation device is particularly explained here.
- In step 1), proteins are trapped in an isolation material by contacting a protein-containing liquid with a device comprising the above-mentioned isolation material in at least one part of a container having a liquid inlet and/or a liquid outlet.
- When the above-mentioned isolation device is used, “contacting a protein-containing liquid with an isolation device” means passing a protein-containing liquid through an isolation device. Here, passing a liquid means introducing a protein-containing liquid from a liquid inlet of an isolation device, transporting the liquid in a given direction and discharging the liquid from a liquid outlet. The means for introducing a protein-containing liquid into an isolation device may be, but not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like. The liquid passage rate is preferably 0.1 ml/min-100 ml/min, and the liquid may be passed through the device once, or plural times by a circulation treatment.
- In step 2), the isolation device is washed with a washing liquid to remove untrapped proteins. When the above-mentioned isolation device is used, untrapped proteins are removed from the isolation material by passing a washing liquid through the isolation device from a liquid inlet in the same direction as protein-containing liquid flow entry direction. Specific examples of the washing liquid include, but are not limited to, buffers such as Tris buffer, phosphate buffer and the like. The means for introducing a washing liquid may be, but is not limited to, a method including use of a machine such as a syringe pump, a peristaltic pump and the like, manual liquid passage using a syringe, a free fall treatment utilizing difference in height and the like. The flow rate of liquid passage using a pump is about 0.1 ml/min-100 ml/min. While the amount of the washing liquid varies depending on the isolation material used for an isolation device and the content volume of the isolation device, washing with a volume of about 1- to 5-fold the content volume is preferable.
- In step 3), trapped proteins are collected from an isolation device. Specifically, proteins are collected by passing a sugar-containing solution and the like through the above-mentioned isolation device. Particularly, from the aspects of protein collection efficiency, a collection liquid containing the same kind of sugar as the sugar structure constituting a part of the isolation material in the isolation device, for example, a collection liquid containing mannose, glucose, galactose, fucose or a mixture thereof is preferably used. The sugar concentration of a sugar-containing solution may be any from 0.01% (W/V) to the saturated solubility of the sugar at 37° C. From the aspects of collection efficiency, it is preferably 0.1% (W/V)-half the saturated solubility, more preferably 0.5% (W/V)-1/5 of the saturated solubility. In addition, the sugar-containing solution preferably contains a buffer such as a phosphate buffer and the like. The above-mentioned isolation device is preferably contacted with the collection liquid for about 3 min-30 min, and the contact method may be leaving method, circulation method and the like. The flow rate during circulation is preferably 0.1 ml/min-200 ml/min. In this case, to increase collection efficiency, cooling down to 4° C. may be concurrently performed. When collection of the protein is insufficient, the above-mentioned collection operation may be repeated.
- The method of the present invention is particularly suitable for harvesting lectin. Lectin is a generic term of proteins that recognize a sugar chain. Lectin specifically binds to a sugar chain having a particular structure, which is present in blood cell, cell surface and the like, and coagulates blood cells and cells. Lectin harvested in the present invention can be used as a cell fractionation reagent, a clinical diagnostic reagent, a clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like. For such uses, lectin may be collected from an isolation device by the above-mentioned method and used, or directly used as a lectin-isolation device composition.
- Now, a sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1], a carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2], an acid-modified oligosaccharide-containing polyurethane represented by the formula [2-1] and an acid-modified sugar residue-modified oligosaccharide represented by the formula [3-1] of the present invention, which are used as sugar chain-containing polymers in the method of the present invention, as well as an oligosaccharide-containing polyurethane represented by the formula [1-3] used as an intermediate in the present invention are each explained in detail hereunder.
- In the above-mentioned formulas [1-1], [1-2], [1-3], [2-1] and [3-1], R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s).
- Examples of the “divalent C1-16 hydrocarbon group” of the above-mentioned “divalent C1-16 hydrocarbon group optionally having substituent(s)” include
- (1) a straight chain or branched chain divalent C1-16 aliphatic hydrocarbon group [e.g., a straight chain or branched chain C1-16 alkylene group (e.g., methylene, ethylene, tetramethylene, pentamethylene, hexamethylene, octamethylene, hexadecamethylene etc.), a straight chain or branched chain C2-16 alkenylene group (e.g., vinylene, propenylene etc.), C3-16 cycloalkylene (e.g., cyclohexylene) and the like],
(2) a divalent C6-14 aromatic hydrocarbon group [e.g., a C6-14 arylene group (e.g., phenylene, naphthylene, biphenylene etc.) and the like],
(3) a hydrocarbon group having 7 to 16 carbon atoms, which contains at least one group selected from the aforementioned straight chain or branched chain divalent C1-16 aliphatic hydrocarbon group and at least one group selected from the divalent C6-14 aromatic hydrocarbon group (e.g., a group represented by the formula - and the like.
- Examples of the “substituent” of the above-mentioned “divalent C1-16 hydrocarbon group optionally having substituent(s)” include
- (1) a C1-6 alkyl group (e.g., methyl etc.);
(2) a C3-8 cycloalkyl group (e.g., cyclohexyl etc.);
(3) a C6-14 aryl group (e.g., phenyl etc.);
and the like. The same or different, 1 to 8, preferably 1 to 4, of these substituents may be present at substitutable position(s) of the above-mentioned “divalent C1-16 hydrocarbon group”. - Specific examples of R1 include a tetramethylene group, a pentamethylene group, a hexamethylene group, an octamethylene group, a hexadecamethylene group, a vinylene group, a propenylene group, a phenylene group, a naphthylene group, a phenylmethylene group, a phenylethylene group, a biphenyl group, a bisphenylmethylene group, a bisphenylethylene group, a phenylene group (e.g., paraphenylene group), a xylylene group, a tetramethylxylylene group, a tolylene group, dicyclohexylmethylene group,
- a group represented by the formula
- and the like, and a bisphenylmethylene group, a phenylmethylene group and a hexamethylene group are preferable.
- In the formulas [1-1], [1-2], [1-3], [2-1] and [3-1], R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s).
- Examples thereof include a divalent group containing the same or different 1 to 100 units in total selected from C2-12 oxyalkylene, a divalent group containing the same or different 1 to 100 units in total selected from divalent C2-12 hydrocarbon unit optionally having substituent(s), and a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s).
- The above-mentioned “divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s)” is, for example, a divalent group containing the same or different 1 to 100 units in total selected from a unit represented by the formula —(BO)h-1—B— and a unit represented by the formula -(E)i-, wherein B is at least one kind of C2-12 alkylene unit, E is at least one kind of the same or different unit selected from a divalent C2-12 hydrocarbon unit optionally having substituent(s), and h and i are each an integer of 1≦h≦100 and 1≦i≦100, respectively.
- In the above-mentioned unit represented by the formula —(BO)h-1—B—, the “C2-12 alkylene group” for B may be a straight chain or branched, and when a plurality of B are present in the unit (2≦h≦100), B may be one kind or two or more kinds. Specific examples of BO include an alkyleneoxy group such as an ethyleneoxy group, a propyleneoxy group, a trimethylenoxy group, a butyleneoxy group, a tetramethyleneoxy group and the like, and specific examples of the unit represented by the formula —(BO)h-1—B— include a unit represented by the formula —CH2—CH2—O—CH2—CH2—CH2— and the like.
- In the above-mentioned unit represented by the formula -(E)i-, the divalent hydrocarbon unit of the “divalent C2-12 hydrocarbon unit optionally having substituent(s)” for E may be a straight chain or branched, and a saturated group or an unsaturated group and, for example, C2-12 alkylene (e.g., ethylene, trimethylene, tetramethylene, hexamethylene, nonamethylene etc.), C2-12 alkenylene (e.g., butadienylene, butenylene etc.) and the like can be mentioned. Examples of the “substituent” that the “divalent C2-12 hydrocarbon unit” optionally has include a halogen atom (e.g., fluorine atom etc.), a C1-6 alkyl group (e.g., methyl etc.) and the like. When a plurality of E are present in the unit (2100), E may be one kind or two or more kinds.
- Specific examples of such unit represented by the formula -(E)i- include an ethylene group, a trimethylen group, a tetramethylene group, a hexamethylene group, a nonamethylene group, a —CH2—CF2—CF2—CF2—CF2—CH2— group, a butadienylene group, a hydrogenated butadienylene group, a divalent group such as a group derived by eliminating one hydrogen atom from each of the carbon atoms on both chain ends of hydrogenated isoprene and the like, and the like.
- In addition, R2 may further contain, in addition to the unit selected from a unit represented by the above-mentioned formula —(BO)h-1—B— wherein B and h are as defined above and/or a unit represented by the formula -(E)i- wherein E and i are as defined above, other repeat unit [for example, repeat unit such as alkylene ester groups (e.g., ethyleneadipate group, propyleneadipate group, butyleneadipate group, hexamethyleneadipate group, neopentyladipate group and the like), alkylenecarbonate groups (e.g., hexamethylenecarbonate group and the like), a ring-opening caprolactone group, a poly(dimethylsiloxy)dimethylsilyl group and the like].
- Specific examples of R2 containing such unit include a divalent group derived by eliminating OH from both ends of polyethylene adipatediol and the like, a poly(dimethylsiloxy)dimethylsilyl-n-propylbisethoxy group and the like.
- As specific examples of R2, a divalent group having a repeat unit such as an ethyleneoxy group, a propyleneoxy group, an ethyleneadipate group, a propyleneadipate group, a hexamethylenecarbonate group, a ring-opening caprolactone group and the like, a trimethylen group, a tetramethylene group, a —CH2—CF2—CF2—CF2—CF2—CH2— group, a hydrogenated butadienylene group, a divalent group derived by eliminating one hydrogen atom from each of the carbon atoms on both chain ends of hydrogenated isoprene, a polydimethyl siloxy dimethylsilyl-n-propylbisethoxy group and the like are preferable.
- In the formulas [1-1], [1-2], [1-4] and [3-1], R3 is a C2-4 alkylene group.
- Specific examples include an ethylene group, a trimethylen group, a tetramethylene group and the like. Of these, an ethylene group and a trimethylen group are preferable, and an ethylene group is more preferable.
- In the formulas [1-1], [1-5] and [3-1], R4 is a monosaccharide- or disaccharide-derived sugar residue. The sugar residue is a residue obtained by removing a certain hydroxyl group from sugar. Examples of the monosaccharide and disaccharide usable for R4 include glucose, mannose, galactose, lactose and the like.
- Of these, preferred as R4 is a sugar residue derived from glucose, mannose or galactose, and a sugar residue derived from glucose is more preferable.
- In the formulas [1-1], [1-2], [1-3], [2-1] and [3-1], OLS is the skeleton of oligosaccharide. The skeleton of oligosaccharide is a residue obtained by removing all hydroxyl group moieties from oligosaccharide. The oligosaccharide to be used in the present invention is not particularly limited as long as it is an oligosaccharide having two primary hydroxyl groups, which may be any of disaccharide, trisaccharide and tetrasaccharide. Specific examples include disaccharides such as trehalose, maltose, lactose, cellobiose and the like, cyclic tetrasaccharides such as cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→}etc., and the like. Of these, disaccharides such as trehalose, maltose, lactose and the like are preferable from the aspects of cost and reactivity.
- In the formulas [1-1], [1-2], [1-3], [2-1] and [3-1], r shows the total number of secondary hydroxyl groups of oligosaccharide. For example, when OLS is disaccharide, trisaccharide or tetrasaccharide, r is 6, 9 or 12, respectively, and when OLS is cyclic tetrasaccharide, r is 10.
- In the formula [1-1], p shows the number of the secondary hydroxyl groups modified with diacid and amino sugar (group represented by the formula —O2C—R3—CO—NH—R4; R3 and R4 are as defined above) of oligosaccharide, which is an integer within the range of 1≦p≦r.
- In the formula [1-1], q shows the number of the secondary hydroxyl groups modified with diacid (group represented by the formula HO2C—R3—CO2—; R3 is as defined above) of oligosaccharide, which is an integer within the range of 0≦q≦r−1.
- In the formula [1-2], p+q shows the number of the secondary hydroxyl groups modified with diacid (group represented by the formula HO2C—R3—CO2—; R3 is as defined above) of oligosaccharide, which is each an integer within the range of 1≦p≦r, 0≦q≦r−1.
- In the formulas [1-1], [1-2], [1-3], [2-1] and [3-1], m and n are numbers of repeat units, m is an integer of 0-1000 and n is an integer of 1-1000, n/(m+n) is a number within the range of 0.01-1.00, preferably within the range of 0.02-0.80 from the aspects of the balance of water absorbability, polymer strength and polymer formability. The arrangement of repeat units in the formulas [1-1], [1-2], [1-3], [2-1] and [3-1] can be either of regular and irregular.
- In the formula [2-1], s shows the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1≦s≦r. Here, the “acid-containing group” is a group represented by the formula XM in the formula [2-1] wherein X and M are as defined above.
- While the acid-derived moiety for the above-mentioned X may be of any kind as long as polyurethane represented by the formula [2-1] has desired properties, SO3 or PO3 is preferable and SO3 is more preferable.
- Examples of the alkali metal atom for the above-mentioned M include a sodium atom, a potassium atom, a lithium atom and the like, with preference given to a sodium atom and a potassium atom.
- Examples of the organic amino group for the above-mentioned M include an amino group 1 to 3 C1-6 alkyl groups [for example, mono-C1-6 alkylamino group (e.g., monomethylamino group, monoethylamino group, monopropylamino group, monobutylamino group, monopentylamino group, monohexylamino group), a di-C1-6 alkylamino group [for example, dimethylamino group, diethylamino group, dipropylamino group (e.g., di-n-propylamino group, di-iso-propylamino group), dibutylamino group], tri-C1-6 alkylamino group (e.g., trimethylamino group, triethylamino group)], a C6-14 aromatic amino group [for example, a C6-14 aralkylamino group (e.g., benzylamino group), a C6-14 aromatic heterocyclic amino group (e.g., pyridyl group)] and the like, and preferred are a dimethylamino group, a trimethylamino group, a triethylamino group, a pyridyl group and a benzylamino group.
- In the formula [3-1], p shows the number of the secondary hydroxyl groups modified with an acid-containing group (group represented by the formula —O2C—R3—CO—NH—R4—(XM)s; R3, R4, X, M and s are as defined above) of oligosaccharide modified with diacid and amino sugar. Here, the “acid-containing group” is a group represented by the formula XMa in the formula [3-1] wherein X and M are as defined above.
- While the acid-derived moiety for the above-mentioned X may be of any kind as long as polyurethane represented by the formula [3-1] has desired properties, SO3 or PO3 is preferable and SO3 is more preferable.
- Examples of the alkali metal atom for the above-mentioned M include a sodium atom, a potassium atom, a lithium atom and the like, with preference given to a sodium atom and a potassium atom.
- Examples of the organic amino group for the above-mentioned M include an amino group having 1 to 3 C1-6 alkyl groups [for example, mono-C1-6 alkylamino group (e.g., monomethylamino group, monoethylamino group, monopropylamino group, monobutylamino group, monopentylamino group, monohexylamino group), di-C1-6 alkylamino group [for example, dimethylamino group, diethylamino group, dipropylamino group (e.g., di-n-propylamino group, di-iso-propylamino group), dibutylamino group], tri-C1-6 alkylamino group (e.g., trimethylamino group, triethylamino group)], a C6-14 aromatic amino group [for example, C6-14 aralkylamino group (e.g., benzylamino group), C6-14 aromatic heterocycleamino group (e.g., pyridyl group)] and the like, and preferred are a dimethylamino group, a trimethylamino group, a triethylamino group, a pyridyl group and a benzylamino group.
- The production methods of the sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1], the carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2], and the oligosaccharide-containing polyurethane (intermediate) represented by the formula [1-3] in the present invention are each explained below.
- In the present invention, the oligosaccharide-containing polyurethane represented by the formula [1-3] can be obtained by reacting an oligosaccharide represented by the formula [1-6]:
- wherein OLS and p are as defined above and, where necessary, a diol represented by the following formula [1-7]:
-
HO—R2—OH [1-7] - wherein R2 is as defined above, with a diisocyanate represented by the following formula [1-8]:
-
O═C═N—R1—N═C═O [1-8] - wherein R2 is as defined above.
- In this case, the oligosaccharide represented by the formula [1-6] may be mixed, where necessary, with the diol represented by the formula [1-7] and the mixture is reacted with the diisocyanate represented by the formula [1-8] (one-shot method), or the diisocyanate represented by the formula [1-8] may be reacted, where necessary, with the diol represented by the formula [1-7] to give a prepolymer, which is then reacted with the oligosaccharide represented by the formula [1-6] (prepolymer method 1), or the oligosaccharide represented by the formula [1-6] may be reacted with the diisocyanate represented by the formula [1-8] to give a prepolymer, which is then reacted, where necessary, with the diol represented by the formula [1-7] (prepolymer method 2).
- In the above-mentioned reactions, the oligosaccharide represented by the formula [1-6], the diisocyanate represented by the formula [1-8] and the diol represented by the formula [1-7] each may be one kind or a mixture of two or more kinds.
- Examples of the diisocyanate of the aforementioned formula [1-8] to be used in the present invention include tetramethylenediisocyanate, pentamethylenediisocyanate, hexamethylenediisocyanate, octamethylenediisocyanate, hexadecamethylenediisocyanate, vinylenediisocyanate, propenylenediisocyanate, naphthylenediisocyanate, phenylmethanediisocyanate, diphenylmethanediisocyanate, phenylethanediisocyanate, diphenylethanediisocyanate, phenylenediisocyanate (e.g., paraphenylenediisocyanate), biphenyldiisocyanate, xylylenediisocyanate, tetramethylxylylenediisocyanate, tolylenediisocyanate, isophoronediisocyanate, dicyclohexylmethanediisocyanate and the like.
- The diol represented by the formula [1-7] is not particularly limited as long as it has a primary hydroxyl group. Specific examples include low molecular weight diols such as ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol, 1,9-nonanediol, 2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol and the like; high molecular weight diols, for example, polyether diols such as polyethylene glycol, polytetramethylene ether glycol, polypropylene glycol, ethyleneoxide-propyleneoxide copolymer, tetrahydrofuran-ethylene oxide copolymer, tetrahydrofuran-propylene oxide copolymer and the like, polyester diols such as polyethylene adipate glycol, polydiethylene adipate glycol, polypropylene adipate glycol, polybutylene adipate glycol, polyhexamethylene adipate glycol, polyneopentyladipate glycol, polycaprolactone glycol and the like, polycarbonate diols such as polyhexamethylenecarbonate glycol and the like, polyolefin glycols such as polybutadiene glycol, hydrogenated polybutadiene glycol, hydrogenated polyisoprene glycol and the like, silicone diols such as bis(hydroxyethoxy-n-propyldimethylsilyl)polydimethyl siloxane and the like, and the like; and the like.
- The solvent used for producing the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3] may be any as long as it can dissolve the reaction product and the resulting polyurethane. Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof.
- For production of the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3], for example, the oligosaccharide represented by the aforementioned formula [1-6] and, where necessary, the diol represented by the formula [1-7] are added to a solution containing the diisocyanate represented by the formula [1-8] while passing a dry inert gas such as nitrogen and the like.
- The molar ratio of the above-mentioned reaction components charged is, for example, compound represented by the formula [1-8]: compound represented by the formula [1-7]: compound represented by the formula [1-6] preferably 3:0.01-2.99:0.01-3, more preferably 3:0.2-2.5:0.5-2.8.
- The reaction temperature of the above-mentioned reaction is preferably 10-150° C., more preferably 20-120° C., and the reaction time is preferably 1-10 hr, more preferably 2-6 hr.
- After completion of the reaction, the oligosaccharide-containing polyurethane represented by the formula [1-3]
- wherein R1, R2, OLS, m, n and r are as defined above, can be obtained. The polyurethane can be purified by, for example, feeding the reaction solution into a single or mixed solvent of methanol, acetone, water and the like, filtration, washing and, where necessary, repeating reprecipitation purification to give a solid content, which is dried under reduced pressure at room temperature −100° C. for about 1-24 hr.
- The production method of the carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2] is explained below.
- A carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2]
- wherein R1, R2, R3, OLS, m, n, p, q and r are as defined above, can be produced by reacting the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3] with an acid anhydride represented by the formula [1-4]
- wherein R3 is are as defined above, and entirely or partially modifying the secondary hydroxyl group of oligosaccharide.
- The above-mentioned reaction is generally performed in a solvent. The solvent for carboxyl group modification may be any as long as it can dissolve the reaction product and the resulting polyurethane. Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof.
- As the acid anhydride represented by the above-mentioned formula [1-4], a dibasic anhydride such as succinic anhydride, glutaric anhydride, adipic anhydride and the like is preferably used, and succinic anhydride is most preferable. The acid anhydride may be used alone or as a mixture of two or more kinds. The amount thereof to be used when a hydroxyl group of straight chain oligosaccharide in polyurethane is to be partially modified is 1- to (r−1)-fold mol relative to the number of secondary hydroxyl groups (r) of oligosaccharide in polyurethane, and the amount when the aforementioned hydroxyl group is to be completely modified is r- to 2r-fold mol, preferably 1.2r- to 1.5r-fold mol.
- In the above-mentioned reaction, where necessary, 4-dimethylaminopyridine or imidazole is preferably used in a proportion of 3-10 mol %, more preferably 5 mol %, as a catalyst.
- The reaction temperature of the above-mentioned reaction is 20-100° C., preferably 50-90° C., and the reaction time is 1-24 hr, preferably 2-20 hr.
- After completion of the reaction, a carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2] of the present invention can be obtained. The polyurethane can be purified by, for example, feeding the reaction solution into a single or mixed solvent of methanol, acetone, water and the like to allow precipitation of a polymer, filtering, washing and, where necessary, repeating reprecipitation purification to give a solid content, which can be dried under reduced pressure at room temperature −100° C. for about 1-24 hr.
- A sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1]
- wherein R1, R2, R3, R4, p, q, r, m, n and OLS are each as defined above, can be obtained by reacting a carboxyl group-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-2] with an aminated sugar represented by the following formula [1-5]:
-
R4−NH2 [1-5] - wherein R4 is as defined above.
- As the aminated sugar represented by the formula [1-5], for example, glucose amine, mannose amine, lactose amine, galactose amine and the like are preferable. Of these, glucose amine and mannose amine are more preferable, and glucose amine is most preferable from the aspects of cost. In addition, the aminated sugar may be used alone or as a mixture of two or more kinds. The amount thereof to be used is adjusted according to the object number of aminated sugar modifications relative to the number of carboxyl groups (p+q) in polyurethane represented by [1-2]. When the number of the aminated sugar modifications is 1 or 2, the amount is 1- or 2-fold mol relative to the number of carboxyl groups (p+q), and when the number of aminated sugar modifications is not less than 3, the amount is 3-fold or more relative to the number of carboxyl groups (p+q).
- The above-mentioned reaction is generally performed in a solvent. The solvent may be any as long as it can dissolve the reaction product and the resulting polyurethane. Specific examples include organic solvents such as dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc) and the like, alone or a mixed solvent thereof, and further, a mixed solvent thereof with methanol, ethanol, water.
- The above-mentioned reaction is preferably performed in the presence of a condensation agent. As the condensation agent, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide (NHS) mixture, dicyclohexylcarbodiimide (DCC), 4(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) and the like are used. An EDC/NHS mixture and DMT-MM are most preferable. The amount thereof to be used is 0.5- to 1.5-fold mol, preferably 0.8- to 1.2-fold mol, relative to the aminated sugar.
- The reaction temperature of the above-mentioned reaction is 20-60° C., preferably 30-50° C., and the reaction time is 5-36 hr, preferably 10-20 hr.
- After completion of the reaction, a sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [1-1] of the present invention can be obtained. The polyurethane can be purified by, for example, evaporating the reaction solvent, feeding a single or mixed solvent of methanol, water and the like to the concentrate to wash the polymer, filtering, and, where necessary, repeating reprecipitation purification to give a solid content, which can be dried under reduced pressure at room temperature −100° C. for about 1-24 hr.
- Since the sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-1] and the carboxyl group-modified oligosaccharide-containing polyurethane represented by the formula [1-2] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping monocyte, lymphocyte, granulocyte, stem cell, virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials. The physiological material here is, for example, a composition containing a polyurethane represented by the above-mentioned formula [1-1] or a polyurethane represented by the formula [1-2] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material. Examples thereof include, but are not limited to, a solution or suspension wherein polyurethane is dissolved or suspended in an organic solvent (DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- The physiological material of the present invention can be used for various applications such as for contact with a body fluid such as blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- The acid-modified oligosaccharide-containing polyurethane of the present invention represented by the formula [2-1]
- wherein each symbol is as defined above, can be obtained by reacting the oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-3] with an acid modifying reagent.
- As the acid modifying reagent, for example, when X is SO3, trimethylaminesulfur trioxide complex, triethylaminesulfur trioxide complex, dimethylformamidesulfur trioxide complex, pyridinesulfur trioxide complex, chlorosulfonate and the like are used, and when X is PO3, orthophosphoric acid, polyphosphoric acid, diphosphorus pentoxide, phosphorus oxychloride and the like are used.
- The above-mentioned reaction is generally performed in a solvent. As the solvent, dimethylformamide, pyridine, dimethyl sulfoxide (DMSO) and the like are generally used. The reaction temperature is generally 0° C.-80° C., and the reaction time is generally 5 min-24 hr. Where necessary, the obtained compound is treated with an ion exchange resin (Na+ type and the like) to convert M to an alkali metal atom (e.g., sodium atom and the like) and the like.
- Since the sulfated oligosaccharide-containing polyurethane represented by the above-mentioned formula [2-1] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials. The physiological material here is, for example, a composition containing a sulfated oligosaccharide-containing polyurethane represented by the above-mentioned formula [2-1] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material. Examples thereof include, but are not limited to, a solution or suspension wherein polyurethane is dissolved or suspended in an organic solvent (DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- The physiological material of the present invention can be used for applications such as for contact with blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- An acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the formula [3-1] of the present invention
- wherein each symbol is as defined above, can be obtained by reacting the sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [1-1] with an acid modifying reagent.
- As the acid modifying reagent, for example, when X is SO3, trimethylaminesulfur trioxide complex, triethylaminesulfur trioxide complex, dimethylformamidesulfur trioxide complex, pyridinesulfur trioxide complex, chlorosulfonic acid and the like are used, and when X is PO3, orthophosphoric acid, polyphosphoric acid, diphosphorus pentoxide, phosphorus oxychloride and the like are used.
- The above-mentioned reaction is generally performed in a solvent. As the solvent, dimethylformamide, pyridine, dimethyl sulfoxide (DMSO) and the like are generally used. The reaction temperature is generally 0° C.-80° C., and the reaction time is generally 5 min-24 hr. Where necessary, the obtained compound is treated with an ion exchange resin (Na+ type and the like) to convert M to an alkali metal atom (e.g., sodium atom and the like) and the like.
- Since the acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [3-1] of the present invention have the above-mentioned structure, the density of the sugar aggregate formed by a substance having a sugar structure, which is introduced into the polymer chain, increases. Therefore, they have superior physiological functions (e.g., function of trapping virus, protein and the like, and the like) for various components derived from living organisms, and can be used as various physiological materials. The physiological material here is, for example, a composition containing an acid-modified sugar residue-modified oligosaccharide-containing polyurethane represented by the above-mentioned formula [3-1] of the present invention in the form of a solution, a suspension, a paste, a polymer blend and the like appropriate for use as a substrate of the isolation material. Examples thereof include, but are not limited to, a solution or suspension wherein polyurethane is dissolved or suspended in a solvent (organic solvent such as DMSO, NMP, DMF, DMAc and the like, alone or a mixed solvent thereof, water etc.), polymer blend of polyurethane and any polymer inactive to the polyurethane and the like.
- The physiological material of the present invention can be used for applications such as for contact with blood and the like, an isolation material to harvest monocyte, lymphocyte, granulocyte, stem cell, virus, protein (lectin and the like) and the like from a body fluid, an isolation device and an isolation filter (e.g., blood isolation filter, monocyte isolation filter, lymphocyte isolation filter, granulocyte isolation filter, stem cell isolation filter, virus isolation filter, protein isolation filter (e.g., lectin isolation filter and the like) and the like) using the material, and the like.
- The present invention is explained in more detail by referring to the following Examples, which are not to be construed as limitative.
- A mannobiose-bound polystyrene derivative (Poly[N-p-vinylbenzyl-O-β-D-mannopyranosyl-(1→4)-D-mannamide], manufactured by SEIKAGAKU CORPORATION) was dissolved in distilled water at a concentration of 0.1% (W/V). The solution (1 ml) was added to a commercially available 1 ml polystyrene petri dish (diameter 35 mm), and left standing at room temperature for about 1 hr. Then, the supernatant polymer was removed, and saline (1 ml) was added. Excess mannobiose-bound polystyrene derivative was washed, and the supernatant was removed. This operation was repeated 3 times to give a mannobiose-bound polystyrene derivative coated petri dish.
- A winged injection needle was punctured into an upper arm of a healthy subject, and the blood (about 7.5 ml) was drawn in a lymphocyte isolation tube (vacutainer tube, manufactured by Becton, Dickinson and Company). After blood sampling, 3.8% citric acid solution was added to the vacutainer tube such that blood:citric acid=10:1, and the vacutainer tube was immediately centrifuged at 3000 rpm for 20 min at room temperature. The plasma component was collected, and the mononuclear cell layer was separately collected in a container. Saline (40 ml) was added, and the mixture was centrifuged at 1500 rpm for 5 min at 4° C. This operation was repeated several times to wash the mononuclear cells. The washed mononuclear cells were re-suspended in the plasma collected above to give a mononuclear cell suspension having a given concentration.
- Then, the prepared mononuclear cell suspension (1 ml, number of nuclear cells 2.0×106 cells) were added to the mannobiose-bound polystyrene derivative coating petri dish of (1), and the mixture was left standing in an incubator at 37° C., 5% CO2 for 30 min. After a predetermined time, the supernatant was collected, and the petri dish was washed 3 times with saline (1 ml). Then, 10% mannose solution (1 ml) was added, and the mixture was left standing in an incubator at 37° C., 5% CO2 for 15 min. The monocytes attached to the petri dish were collected by pipetting. The collection rate of the monocytes was determined by the following formula.
-
Monocyte collection rate(%)=(number of monocytes collected from the petri dish/number of monocytes before inoculation)×100 formula (1) - The number of monocytes was determined by measuring the number of leukocytes in the cell suspension collected from the petri dish by a blood cell counter (KX-21NV, manufactured by Sysmex Corporation), labeling the cell suspension with CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), determining the monocyte ratio by a flow cytometer (BD FACS Canto, manufactured by Japan Becton, Dickinson and Company), and multiplying the number of leukocytes by the monocyte ratio. The number of monocytes before inoculation was also determined by performing a similar operation for a cell suspension before inoculation as a target.
- The purity of the monocyte was determined by labeling the cell suspension collected from the petri dish with a CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), and measuring by a flow cytometer (BD FACS Canto, manufactured by Japan Becton, Dickinson and Company). As a result, the monocyte recovery rate was 78% and the purity was 96%, and the monocyte was found to have been selectively isolated and collected.
- In the same manner as in Example A1 except that a lactose-bound polystyrene derivative (nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION) was used instead of the mannobiose-bound polystyrene derivative, the recovery rate and purity of the monocyte were measured. As a result, the recovery rate of monocyte was 81% and the purity thereof was 73%, and the monocyte was found to have been selectively isolated and collected.
- In the same manner as in Example A1 except that a maltose-bind polystyrene derivative (nonreducing terminal sugar is galactose, manufactured by SEIKAGAKU CORPORATION) was used instead of the mannobiose-bound polystyrene derivative, the recovery rate and purity of the monocyte were measured. As a result, the recovery rate of monocyte was 76% and the purity thereof was 71%, and the monocyte was found to have been selectively isolated and collected.
- In the same manner as in Example A1 except that a polystyrene petri dish free of polymer coating was used, the collection rate and purity of the monocyte and the recovery rate of the dendritic cell were measured. As a result, the recovery rate of monocyte was 56% and the purity thereof was 46%.
- The above results are summarized in Table A1.
-
TABLE A1 Isolation/collection of monocyte using cell isolation device Recovery rate (%) Purity (%) of monocyte of monocyte Ex. A1 78 96 Ex. A2 81 73 Ex. A3 76 71 Com. Ex. A1 56 46 - A mononuclear cell suspension (1 ml, the number of nuclear cells 2.0×106 cells) prepared according to the method of Example A1(1) was added to a mannobiose-bound polystyrene derivative coated petri dish prepared according to the method of Example A1(1), and the mixture was left standing in an incubator at 37° C., 5% CO2 for 30 min. After 30 min, the supernatant was removed, saline (1 ml) was added, the petri dish was stirred slowly, and the supernatant was removed. Untrapped cells were washed by repeating the washing operation 5 times. Then AIM-V (manufactured by GIBCO) medium (1.5 ml) prepared to IL-4: 500 IU/ml, GM-CSF: 500 IU/ml was added, and the cells were cultured for 6 days.
- After culture for 6 days, the cells floating in the petri dish supernatant were collected, 10% mannose solution (1 ml) was further added to the petri dish, and the mixture was left standing in an incubator at 37° C., 5% CO2 for 15 min. After 15 min, the cells trapped in the petri dish were collected by a pipetting operation, combined with the cells collected earlier, and the total number of the collected cells was determined by a blood cell counting chamber.
- The cell suspension obtained by a dendritic cell collection operation were taken by 200 μl in a polypropylene test tube, 10 μl each of anti-CD14 antibody (PE-labeled), and anti-HLA-DR antibody (FITC-labeled, manufactured by Becton, Dickinson and Company) was added, and the mixture was left standing in a dark and cold place for 20 min. After a predetermined time, the mixture was centrifuged at 1500 rpm for 5 min, and the supernatant was removed. Then phosphate buffer (1 ml) was added, and the measurement was performed by a flow cytometer. As a result of the measurement, surface antigen CD14+and HLA-DR+ was taken as monocyte, CD14- and HLA-DR+ was taken as dendritic cell, and the positive rate of each cell was determined.
- The recovery rate of the dendritic cell was measured by the following formulas (2) and (3).
-
number of dendritic cells collected from the petri dish=total number of cells collected from the petri dish×dendritic cell positive rate formula (2) -
recovery rate(%) of dendritic cell=(number of dendritic cells collected from the petri dish/number of monocytes trapped in petri dish)×100 formula (3) - As a result, the recovery rate of the dendritic cell was 47.6%.
- In the same manner as in Example A4 except that a polystyrene petri dish free of coating with a mannobiose-bound polystyrene derivative polymer was used, the recovery rate of dendritic cell was measured. As a result, the recovery rate of dendritic cell was 23.6%.
- The above results are summarized in Table A2.
-
TABLE A2 Recovery rate of dendritic cell using cell isolation device Recovery rate (%) of dendritic cell Ex. A4 47.6 Com. Ex. A2 23.6 - Cellulose acetate was dissolved in a mixed solvent of dimethyl sulfoxide and propylene glycol, the solution was prepared into droplets by the method (vibration method) described in JP-A-63-117039, coagulated to give cellulose acetate spherical particles. The obtained spherical particles had a particle size of about 400 μm. The particles were mixed with 4N aqueous sodium hydroxide solution at a sedimentation volume ratio of 1:1 (V/V) to allow contact at 10° C.-15° C. for 120 min for hydrolysis. The obtained porous cellulose carrier (40 ml by sedimentation volume) was separated, 40 ml of reverse osmosis water (Yamato Pure line RO21, manufactured by Yamato Scientific Co., Ltd.) was added, and the inside temperature was raised to 40° C. 2N NaOH (24 ml) was added, and the mixture was shaken at 40° C. for 30 min. Then, epichlorohydrin (8.2 ml) was added, and the mixture was reacted at 40° C. for 2 hr. After completion of the reaction, carrier was washed with water (about 4 L) to give an epoxydized carrier (epoxy introduction amount; 32.9 μmol/g). Then, mannose amine (manufactured by Sigma Ltd., molecular weight about 215, 0.783 g) was dissolved in 0.5M sodium hydrogen carbonate buffer (51 ml) adjusted to pH 10.5. The epoxydized carrier (51 ml by sediment volume) was added, and the mixture was reacted at 37° C. for 16 hr to immobilize mannose amine. After completion of the reaction, the carrier was washed until the washing liquid was neutralized to give a mannose amine-immobilized carrier. Reverse osmosis water was added to the mannose amine-immobilized carrier (51 ml by sedimentation volume) to the total amount of 102 ml. Monoethanolamine (510 μl) was added thereto, and the mixture was reacted at 45° C. for 2 hr. After completion of the reaction, the carrier was washed until the washing liquid was neutralized. By this reaction, unreacted epoxy group was blocked.
- The obtained above-mentioned mannose amine-immobilized carrier was washed with heparin (heparin sodium injection, manufactured by Mitsubishi Tanabe Pharma Corporation) added saline (prepared to the heparin final concentration of 5 IU/ml) for heparin equilibration. Then mannose amine-immobilized carrier was defoamed, and 1.0 ml by sedimentation volume was filled in a mini column (acrylic, inner diameter 10 mm, height 10 mm). A polyvinyl chloride tube (inner diameter 1 mm, outer diameter 3 mm, length 50 cm) was mounted on the column entry side, and a similar polyvinyl chloride tube (length 20 cm) was mounted on the column exit side.
- The mononuclear cell suspension (5 ml, total number of nuclear cells 6.0×105 cells) prepared according to the method described in Example A1(1) was passed through the mini column at a flow rate of 0.2 ml/min. The time point when the mononuclear cell suspension was discharged from the column exit side was taken as the start point, and the tip of the tube on the column exit side was returned to the cell pool container and the perfusion was performed for 60 min.
- After a predetermined time, the cell suspension on the column exit side was harvested, the number of leukocytes was measured by a blood cell counting apparatus (KX-21NV manufactured by SYSMEX CORPORATION), and the monocyte ratio was determined by a flow cytometer (FACSCanto, Becton, Dickinson and Company). The results are shown in Table 3.
- As a result, the number of lymphocyte did not change. However, since the number of monocytes drastically decreased after the column treatment, it was found that the monocytes were selectively trapped by the cell isolation material in the column. The results are shown in Table A3.
-
TABLE A3 Changes of numbers of various cells before and after treatment with cell isolation material packed column (treatment time 60 min) number of nuclear cells positive rate number of cells (×10↑5 (%) (×10↑5 cells) cells) monocyte lymphocyte monocyte lymphocyte before 30 27.0 70.8 8.0 21 treatment after 25 10.8 88.0 2.5 22 treatment - Now the production methods of a sugar residue-modified oligosaccharide-containing polyurethane and a carboxyl group-modified oligosaccharide-containing polyurethane of the present invention are explained in detail based on the Examples, which are not to be construed as limitative.
- The monomer compounds to be used for polymerization are abbreviated as follows.
- OLS=oligosaccharide skeleton
- TRE=trehalose
- CTS=cyclic tetrasaccharide: cyclo{→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→)
- MDI=methanediphenyldiisocyanate
- PPG4=polypropylene glycol (molecular weight 400)
- PPG7=polypropylene glycol (molecular weight 700)
- SUC=succinic anhydride
- GluA=glucose amine
- 2-ManA=mannose amine
- Methane diphenyl diisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was concentrated and poured into water (500 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 81%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Methane diphenyl diisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (3.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was concentrated and poured into water (500 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 87%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Methane diphenyl diisocyanate (11.59 g) and dimethylacetamide (150 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 400, 9.26 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, cyclic tetrasaccharide (15.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 6 hr. The reaction solution was concentrated and poured into water (1000 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 70%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Methane diphenyl diisocyanate (7.7 g) and dimethylacetamide (175 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 700, 10.80 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, cyclic tetrasaccharide (10.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 6 hr. The reaction solution was concentrated and poured into water (1000 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 73%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.00 g) in Synthetic Example B1 and dimethylformamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.24 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated and poured into water (75 ml) to allow precipitation of a product. 1M Hydrochloric acid (3 drops) was added, and the precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 95%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.00 g) in Example B1 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.57 g), N-hydroxysuccinimide (0.34 g) and triethylamine (0.59 g) were added and dissolved by stirring at room temperature. Then, D-mannose amine hydrochloride (0.53 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into water (75 ml) to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 96%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.00 g) in Synthetic Example B1 was dissolved in dimethylformamide (25 ml) to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer at room temperature. Then, dimethylaminopyridine (0.025 g) was added to the reaction mixture, succinic anhydride (0.966 g) was added with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated and poured into water (75 ml) to allow precipitation of a product, and 1M-hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried at 80° C. to give a product (yield 91%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B3 and dimethylformamide (35 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.83 g), N-hydroxysuccinimide (0.49 g) and triethylamine (0.86 g) were added and dissolved by stirring at room temperature. Then, D-mannose amine hydrochloride (0.46 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 91%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B3 and dimethylformamide (35 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.83 g), N-hydroxysuccinimide (0.49 g) and triethylamine (0.86 g) were added and dissolved by stirring at room temperature. Then, D-mannose amine hydrochloride (0.93 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 91%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B3 and dimethylformamide (35 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.83 g), N-hydroxysuccinimide (0.49 g) and triethylamine (0.86 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (1.24 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 96%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.00 g) in Synthetic Example 2 and dimethylacetamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.39 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 95%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B7 and dimethylacetamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.47 g), N-hydroxysuccinimide (0.28 g) and triethylamine (0.82 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-mannose amine hydrochloride (0.53 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 85%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (0.80 g) in Synthetic Example B3 and dimethylformamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.90 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 73%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (0.60 g) in Example B9 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.35 g), N-hydroxysuccinimide (0.21 g) and triethylamine (0.52 g) were added and dissolved by stirring at room temperature. Then, D-glucose amine hydrochloride (1.24 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was filtered and vacuum dried to give a product (yield 67%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide) 1.05, 1.20; CH3—
- Polyurethane (0.800 g) in Synthetic Example B3 and dimethylformamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.26 g) and 4-dimethylaminopyridine (0.25 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 70%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (0.35 g) in Example B11 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.29 g), N-hydroxysuccinimide (0.17 g) and triethylamine (0.30 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (0.33 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 70%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (0.80 g) in Synthetic Example B3 and dimethylformamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.23 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 60%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (0.50 g) in Example B13 and dimethylacetamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.38 g), N-hydroxysuccinimide (0.23 g) and triethylamine (0.53 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (0.57 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 98%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (0.80 g) in Example B13 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.02 g), N-hydroxysuccinimide (0.60 g) and triethylamine (0.70 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (1.15 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 71%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B13 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.64 g), N-hydroxysuccinimide (0.38 g) and triethylamine (0.66 g) were added and dissolved at room temperature by stirring. Then, D-mannose amine hydrochloride (0.72 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (100 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 99%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.00 g) in Synthetic Example 4 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.21 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 87%).
- Polyurethane (5.00 g) in Example B17 and dimethylformamide (175 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (5.62 g), N-hydroxysuccinimide (3.37 g) and triethylamine (5.86 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (6.32 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (300 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 73%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- Polyurethane (1.50 g) in Example B17, dimethylformamide (10 ml), and then methanol (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 4(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorphorinium chloride (DMT-MM) (1.62 g)/methanol (5 ml) solution was added at room temperature with stirring. Then, D-glucose amine hydrochloride (1.26 g)/water (10 ml)) solution and then triethylamine (1.50 g) were added to the reaction mixture, and the mixture was reacted at room temperature for 9 hr. The reaction solution was filtered, concentrated and poured into methanol (300 ml) to allow precipitation of a product, which was collected by filtration, washed with methanol and vacuum dried to give a product (yield 50%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (10.00 g) in Example B17 and dimethylformamide (300 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (10.83 g), N-hydroxysuccinimide (6.49 g) and triethylamine (11.28 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (12.16 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was filtered, concentrated and poured into acetone (900 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 90%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Example B17 and dimethylformamide (40 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.50 g), N-hydroxysuccinimide (0.30 g) and triethylamine (0.52 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-mannose amine hydrochloride (0.56 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated, filtered, concentrated and poured into acetone (200 ml) to allow precipitation of a product, which was collected by filtration, vacuum dried, washed with water and vacuum dried to give a product (yield 80%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- 1. The properties of the carboxyl group-modified oligosaccharide-containing polyurethane and the sugar residue-modified oligosaccharide-containing polyurethane of the present invention were evaluated by the following methods (1)-(3).
(1) molecular weight: The weight average molecular weight (Mw) of the polyurethane derivatives produced in the Examples was measured by GPC (gel permeation chromatography) method using DMF (dimethylformamide) as an eluent and RI detector (differential refractometer) with standard polyethylene glycol (PEG) as the standard.
(2) softening point: The softening point of polyurethane produced in the Examples was measured using a melting point measurement apparatus by starting heating from room temperature (5° C./min) and at the temperature at which the sample was dissolved.
(3) solvent solubility: Whether or not various polyurethanes (0.1 g) obtained in the Examples can be dissolved in dimethylacetamide (DMAc, 1 ml) was examined. The results of (1)- (3) are shown in Tables B1 and B2. - Various polyurethanes (30 mg) obtained in the Synthetic Examples were dissolved in dimethylacetamide (10 ml), filtered through a membrane filter to give polyurethane solutions. This solution (1 ml) was placed in a glass petri dish (diameter 35 mm) and dried under reduced pressure at 70° C. for 3 hr to give polyurethane-coated petri dishes.
- The above-mentioned adapter was connected to a winged intravenous injection needle, and a holder was connected to the other end of the adapter. The needle was punctured into an upper arm of a healthy subject, and the blood (about 7.5 ml) was drawn in a lymphocyte isolation tube (vacutainer tube, manufactured by Becton, Dickinson and Company). After blood sampling, 3.8% citric acid solution was added to the vacutainer tube such that blood:citric acid=10:1, and the vacutainer tube was immediately centrifuged at 3000 rpm for 20 min at room temperature. The plasma component was collected, and the mononuclear cell layer was separately collected in a container. Saline (40 ml) was added, and the mixture was centrifuged at 1500 rpm for 5 min at 4° C. This operation was repeated several times to wash the mononuclear cells. The washed mononuclear cells were re-suspended in the plasma collected above to give a lymphocyte suspension having a given concentration.
- (2) Interaction with Polyurethane-Coated Petri Dish
- Saline (1 ml) was added to various polyurethane-coated petri dishes and the supernatant was removed. This operation was repeated 3 times to wash the petri dishes. Then the mononuclear cell suspension (1 ml) prepared in (1) was added, and the mixture was left standing in an incubator at 37° C., 5% CO2 for 30 min.
- After a predetermined time, the supernatant was collected, and the petri dish was washed 3 times with saline (1 ml). Then, 10% mannose solution (1 ml) was added, and the mixture was left standing in an incubator at 37° C., 5% CO2 for 15 min. Thereafter, the monocytes attached to the petri dish were collected by pipetting. The monocyte collection rate was determined by the following formula.
-
- The number of monocytes was obtained by measuring the number of leukocytes in the cell suspension collected from the petri dish by a blood cell counter (KX-21NV, Sysmex Corporation), labeling the cell suspension with a CD14-PE fluorescence antibody (Japan Becton, Dickinson and Company), determining the monocyte ratio by a flow cytometer (BD FACS Canto, Japan Becton, Dickinson and Company), and multiplying the above-mentioned number of leukocytes by the monocyte ratio to be mentioned below. The number of monocytes on inoculation was also determined in the same manner using a cell suspension on inoculation as a target.
- The purity of the monocyte was determined by labeling the cell-containing liquid collected from the petri dish with a CD14-PE fluorescence antibody (manufactured by Japan Becton, Dickinson and Company), and measuring the positive rate of monocyte by a flow cytometer (BD FACS Canto, Japan Becton, Dickinson and Company), which was taken as the purity.
- The above results are shown in Tables B1-B5.
-
TABLE B1 Ex. B1 Ex. B2 Ex. B3 Ex. B4 molar ratio MDI 2 2 2 2 PPG PPG4 PPG4 PPG4 PPG4 1 1 1 1 OLS TRE TRE TRE TRE 1 1 1 1 SUC 3 3 5 5 GluA 0 0 0 0 2-ManA 0 1 0 1 collection rate (%) 95 96 96 91 Mw (RI) 45,600 82,000 — 40,000 softening point (° C.) 105 100 — 75 DMAc solubility dissolved dissolved dissolved dissolved monocyte collection 51 88 50 86 rate (%) monocyte purity ( %) 41 80 46 81 -
TABLE B2 Ex. B5 Ex. B6 Ex. B7 Ex. B8 molar ratio MDI 2 2 2 2 PPG PPG4 PPG4 PPG7 PPG7 1 1 1 1 OLS TRE TRE TRE TRE 1 1 1 1 SUC 5 5 3 3 GluA 0 2 0 0 2-ManA 2 0 0 1 collection rate (%) 91 96 95 85 Mw (RI) 100,000 38,500 37,000 150,000 softening point (° C.) 60 60 100 100 DMAc solubility dissolved dissolved dissolved dissolved monocyte collection 96 89 46 73 rate (%) monocyte purity ( %) 85 81 46 82 -
TABLE B3 Ex. B9 Ex. B10 Ex. B11 Ex. B12 molar ratio MDI 2 2 2 2 PPG PPG4 PPG4 PPG4 PPG4 1 1 1 1 OLS CTS CTS CTS CTS 1 1 1 1 SUC 2 2 3 3 GluA 0 1.4 0 2.4 2-ManA 0 0 0 2 collection rate (%) 73 67 70 70 Mw (RI) — 17,000 — 20,000 softening point (° C.) — 120 — 90 DMAc solubility dissolved dissolved dissolved dissolved monocyte collection — 89 — 77 rate (%) monocyte purity ( %) — 74 — 78 -
TABLE B4 Ex. B13 Ex. B14 Ex. B15 Ex. B16 molar ratio MDI 2 2 2 2 PPG PPG4 PPG4 PPG4 PPG4 1 1 1 1 OLS CTS CTS CTS CTS 1 1 1 1 SUC 5 5 5 5 GluA 0 2 4 0 2-ManA 0 0 0 3 collection rate (%) 60 98 71 99 Mw (RI) — 32,000 38,500 87,000 softening point (° C.) — 85 80 95 DMAc solubility dissolved dissolved dissolved dissolved monocyte collection — 94 98 90 rate (%) monocyte purity ( %) — 86 91 81 -
TABLE B5 Ex. B17 Ex. B18 Ex. B19 Ex. B20 molar ratio MDI 2 2 2 2 PPG PPG7 PPG7 PPG7 PPG7 1 1 1 1 OLS CTS CTS CTS CTS 1 1 1 1 SUC 5 5 5 5 GluA 0 2 3 0 2-ManA 0 0 0 2 collection rate (%) 87 73 90 80 Mw (RI) 39,000 47,000 190,000 56,000 softening point (° C.) 120 100 80 95 DMAc solubility dissolved dissolved dissolved dissolved monocyte collection 23 90 81 83 rate (%) monocyte purity ( %) 87 91 84 79 - From the above results, it was found that the sugar residue-modified oligosaccharide-containing polyurethane has superior and selective monocyte trapping capability.
- A mononuclear cell suspension (1 ml, the number of nuclear cells 2.0×106 cells) prepared according to the method of Example A1(1) was added to a mannose-bound polyurethane derivative (Example B20)-coated petri dish prepared according to the method of Example A1(1), and the mixture was left standing in an incubator at 37° C., 5% CO2 for 30 min. After 30 min, the supernatant was removed, saline (1 ml) was added, the petri dish was stirred slowly, and the supernatant was removed. Untrapped cells were washed by repeating the washing operation 5 times. Then AIM-V (manufactured by GIBCO) medium (1.5 ml) prepared to IL-4: 500 IU/ml, GM-CSF: 500 IU/ml was added, and the cells were cultured for 6 days.
- After culture for 6 days, the cells floating in the petri dish supernatant were collected, 10% mannose solution (1 ml) was further added to the petri dish, and the mixture was left standing in an incubator at 37° C., 5% CO2 for 15 min. After 15 min, the cells trapped in the petri dish were collected by a pipetting operation, combined with the cells collected earlier, and the total number of the collected cells was determined by a blood cell counting chamber.
- The cell suspension obtained by a dendritic cell collection operation were taken by 200 μl in a polypropylene test tube, 10 μl each of anti-CD14 antibody (PE-labeled), and anti-HLA-DR antibody (FITC-labeled, manufactured by Becton, Dickinson and Company) was added, and the mixture was left standing in a dark and cold place for 20 min. After a predetermined time, the mixture was centrifuged at 1500 rpm for 5 min, and the supernatant was removed. Then phosphate buffer (1 ml) was added, and the measurement was performed by a flow cytometer. As a result of the measurement, surface antigen CD14+and HLA-DR+ was taken as monocyte, CD14- and HLA-DR+ was taken as dendritic cell, and the positive rate of each cell was determined.
- The recovery rate of the dendritic cell was determined by the following formulas (A) and (B).
-
number of dendritic cells collected from the petri dish=total number of cells collected from the petri dish×dendritic cell positive rate formula (A) -
dendritic cell recovery rate(%)=(number of dendritic cells collected from the petri dish/number of monocytes trapped in petri dish)×100 formula (B) - As a result, the dendritic cell recovery rate was 37.2%.
- Since the recovery rate of the dendritic cell in a polystyrene petri dish free of coating with a mannose-bound polyurethane derivative polymer (Comparative Example A2) was 23.6%, the mannose-bound polyurethane derivative polymer was shown to have a high dendritic cell recovery rate.
- Now the acid-modified oligosaccharide-containing polyurethane of the present invention is explained in more detail based on the Examples, which are not to be construed as limitative.
- The monomer compounds and the like to be used for polymerization are abbreviated as follows.
- OLS=oligosaccharide skeleton
- TRE=trehalose
- LAC=lactose
- MAL=maltose
- MDI=diphenylmethanediisocyanate
- PPG4=polypropylene glycol (molecular weight 400)
- PPG7=polypropylene glycol (molecular weight 700)
- Py=pyridyl group
- Diphenylmethanediisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 700, 10.23 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (1.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 86%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- In the same manner as in Synthetic Example C1 and using diphenylmethanediisocyanate (4.39 g), dimethylacetamide (65 ml), polypropylene glycol (average molecular weight 700, 10.23 g) and lactose (1.00 g), a product was obtained (yield 90%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- In the same manner as in Synthetic Example C1 and using diphenylmethanediisocyanate (4.39 g), dimethylacetamide (65 ml), polypropylene glycol (average molecular weight 700, 10.23 g) and maltose (1.00 g), a product was obtained (yield 93%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Diphenylmethanediisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (weight average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 81%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Polyurethane (1.00 g) in Synthetic Example C1 and dimethylformamide (50 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.06 g) was added at room temperature with stirring, and the mixture was reacted at room temperature for 24 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 94%).
- The product was confirmed to be the object product by proton NMR and IR spectrum. In addition, from the integration value of pyridyl group in proton NMR, it was found that two sulfuric acid groups were introduced per one oligosaccharide. proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 2.50-2.60; —OCO—CH2—CH2—COO
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 6.50; —NH—CO—
- 7.16, 7.43; —C6H4—
- 8.10-9.00; —C5H5NH (pyridyl group)
- 8.65, 9.60; —NH—CO—
- IR(KBr):1040, 1120 cm−1 (SO3)
- Polyurethane (1.00 g) in Synthetic Example C2, dimethylformamide (50 ml) and dimethyl sulfoxide (5 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.06 g) was added at room temperature with stirring, and the mixture was reacted at room temperature for 24 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 98%).
- The product was confirmed to be the object product by proton NMR and IR spectrum. In addition, from the integration value of pyridyl group in proton NMR, it was found that two sulfuric acid groups were introduced per one oligosaccharide.
- Polyurethane (1.00 g) in Synthetic Example C3, dimethylformamide (50 ml) and dimethyl sulfoxide (5 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.06 g) was added at room temperature with stirring, and the mixture was reacted at room temperature for 24 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 98%).
- The product was confirmed to be the object product by proton NMR and IR spectrum. In addition, from the integration value of pyridyl group in proton NMR, it was found that two sulfuric acid groups were introduced per one oligosaccharide.
- Polyurethane (1.00 g) in Synthetic Example C4 and dimethylformamide (15 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.15 g) was added at room temperature with stirring, and the mixture was reacted at 40° C. for 6 hr. The reaction solution was concentrated and methanol was added to allow precipitation of a product, which was collected by filtration, washed with methanol and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum. In addition, from the integration value of pyridyl group in proton NMR, it was found that two sulfuric acid groups were introduced per one oligosaccharide. proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH3—
- 2.50-2.60; —OCO—CH2—CH2—COO—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 6.50; —NH—CO—
- 7.16, 7.43; —C6H4—
- 8.10-9.00; —C5H5NH (pyridyl group)
- 8.65, 9.60; —NH—CO—
- IR(KBr):1040, 1120 cm−1(SO3)
- (1) solvent solubility: Whether or not various polyurethanes (0.1 g) obtained in the Examples can be dissolved in dimethylacetamide (1 ml) was examined.
(2) softening point: The softening point of polyurethane produced in the Examples was measured using a melting point measurement apparatus by starting heating from room temperature (5° C./min) and at the temperature at which the sample was dissolved. - The results are shown in Table C1.
-
TABLE C1 Ex. C1 Ex. C2 Ex. C3 Ex. C4 molar ratio MDI 3 3 3 2 PPG PPG7 PPG7 PPG7 PPG4 2.5 2.5 2.5 1 OLS TRE LAC MAL TRE 0.5 0.5 0.5 1 SO3 2 2 2 2 Mw (RI) 27,000 57,000 53,000 32,000 softening point (° C.) 80 60 65 95 DMAc solubility dissolved dissolved dissolved dissolved - From the above results, the acid-modified oligosaccharide-containing polyurethane of the present invention was shown to have thermoplasticity and solvent solubility.
- Now the acid-modified sugar residue-modified oligosaccharide-containing polyurethane of the present invention is explained in more detail based on the Examples, which are not to be construed as limitative.
- The monomer compounds to be used for polymerization are abbreviated as follows.
- OLS=oligosaccharide skeleton
- TRE=trehalose
- MDI=diphenylmethanediisocyanate
- PPG4=polypropylene glycol (molecular weight 400)
- PPG7=polypropylene glycol (molecular weight 700)
- SUC=succinic anhydride
- GluA=glucose amine
- ManA=mannose amine
- Py=pyridyl group
- Diphenylmethanediisocyanate (5.85 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (weight average molecular weight 400, 4.68 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (4.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 81%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Diphenylmethanediisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (weight average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (3.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 87%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Methane diphenyl diisocyanate (4.39 g) and dimethylacetamide (65 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Polypropylene glycol (average molecular weight 700, 6.14 g) was added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, trehalose (1.00 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 4 hr. The reaction solution was poured into a methanol/water (volume ratio 1/3) mixed solvent to allow precipitation of a product, which was collected by filtration, washed with a methanol/water solvent and vacuum dried to give a product (yield 86%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Synthetic Example 1 and dimethylacetamide (25 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.24 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 95%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 2.50-2.60; —OCO—CH2—CH2—COO—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Polyurethane (1.00 g) in Synthetic Example 4 and dimethylformamide (30 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 0.57 g), N-hydroxysuccinimide (0.34 g) and triethylamine (0.59 g) were added and dissolved at room temperature by stirring. Then, D-mannose amine hydrochloride (0.53 g) was added to the solution, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into water to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 96%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 2.50-2.60; —OCO—CH2—CH2—COO—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 6.50; —NH—CO—
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Polyurethane (1.00 g) in Synthetic Example D1 was dissolved at room temperature in dimethylacetamide (25 ml) in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Dimethylaminopyridine (0.025 g) was added and then succinic anhydride (0.966 g) was added with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (0.25 ml) was added. The precipitate was collected by filtration, washed with water and vacuum dried at 80° C. to give a product (yield 91%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.00 g) in Synthetic Example 5 and dimethylacetamide (35 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.83 g) and N-hydroxysuccinimide (0.49 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-glucose amine hydrochloride (1.24 g) and triethylamine (1.45 g) were added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into water to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 96%).
- The product was confirmed to be the object product by proton NMR.
- proton NMR proton (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 2.50-2.60; —OCO—CH2—CH2—COO—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 6.50; —NH—CO—
- 7.16, 7.43; —C6H4—
- 8.65, 9.60; —NH—CO—
- Polyurethane (2.00 g) in Synthetic Example D2 and dimethylacetamide (50 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (0.79 g) and 4-dimethylaminopyridine (0.025 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 84%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (1.50 g) in Synthetic Example D8 and dimethylacetamide (50 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.47 g), N-hydroxysuccinimide (0.28 g) and triethylamine (0.62 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-mannose amine hydrochloride (0.53 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into water to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 78%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (5.00 g) in Synthetic Example D3 and dimethylacetamide (100 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Succinic anhydride (1.15 g) and 4-dimethylaminopyridine (0.035 g) were added at room temperature with stirring, and the mixture was reacted at 70° C. for 5 hr. The reaction solution was concentrated, poured into water (75 ml) to allow precipitation of a product, and 1M hydrochloric acid (3 drops) was added. The precipitate was collected by filtration, washed with water and vacuum dried to give a product (yield 98%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (3.00 g) in Synthetic Example D10 and dimethylacetamide (100 ml) were added to a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.50 g), N-hydroxysuccinimide (0.30 g) and triethylamine (0.66 g) were added at room temperature with stirring, and the mixture was reacted for 1 hr. Then, D-mannose amine hydrochloride (0.28 g) was added to the reaction mixture, and the mixture was reacted at said temperature for 24 hr. The reaction solution was concentrated and poured into water to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product (yield 85%).
- The product was confirmed to be the object product by proton NMR.
- Polyurethane (0.100 g) in Synthetic Example D5 and dimethylformamide (15 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.15 g) was added at room temperature with stirring, and the mixture was reacted for 8 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum.
- proton NMR (solvent: dimethyl sulfoxide)
- 1.05, 1.20; CH2—
- 2.50-2.60; —OCO—CH2—CH2—COO—
- 3.20-3.80; —O—CH—CH2—O—, —CH2—, —CH—
- 3.86; —CH2—
- 4.30-5.00; —O—CH—O—, —OH
- 6.50; —NH—CO—
- 7.16, 7.43; —C6H4—
- 8.10-9.00; —C5H5N.H+
- 8.65, 9.60; —NH—CO—
- IR(KBr):1040, 1120 cm−1 (SO2)
- Polyurethane (1.00 g) in Synthetic Example D7 and dimethylformamide (15 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.30 g) was added at room temperature with stirring, and the mixture was reacted for 8 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum.
- Polyurethane (1.00 g) in Synthetic Example D11 and dimethylformamide (50 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.027 g) was added at room temperature with stirring, and the mixture was reacted for 8 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum.
- Polyurethane (1.00 g) in Synthetic Example 11 and dimethylformamide (50 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.054 g) was added at room temperature with stirring, and the mixture was reacted for 8 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum.
- Polyurethane (1.00 g) in Synthetic Example 8 and dimethylformamide (70 ml) were added to and dissolved in a 4-mouth flask (purged with nitrogen gas) equipped with a mechanical stirrer. Pyridinesulfur trioxide complex (0.078 g) was added at room temperature with stirring, and the mixture was reacted for 8 hr. The reaction solution was concentrated and water was added to allow precipitation of a product, which was collected by filtration, washed with water and vacuum dried to give a product.
- The product was confirmed to be the object product by proton NMR and IR spectrum.
- (1) molecular weight: The weight average molecular weight (Mw) of the polyurethane derivatives produced in the Examples was measured using DMF (dimethylformamide) as an eluent and standard polyethylene glycol (PEG) as the standard.
(2) softening point: The softening point of polyurethane produced in the Examples was measured using a melting point measurement apparatus by starting heating from room temperature (5° C./min) and at the temperature at which the sample was dissolved.
(3) solvent solubility: Whether or not various polyurethanes (0.1 g) obtained in the Examples can be dissolved in dimethylacetamide (1 ml) was examined. - The results are shown in Table D1.
-
TABLE D1 Ex. D1 Ex. D2 Ex. D3 Ex. D4 Ex. D5 molar MDI 2 2 3 3 2 ratio PPG PPG4 PPG4 PPG7 PPG7 PPG7 1 1 2.5 2.5 1 OLS TRE TRE TRE TRE TRE 1 1 0.5 0.5 1 SUC 3 5 5 5 3 GluA 0 2 0 0 0 ManA 1 0 1 1 1 SO3 1 2 1 2 1 Mw (RI) 27,000 51,000 39,000 35,000 34,000 softening 60 50 75 70 70 point (° C.) DMAc dis- dis- dis- dis- dis- solubility solved solved solved solved solved - From the above results, the sugar residue-modified oligosaccharide-containing polyurethane was shown to have thermoplasticity and solvent solubility.
- 0.0125, 0.0250, 0.050 mg/ml phosphate buffers (pH 7.2) of FITC-labeled two kinds of lectin ConA-FITC (manufactured by SEIKAGAKU CORPORATION) and WGA-FITC (manufactured by SEIKAGAKU CORPORATION) were prepared.
- (2) Preparation of analytical curve: the above-mentioned two kinds of lectin solution were taken in quartz cell, and the fluorescence intensity (apparatus: fluorescence spectrophotometer FP-6500 manufactured by JASCO Corporation, wavelength 519 nm) was plotted against the concentration. It was confirmed that a linear line was obtained.
(3) Preparation of polyurethane-coated petri dish - Phosphate buffer (pH 7.2, 1 ml) was added to a petri dish coated with the polyurethane obtained in Example B18, and the supernatant was removed. This operation was repeated 3 times to wash the petri dish.
- (4) The fluorescence intensity (I0) of 0.050 mg/ml phosphate buffer (pH 7.2) was measured. 3 ml thereof was placed in a glass petri dish coated with the polyurethane obtained in Example B18. After leaving at 20° C. for 30 min, the supernatant was taken in a quartz glass cell, and the fluorescence intensity (I1) was measured.
- The lectin trap rate was determined by the following formula.
-
trap rate(%)=(I 1 −I 0)/(I 0)×100 - The results are respectively shown in the following Table E as Examples E1 and E2. For comparison, petri dishes free of polyurethane coating were subjected to a similar experiment (Comparative Examples E1 and E2).
-
TABLE E Com. Com. Ex. E1 Ex. E2 Ex. E1 Ex. E2 polymer Example B18 none lectin type ConA WGA ConA WGA lectin trap rate 72 8 0 0 (%) - From the above, the sugar residue-modified oligosaccharide-containing polyurethane of the present invention was found to have a superior lectin trapping capability.
- The lectin harvested in the present invention can be used as a cell fractionation reagent, a clinical diagnostic reagent, a clinical therapeutic drug and the like, based on its sugar chain binding specificity, blood type specificity, anticancer effect and the like. For such uses, lectin may be directly used as a lectin-isolation device composition.
- According to the method of the present invention, a cell such as monocyte and the like or a protein such as lectin and the like can be collected conveniently at high purity and in a high collection rate. Moreover, by inducing monocytes to further differentiate into dendritic cells according to the method of the present invention, dendritic cells can be prepared conveniently and highly efficiently.
- In addition, the sugar residue-modified oligosaccharide-containing polyurethane, carboxyl group-modified oligosaccharide-containing polyurethane, acid-modified oligosaccharide-containing polyurethane and acid-modified sugar residue-modified oligosaccharide-containing polyurethane of the present invention are solvent soluble and thermoplastic, and superior in film forming capability. Furthermore, since these polyurethanes are particularly superior in trapping capability of cell (e.g., monocyte and the like), protein, virus and the like, they are useful as highly functional materials used in the fields of isolation, analysis and the like of cells, proteins and viruses, particularly, for use involving contact with blood (e.g., various isolation devices, isolation filters and the like for harvesting blood, cell, monocyte, protein and the like) and the like.
- Of these, the acid-modified oligosaccharide-containing polyurethane and acid-modified sugar residue-modified oligosaccharide-containing polyurethane of the present invention are expected to have affinity for particular cells, proteins and viruses, since oligosaccharide or sugar residue is further modified with an acid. Therefore, these polyurethanes are useful as highly functional materials for use in the fields of medicine and livingwares.
- This application is based on application Nos. 2006-148620, 2006-149031, 2006-163955 and 2006-179690 filed in Japan, the contents of which are incorporated hereinto by reference. In addition, the patent documents and non-patent documents cited in the present specification are hereby incorporated by reference, to the extent that the entire contents have been disclosed herein.
Claims (1)
1. A method of harvesting a cell comprising performing
1) a step for trapping a cell on an isolation material by contacting a body fluid with the isolation material comprising, on at least a part of a surface thereof, a substance having a sugar structure,
2) a step for removing untrapped cells by washing the isolation material with a washing liquid, and
3) a step for collecting a trapped cell from the isolation material, in this order, wherein the substance having a sugar structure is the polyurethane represented by the following formula [1-1]:
wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00,
the following formula [1-2]:
wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00,
the following formula [2-1]:
wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety,
s shows the number of the secondary hydroxyl groups of an oligosaccharide modified with an acid-containing group, which is an integer within the range of 1≦s≦r, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00, or
the following formula [3-1]:
wherein
R1 is a divalent C1-16 hydrocarbon group optionally having substituent(s),
R2 is a divalent group containing the same or different 1 to 100 units in total selected from a C2-12 oxyalkylene unit and a divalent C2-12 hydrocarbon unit optionally having substituent(s),
R3 is a C2-4 alkylene group,
R4 is a monosaccharide- or disaccharide-derived sugar residue,
XM is an acid-containing group wherein M is a hydrogen atom, an alkali metal atom, an ammonium group or an organic amino group, and X is an acid-derived moiety, s shows the number of hydroxyl groups of a sugar residue R4 modified with an acid-containing group, which is an integer within the range of 1≦s≦4,
OLS is an oligosaccharide skeleton having two primary hydroxyl groups,
r shows the total number of secondary hydroxyl groups of oligosaccharide,
p and q are each an integer within the range of 1≦p≦r, 0≦q≦r−1, and
m and n are each a repeat unit number, m is an integer of 0-1000 and n is an integer of 1-1000, and n/(m+n) is a number within the range of 0.01-1.00.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/403,212 US20120322133A9 (en) | 2006-05-29 | 2012-02-23 | Separating material and method for collecting cell or the like using the same |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006148620A JP4969918B2 (en) | 2006-05-29 | 2006-05-29 | Monocyte separation material and method for preparing monocytes / dendritic cells using the same |
JP2006-148620 | 2006-05-29 | ||
JP2006-149031 | 2006-05-29 | ||
JP2006149031A JP5081397B2 (en) | 2006-05-29 | 2006-05-29 | Polyurethane derivative and method for producing the same, and physiologically functional material using the polyurethane derivative |
JP2006163955A JP5081401B2 (en) | 2006-06-13 | 2006-06-13 | Sulfated sugar-containing polyurethane derivative and process for producing the same |
JP2006-163955 | 2006-06-13 | ||
JP2006179690A JP5081406B2 (en) | 2006-06-29 | 2006-06-29 | Sulfated sugar-containing polyurethane derivative and process for producing the same |
JP2006-179690 | 2006-06-29 | ||
PCT/JP2007/060721 WO2007139028A1 (en) | 2006-05-29 | 2007-05-25 | Separating material and method for collecting cell or the like using the same |
US30288109A | 2009-06-09 | 2009-06-09 | |
US13/403,212 US20120322133A9 (en) | 2006-05-29 | 2012-02-23 | Separating material and method for collecting cell or the like using the same |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/060721 Division WO2007139028A1 (en) | 2006-05-29 | 2007-05-25 | Separating material and method for collecting cell or the like using the same |
US30288109A Division | 2006-05-29 | 2009-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120156749A1 US20120156749A1 (en) | 2012-06-21 |
US20120322133A9 true US20120322133A9 (en) | 2012-12-20 |
Family
ID=38778549
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/302,881 Expired - Fee Related US8357522B2 (en) | 2006-05-29 | 2007-05-25 | Separating material and method for collecting cell or the like using the same |
US13/403,212 Abandoned US20120322133A9 (en) | 2006-05-29 | 2012-02-23 | Separating material and method for collecting cell or the like using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/302,881 Expired - Fee Related US8357522B2 (en) | 2006-05-29 | 2007-05-25 | Separating material and method for collecting cell or the like using the same |
Country Status (2)
Country | Link |
---|---|
US (2) | US8357522B2 (en) |
WO (1) | WO2007139028A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009057574A1 (en) * | 2007-10-30 | 2009-05-07 | Kaneka Corporation | Polyurethane derivative, and filter material for removal of leukocyte comprising the same |
JP2009207381A (en) * | 2008-03-03 | 2009-09-17 | Kaneka Corp | Device for capturing monocyte |
WO2013069503A1 (en) * | 2011-11-09 | 2013-05-16 | 株式会社カネカ | Stem cell isolation method |
US8999376B2 (en) | 2012-02-03 | 2015-04-07 | Xcede Technologies, Inc. | Tissue patch |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
AU2016307447A1 (en) | 2015-08-07 | 2018-02-22 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2660175B2 (en) * | 1994-10-19 | 1997-10-08 | 北海道 | Lectin from Jerusalem artichoke and its separation and purification method |
JP2997768B2 (en) * | 1998-03-05 | 2000-01-11 | 工業技術院長 | Sulfated galactose compound, intermediate thereof, and method for producing the sulfated galactose compound |
ATE307881T1 (en) | 1999-03-30 | 2005-11-15 | Netech Inc | METHOD FOR SELECTIVE SEPARATION OF BLOOD CELLS USING LECTIN |
WO2002055021A2 (en) * | 2001-01-12 | 2002-07-18 | Univ Emory | Glycopolymers and free radical polymerization methods |
EP1509595A4 (en) * | 2001-07-05 | 2006-02-22 | Phylogix Inc | Dendritic cell isolation methods |
ES2254759T3 (en) * | 2001-10-19 | 2006-06-16 | Natimmune A/S | INSULATION OF LECTINES. |
AU2002357588B2 (en) | 2001-12-11 | 2008-11-20 | Netech Inc. | Blood cell separation system |
CN1761744A (en) * | 2003-02-10 | 2006-04-19 | 西北生物治疗药物公司 | Cultured CD14+ antigen presenting cells |
JPWO2005070964A1 (en) | 2004-01-27 | 2008-01-17 | 株式会社医学生物学研究所 | How to isolate monocytes |
-
2007
- 2007-05-25 WO PCT/JP2007/060721 patent/WO2007139028A1/en active Application Filing
- 2007-05-25 US US12/302,881 patent/US8357522B2/en not_active Expired - Fee Related
-
2012
- 2012-02-23 US US13/403,212 patent/US20120322133A9/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007139028A1 (en) | 2007-12-06 |
US20090239300A1 (en) | 2009-09-24 |
US8357522B2 (en) | 2013-01-22 |
US20120156749A1 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120322133A9 (en) | Separating material and method for collecting cell or the like using the same | |
US10705091B2 (en) | Preparing genetically modified cells using a device that is configured for sterile processing of cells at the bedside or in a surgical room | |
ES2611772T3 (en) | Use of a tangential flow filtration device and methods for leukocyte enrichment | |
Faradji et al. | Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients | |
US20190184371A1 (en) | Material for blood purification | |
CN114479090B (en) | Fluorinated polyethylene glycol-polyethyleneimine and preparation method and application thereof | |
US9867927B2 (en) | Carrier for blood component adsorption and blood component adsorption column | |
JP4229226B2 (en) | Selective separation of blood cells using lectins | |
CN113502268A (en) | Preparation method of dendritic cells | |
JP2007312737A (en) | Monocyte separating material and monocyte and method for preparing dendritic cell utilizing the same | |
JP5051362B2 (en) | Cytocidal activity enhancing material and extracorporeal circulation column | |
JP5081397B2 (en) | Polyurethane derivative and method for producing the same, and physiologically functional material using the polyurethane derivative | |
JP2017112910A (en) | Cell separation material and use therefor | |
JP2006333850A (en) | Base material for separating biological particle | |
JPH04242661A (en) | Agent for concentrating natural killer cell, concentrating device and concentrating method | |
JPH04114662A (en) | Adsorbing agent for separation of lymphocyte and separator | |
JP2000308826A (en) | Adsorption body, adsorption column and method for removing cytokine | |
JPH04346801A (en) | Agent, device and method for separating lymphocyte subclass | |
JPH0362700B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |
|
AS | Assignment |
Owner name: KANEKA CORPORATION, JAPAN Free format text: CHANGE OF ADDRESS;ASSIGNOR:KANEKA CORPORATION;REEL/FRAME:031207/0283 Effective date: 20130107 |